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Over the long term, symbiosis is more useful than 
parasitism. More fun, too. Ask any mitochondria.
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Reduced mitochondrial DNA (mtDNA) content in breast cancer cell lines 
has been associated with transition towards a mesenchymal phenotype, but 
its clinical consequences concerning breast cancer dissemination remain 
unidentified. Here, we aimed to clarify the link between mtDNA content 
and a mesenchymal phenotype and its relation to prognosis of breast cancer 
patients. We analysed mtDNA content in 42 breast cancer cell lines and 207 
primary breast tumour specimens using a combination of quantitative PCR 
and array-based copy number analysis. By associating mtDNA content with 
expression levels of genes involved in epithelial-to-mesenchymal transition 
(EMT) and with the intrinsic breast cancer subtypes, we could not identify 
a relation between low mtDNA content and mesenchymal properties in 
the breast cancer cell lines or in the primary breast tumours. In addition, 
we explored the relation between mtDNA content and prognosis in our 
cohort of primary breast tumour specimens that originated from patients 
with lymph node-negative disease who did not receive any (neo)adjuvant 
systemic therapy. When patients were divided based on the tumour quartile 
levels of mtDNA content, those in the lowest quarter (≤350 mtDNA 
molecules per cell) showed a poorer 10-year distant metastasis-free survival 
than patients with >350 mtDNA molecules per cell (HR 0.50 [95% CI 
0.29-0.87], P = 0.015). The poor prognosis was independent of established 
clinicopathological markers (HR 0.54 [95% CI 0.30-0.97], P = 0.038). 
We conclude that, despite a lack of evidence between mtDNA content and 
EMT, low mtDNA content might provide meaningful prognostic value for 
distant metastasis in breast cancer.
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Introduction
Mitochondria play a role in many cellular processes including oxidative phosphorylation, 
redox homeostasis, controlling calcium levels for regulation of signal transduction 
pathways, and the intrinsic apoptotic pathway [1]. The mitochondria contain their own 
genome – mtDNA – encoding their own translational machinery and 13 crucial proteins 
for the oxidative phosphorylation system. Related to energy needs, numerous mtDNA 
molecules may exist in a single cell. This number is not only dependent on the amount of 
mitochondria per cell but also on the number of mtDNA molecules per mitochondrion. 
Broad ranges in mtDNA content have been reported, from a few molecules in embryonic 
and pluripotent stem cells [2, 3] up to several thousands in subcutaneous adipocytes [4] 
or cardiac myocytes [5]. The cell-specific mtDNA content is assumed to be fairly stable 
under physiological conditions but can be altered by stress such as exogenous toxins [6], 
viral infection [7] and by genetic mutations [8]. The effects of changes in mtDNA content 
are illustrated in several mtDNA depletion syndromes [9], which are all characterized by 
impaired energy production. 
Several studies examined mtDNA content in the context of cancer but so far no clear 
picture has emerged. In preclinical models, depletion of mtDNA yielded both increased 
and decreased in vitro tumorigenic phenotypes [10-17]. The in vivo findings using mouse 
xenografts are indecisive as well, as both gain and loss of tumorigenic potential upon 
mtDNA depletion has been reported [16-21]. Additionally, contradictory findings have 
been described for mtDNA content in human tumour specimens compared to their 
healthy counterparts in multiple cancer types (as reviewed in [22, 23]). 
With regard to breast cancer, the impact of the mtDNA content on phenotype, 
prognosis and drug response has been investigated in several studies. Lower mtDNA 
content is observed in approximately 70% of breast cancer specimens when compared 
to their surrounding normal epithelium [24-31]. There are indications that low mtDNA 
content in breast cancer may yield a more aggressive phenotype and altered therapy 
responses. First, depletion of mtDNA in in vitro models affects the mRNA and protein 
expression levels of several genes involved in epithelial-to-mesenchymal transition 
(EMT) [12, 14]. The transition towards the mesenchymal phenotype has been implied 
as an essential mechanism contributing to cancer dissemination [32]. Consequently, 
low mtDNA content as a marker for the mesenchymal phenotype potentially identifies 
tumour aggressiveness. Second, a link between reduced mtDNA content and resistance 
to anti-estrogen regimens has been established in in vitro models [33]. Nevertheless, no 
association between estrogen receptor status and mtDNA content was observed in breast 
tumours [24-29]. Also, reduced mtDNA content was linked to a shift in drug response 
for breast cancer cell lines [17, 24, 34]. An in vitro reduction in mtDNA content revealed 
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increased sensitivity to cisplatin [17] and doxorubicin [24], but also decreased sensitivity 
to vincristine, paclitaxel and – in contrast to a previous study – doxorubicin [34]. In a 
small patient cohort, low mtDNA content was associated with longer disease-free survival 
in patients receiving adjuvant chemotherapy, whereas this was not the case for patients 
not receiving adjuvant treatment [24]. Few additional studies reported on breast cancer 
patient disease free- or overall survival in relation to tumorous mtDNA content [25-27]. 
However, these studies had either relatively small sample sizes or no information about 
treatments administered, the mtDNA content determination methods varied, and results 
were inconclusive. 
Here, we further explore the putative link between mtDNA content and prognostic 
features in breast cancer. In a broad panel of human breast cancer cell lines the link 
between mtDNA content and a mesenchymal phenotype was studied by correlating it with 
expression levels of EMT-related genes and with the intrinsic subtypes of breast cancer [35, 
36]. In a well-defined patient cohort of primary breast tumour specimens [37], tumour 
mtDNA content was examined in relation to expression levels of EMT-related genes, to 
the intrinsic subtypes, as well as to established clinicopathological variables. Primarily, 
in our cohort of primary breast cancer patients with lymph node-negative disease who 
did not receive any (neo)adjuvant systemic therapy, we examined the prognostic value of 
mtDNA content using distant metastasis-free survival as the main endpoint. 
Results
mtDNA content in breast cancer cell lines and primary tumour specimens
In total, we analysed DNA extracts from 42 breast cancer cell lines and 207 primary 
tumour specimens. Multiplex real time quantitative PCR (qPCR) targeting a nuclear-
encoded and a mitochondrial-encoded gene combined with array-based copy number 
changes of the nuclear-encoded gene to correct for sample specific somatic variation at 
the reference locus was used to obtain the mtDNA content in the DNA extracts of these 
samples. Inter-assay variability of the multiplex qPCR assay was monitored using the 
calibration curves taken along in each run (n = 7). Amplification in the calibration curve 
samples was linear between 0.16 and 16 ng DNA per reaction with mean efficiencies 
and standard error of 97.6 ± 4.4% for nuclear encoded HMBS and 91.5 ± 5.2% for 
mitochondrial encoded MT-TL1. Copy number variation of the nuclear encoded HMBS 
gene was observed in 39% of the breast cancer cell lines including 1 with homozygous 
loss, 12 with heterozygous loss and 3 with gain, and in 14% of the primary tumour 
specimens including 20 with heterozygous loss and 10 with gain. Because of a homozygous 
HMBS loss in SUM1315MO2, this cell line was excluded from further analysis. Because 
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of absence of HMBS qPCR signal amplification in three primary tumour specimens, 
these samples were excluded from further analysis as well. The median mtDNA content 
and interquartile ranges (IQR) in the 41 breast cancer cell lines and in the 204 primary 
breast tumour specimens were respectively 489 (IQR 360) and 462 (IQR 294) mtDNA 
molecules per cell.
Table 1 mtDNA content in the intrinsic breast cancer subtypes.
Subtype n (%) mtDNA content (IQR) P 
Breast cancer cell lines Basal 5 (12.5%) 269 (149) 0.1†
ERBB2 7 (17.5%) 620 (521)
Luminal 19 (47.5%) 518 (359)
Normal 9 (22.5%) 489 (142)
Primary breast tumour specimens Basal 65 (31.8%) 454 (287) 0.8†
ERBB2 35 (17.2%) 566 (351)
Luminal A 56 (27.5%) 423 (224)
Luminal B 40 (19.6%) 514 (343)
Normal 8 (3.9%) 377 (286)
Median mtDNA content [number of mtDNA molecules per cell] with interquartile range (IQR) for each group and 
corresponding probabilities (P value) for equal distribution using Kruskal-Wallis one-way analysis of variance (†).
mtDNA content and the mesenchymal characteristics 
In vitro reduction of mtDNA content has been linked to changes in expression of the 
EMT-related genes CDH1 [12, 14], CDH2 [14], ESRP1 [14], FN1 [14], MMP9 [14], 
SNAI1 [14], SNAI2 [14], TGFB1 [12], TGFBR1 [12], TWIST1 [14] and VIM [12, 
14]. To address whether a more mesenchymal phenotype is a physiological characteristic 
linked to low mtDNA content [12, 14], we analysed the relation between mtDNA 
content and the RNA expression levels of genes related to EMT. Expression data for the 
above mentioned genes were available for 40 of the 41 breast cancer cell lines and all 204 
primary breast tumour specimens. Expression data of TGFBR1 was excluded because 
the probe gave expression levels close to background noise. Correlation between gene 
expression levels and mtDNA content did not exceed a correlation coefficient ρ of 0.35, 
and we could not demonstrate statistical significance after correction for multiple testing 
(all P > 0.027, Supplementary Table 1) in the breast cancer cell lines. In our primary 
breast tumour specimens, correlation between mtDNA content and the expression of 
ESRP1 (ρ = 0.25, P < 0.001), SNAI1 (ρ = 0.23, P < 0.001) and TGFB1 (ρ = 0.18, P < 
0.01) was statistically significant after correction for multiple testing (Supplementary 
Table 1). To further explore the link between mtDNA content and EMT, we analysed 
the association between mtDNA content and the intrinsic subtypes of breast cancer, 
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Table 2 Association between clinicopathological variables and mtDNA content.
Variable Group n (%) mtDNA content (IQR) P 
Age at diagnosis ≤ 40 21 (10.3%) 491 (532) 0.21†
> 40-55 88 (43.1%) 433 (273)
> 55-70 64 (31.4%) 466 (259)
> 70 31 (15.2%) 546 (490)
Menopausal status Pre 99 (48.5%) 427 (323) 0.15#
Post 105 (51.5%) 500 (280)
Tumour size ≤ 2 cm 99 (48.5%) 421 (280) 0.019#
> 2 cm 105 (51.5%) 514 (382)
Genomic Grade Index 1 35 (17.2%) 440 (225) 0.028†
2 59 (32.4%) 410 (260)
3 103 (50.5%) 523 (389)
Estrogen receptor status Negative 87 (42.7%) 483 (328) 0.12#
Positive 115 (56.4%) 424 (290) 
Progesterone receptor status Negative 97 (47.5%) 480 (335) 0.073#
Positive 96 (47.1%) 413 (281)
ERBB2 amplification Negative 169 (82.8%) 454 (287) 0.46#
Positive 29 (14.2%) 463 (385) 
Number of patients and corresponding median mtDNA content [number of mtDNA molecules per cell] with 
interquartile range (IQR) for each group and corresponding probabilities (P value) for either equal distribution using 
Mann-Whitney U test (#) or Kruskal-Wallis one-way analysis of variance (†). Due to missing values the numbers of 
samples per variable do not always add up to 204.
which have been assigned with epithelial or mesenchymal characteristics [36, 38, 39]. 
Comparisons between the intrinsic subtypes for both the breast cancer cell lines as well 
as the primary tumour specimens did not show differences in mtDNA content among 
the subtypes (P > 0.05) (Table 1).
Association of tumour mtDNA content with established prognostic clinicopathologi-
cal variables
In our patient cohort, we analysed tumour mtDNA content in relation to patient age at 
diagnosis, menopausal status, tumour size, histological grade, estrogen receptor status, 
progesterone receptor status and ERBB2 amplification (Table 2). Because the currently 
used conventional histological grade (modified Bloom-Richardson) was not available for 
nearly 25% of our cohort – samples originated from multiple hospitals and from time 
periods when histological grading according to Bloom-Richardson was not common – 
we included a molecular grading system shown to be equivalent, the qRT-PCR genomic 
grade index (GGI) [40]. There were no statistically significant associations between the 
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tumour mtDNA content and age at diagnosis, menopausal status, estrogen receptor 
status, progesterone receptor status or ERBB2 amplification status (P > 0.05). However, 
tumours smaller than 2 cm had statistically significant lower mtDNA content (median 421 
mtDNA molecules per cell) compared to tumours larger than 2 cm (median 514 mtDNA 
molecules per cell) (Mann-Whitney P = 0.019). In addition, tumour mtDNA content 
varied between the GGI groups (Kruskal-Wallis P = 0.028), with the highest mtDNA 
content in the GGI group representing poorly differentiated high grade 3 tumours 
(median 523 mtDNA molecules per cell). However, we did not observe a significant trend 
in tumour mtDNA content across the GGI groups (Cuzick’s test for trend P = 0.066).
Distant metastasis-free survival and primary tumour mtDNA content 
Finally, we studied in our patient cohort the prognostic value of tumour mtDNA content 
with respect to the length of distant metastasis-free survival. All included breast cancer 
patients presented as lymph node-negative and did not receive any (neo)adjuvant systemic 
treatment. The distribution of mtDNA content in our cohort was skewed and could 
not be normalized by transformation (Skewness and Kurtosis test P < 0.05). To assess 
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Figure 1 Kaplan-Meier curve showing probability of distant metastasis-free survival as a function of tumour 
mtDNA content of 204 patients (60 events). Numbers of patients at risk at 24 month time intervals are indicated.
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tumour mtDNA content for the length of metastasis-free survival in our exploratory 
analysis, we first divided the cohort based on mtDNA content quartiles in four groups 
(Q1 – Q4). Because the patients within the first quarter Q1 presented a different rate 
Table 3 Univariate and multivariable analyses for distant metastasis-free survival in lymph node-negative 
patients who did not receive any (neo)adjuvant systemic therapy.
Univariate Multivariable
Variable Group n (%)
Hazard ratio 
(95% CI) P
Hazard ratio 
(95% CI) P
Age ≤ 40 19 (10.2%) 1 1
> 40-55 81 (43.5%) 0.40
(0.19-0.88)
0.022 0.34
(0.15-0.76)
0.009
> 55-70 59 (31.7%) 0.42
(0.19-0.95)
0.038 0.27
(0.08-0.92)
0.037
> 70 27 (14.5%) 0.39
(0.14-1.05)
0.062 0.25
(0.06-0.97)
0.045
Menopausal status Pre 91 (48.9%) 1 1
Post 95 (51.1%) 0.94
(0.55-1.61)
0.8 1.55
(0.54-4.44)
0.4
Tumour size ≤ 2 cm 87 (46.8%) 1 1
> 2 cm 99 (53.2%) 1.06
(0.62-1.83)
0.8 0.92
(0.54-1.64)
0.8
Genomic Grade Index 1 33 (17.7%) 1 1
2 56 (30.1%) 1.62
(0.63-4.18)
0.3 1.43
(0.54-3.76)
0.5
3 97 (52.2%) 2.65
(1.03-6.83)
0.043 2.52
(0.95-6.66)
0.063
Progesterone receptor status Negative 96 (51.6%) 1 1
Positive 90 (48.4%) 0.74
(0.38-1.45)
0.4 0.88
(0.43-1.81)
0.7
ERBB2 amplification Negative 159 (85.5%) 1 1
Positive 27 (14.5%) 1.39
(0.70-2.78)
0.3 1.45
(0.70-2.97)
0.3
mtDNA content ≤350 48 (25.8%) 1 1
>350 138 (74.2%) 0.50
(0.29-0.87)
0.015 0.54
(0.30-0.97)
0.038
Number of patients and corresponding hazard ratio for distant metastasis-free survival with its 95% confidence intervals 
(CI) and corresponding probabilities for equal risk (P value) for each group. Analyses were stratified for estrogen receptor 
status and limited to the 186 patients (54 events) with no missing values.
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of metastasis-free survival compared to the other quarters (Q2 – Q4) (Supplementary 
Figure 1), we divided the cohort in two patient groups of low mtDNA content (Q1 
with mtDNA content ≤350 mtDNA molecules per cell) versus the rest (Q2 – Q4 with 
mtDNA content >350 mtDNA molecules per cell). To visualize the length of metastasis-
free survival as a function of the levels of tumour mtDNA content (Q1 vs Q2 – Q4) we 
used the Kaplan-Meier survival analysis method (Figure 1). Patients in the low mtDNA 
content group Q1 showed a higher metastasis probability (log-rank P = 0.047). In 
univariate and multivariable Cox regression analysis including only the 186 patients with 
no missing values (Table 3), patients in the Q2 – Q4 mtDNA content group showed a 
longer distant metastasis-free survival compared to patients in the low mtDNA tumour 
content group (univariate: HR 0.50, 95% CI: 0.29-0.87, P = 0.015; multivariable: HR 
0.54, 95% CI: 0.30-0.97, P = 0.038).
Discussion
Many contradictions about the physiological consequences of reduced mtDNA content 
exist in the literature. A critical reduction in mtDNA content compromises mitochondrial 
functioning with downstream effects. Subsequent changes in cellular processes such as 
aerobic respiration, calcium homeostasis or the intrinsic apoptotic pathway could in turn 
impact tumorigenic properties. Previous findings have pointed towards a link between 
low mtDNA content and breast cancer aggressiveness but the exact association remains 
uncertain. Here, to elucidate its potential as a prognostic marker, the putative relation 
between tumour mtDNA content and mesenchymal features or distant metastasis-free 
survival in breast cancer was explored. Using a quantitative PCR approach, the mtDNA 
content of 41 breast cancer cell lines and 204 primary breast tumour specimens was 
obtained. A correction for copy number variations of the nuclear-encoded reference locus 
(HMBS) minimized bias due to tumour-related genomic aberrations in the obtained 
number of mtDNA molecules per cell. Furthermore, the quantitative mtDNA target 
in our current assay lies outside of the common deletion region [41] and therefore it is 
likely that we measure a mixture of functional and dysfunctional mtDNA molecules. 
Previous in vitro studies reported induction of EMT and stem-cell features upon 
depletion of mtDNA [12, 14, 19]. In the panel of breast cancer cell lines – homologous 
cell populations – no relation between mtDNA content and expression levels of genes 
involved in EMT could be demonstrated. In the cohort of primary breast tumour 
specimens – more heterogeneous cell populations – we find a positive but weak 
correlation (ρ ≤ 0.25) between mtDNA content and ESRP1, SNAI1 and TGFB1. In in 
vitro studies, a reduction in mtDNA content resulted in decreased ESRP1 protein levels 
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but, contradictory to our findings, increased SNAI1 mRNA expression or TGFB protein 
expression. In addition, we could not demonstrate a difference in mtDNA content 
between the intrinsic subtypes in our cell line panel nor in the cohort of primary breast 
specimens. Mesenchymal properties have been attributed to the basal and normal-like 
subtypes, whereas the luminal subtypes are generally epithelial [36, 38, 39]. Accordingly, 
the evaluated EMT-related genes were commonly highly statistically significant related 
to each other and differentially expressed between the intrinsic subtypes within our cell 
line panel and the cohort of primary breast tumour specimens (Supplementary Table 
1). Apart from a true lack of association between mtDNA and EMT-features in breast 
cancer, there are several other reasons which may explain the absence of this association 
in our data set. To understand the physiological effects of mtDNA content, previous 
studies suggesting a relation between mtDNA and EMT often used cell lines artificially 
depleted of mtDNA, termed rho0 clones [42]. The endogenous mtDNA content of the 
cell lines and primary tumour specimens in our study is a few hundred molecules per 
cell, which is still orders of magnitude higher than of the rho0 clones. Since the extent of 
mtDNA reduction is of importance in gaining tumorigenic properties, as demonstrated 
in glioblastoma models [43], perhaps the mtDNA content in our data set is not at the 
critically low level necessary to induce a transition towards a mesenchymal phenotype. 
Alternatively, low mtDNA levels may be important during the process of EMT, but might 
be restored to normal after the transition is accomplished. Despite the unknown exact 
reason, we conclude that in our data set mtDNA content is not related to the molecular 
features connected to a mesenchymal-like phenotype. 
To address a possible relation between mtDNA content and aggressive behaviour in 
vivo, we analysed primary breast tumour mtDNA content and prognosis in a cohort of 204 
breast cancer patients. Notably, the mtDNA content in our primary tumour specimens 
is only an estimate, representing not only a heterogeneous tumour cell population but 
also non-neoplastic cells incorporated in the tumour specimen. However, because no 
evidence for a relation between mtDNA content and tumour infiltrating lymphocytes 
[44] was observed (Supplementary Table 2) and stromal content was minimized 
(Materials and Methods), we estimate the contribution of non-neoplastic cells to the 
final mtDNA content to be minimal. A few associations between mtDNA content 
and clinicopathological variables have been reported in previous studies, albeit never 
consistently [24-29]. These studies included either a low number of study participants or 
heterogeneous groups regarding treatment regimen or disease stage, making interpretation 
difficult. In this study, we included a population of lymph node-negative primary breast 
cancer patients who did not receive any (neo)adjuvant systemic treatment. In this 
patient group, lower mtDNA content was observed in tumours smaller than 2 cm across 
compared to tumours larger than 2 cm across. Previous studies could not demonstrate 
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such a difference [27, 28] or reported lower mtDNA content in tumours over 5 cm across 
compared to smaller tumours [26]. Larger tumours presumably underwent more cell 
divisions potentially resulting in additional replication-induced mtDNA damage [45], 
which in turn might require additional compensatory mtDNA molecules to maintain 
proper mitochondrial functioning. It is also plausible that a hypoxic environment in larger 
tumours reduces mtDNA content as suggested previously [26]. However, in our primary 
tumour cohort no relation was observed between mtDNA content and hypoxia-related 
gene expression [46] as surrogate for the hypoxic state of the tumour (Supplementary 
Table 2). In addition, our results show a relation between mtDNA content and GGI, 
a gene expression-based identifier of the histological grade of tumours [40], with the 
highest grade representing poorly differentiated tumours showing higher mtDNA content. 
However, we could not demonstrate a conventional significant trend between mtDNA 
content and GGI. The relation between mtDNA content and histological grade has been 
reported before [26]. An increase in mtDNA content occurs in early S-phase of the cell 
cycle [47], and we attribute the relation between grade 3 tumours and higher mtDNA 
content to the high-proliferative nature of these higher grade tumours. Nevertheless, we 
note that the median difference in mtDNA content for both tumour size and GGI is 
only 20%, making a substantial biological consequence of these associations less likely. 
Importantly, our cohort is highly suitable to study the prognostic value of mtDNA 
content for distant metastasis-free survival because all included patients presented with 
lymph node-negative disease and did not receive any (neo)adjuvant systemic treatment. 
The size of our cohort did not allow for separate analyses for estrogen receptor-negative 
and -positive tumours, which show different proportionality over time (test of proportional 
hazards assumption P = 0.016). Therefore, stratification for estrogen receptor status was 
applied in all proportional hazard analyses. After adjustment for established prognostic 
clinicopathological variables, we observed a prognostic effect for mtDNA content. The 
patients with the 25% lowest mtDNA content (≤350 mtDNA molecules per cell) showed 
a significant unfavourable prognosis with shorter time to metastasis compared to patients 
with higher mtDNA content. One previous study reported on low tumour mtDNA 
content corresponding to a higher risk of death [26]. However in that study, no clear 
information was provided about treatments administered, disease stage at diagnosis and 
other clinical variables included in their statistical analysis. This renders interpretation 
and comparison with that previous study difficult. Interestingly, low mtDNA content 
predicted for a favourable response to anthracycline treatment in a small patient cohort 
[24]. It is plausible that cells with low mtDNA content are susceptible to such regimen, 
because damage of mtDNA in cells containing fewer mtDNA molecules can affect 
mitochondrial functionality more effectively. In our cohort we could study the prognostic 
value of mtDNA content independent of treatment regimen. 
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To conclude, we demonstrate a link between particularly low mtDNA content and 
metastatic potential in breast cancer, which appears to be independent of the mesenchymal 
phenotype. Low primary tumour mtDNA content potentially identifies patients with 
unfavourable prognosis but at the same time might predict therapeutic efficacy of DNA-
damaging treatment regimen in this group. Larger cohorts of uniformly treated patients 
are necessary to validate these results and to further unravel the clinical relevance of 
mtDNA content determination in cancer.
Materials and methods
Study cohort and sampling
We employed a panel of 42 breast cancer cell lines (including BT20, BT474, BT483, 
BT549, CAMA1, DU4475, EVSAT, HCC1937, Hs578T, MCF7, MDAMB134VI, 
MDAMB157, MDAMB175VII, MDAMB231, MDAMB330, MDAMB361, 
MDAMB415, MDAMB435s, MDAMB436, MDAMB453, MDAMB468, MPE600, 
OCUBF, OCUBM, SKBR3, SKBR5, SKBR7, SUM102PT, SUM1315MO2, 
SUM149PT, SUM159PT, SUM185PE, SUM190PT, SUM225CWN, SUM229PE, 
SUM44PE, SUM52PE, T47D, UACC812, UACC893, ZR751 and ZR7530 [36, 44]). In 
addition, DNA extracts from fresh frozen primary breast tumour specimens from an earlier 
study [37] were selected from our bio-bank at the Erasmus MC. The study was approved 
by the medical ethics committee of the Erasmus MC (MEC 02.953) and conducted in 
accordance to the code of conduct of Federation of Medical Scientific Societies in the 
Netherlands. Whenever possible, we adhered to the Reporting Recommendations for 
Tumour Marker Prognostic Studies (REMARK) [48]. Patient selection criteria have been 
described before [49] and include lymph node-negative primary breast cancer with local 
treatment but no systemic (neo)adjuvant therapies. Our selection (Supplementary Figure 
2) was based on availability of genotypic data and gene expression data from the primary 
tumours (n = 337) and availability of uniformly extracted DNA (see below) (n = 250). 
Next, specimens with a tumour cell percentage below 50% were excluded to minimize 
skewed values due to stromal cell contamination (n = 38). In addition, five patient samples 
were ineligible in retrospect and excluded. Thus, mtDNA content was examined in a total 
of 207 patients. Patients’ follow-up involved examinations every 3 months for the first 
two 2 years, every 6 months for years 3–5, and every 12 months from year 5 onwards. 
Estrogen receptor and progesterone receptor status were determined as described before 
[50]. Evaluation of ERBB2 amplification via RNA expression levels and the qRT-PCR 
Genomic Grade Index were determined as described before respectively [51] and [40]. 
Chapter_2_Marjolein.indd   26 21-12-2018   15:34:23
C
ha
pt
er
 2
mtDNA content as a prognostic marker in primary breast cancer   |   27 
DNA extraction
DNA was extracted from cultured cell lines using the DNeasy Blood & Tissue kit (Qiagen, 
Venlo, the Netherlands) according the suppliers’ protocol. We selected the DNA which 
was previously extracted from cryostat sections of the primary tumour tissues based 
on uniformity in extraction procedure (QIAamp DNA mini kit (Qiagen) as described 
before [37]). DNA extracts were quantified using the Qubit dsDNA HS assay kit 
(Life Technologies, Carlsbad, United States of America) and all samples were diluted to a 
concentration of 0.2 ng/µL DNA prior to mtDNA content analysis.
Copy number analysis
Copy number variation of the nuclear encoded HMBS gene – which served as a reference 
to obtain mtDNA content – was obtained from our previously described microarray data 
(Gene Expression Omnibus database accession numbers GSE10099 [37] and GSE41308 
[52]). The breast cancer cell lines were genotyped on the Genome Wide Human SNP Array 
6.0 (Affymetrix, Santa Clara, United States of America), the primary tumour specimens 
on the GeneChip Human Mapping 100K SNP Array (Affymetrix).
mtDNA content 
Mitochondrial DNA content was determined in duplicate runs using a multiplex quantitative 
PCR targeting the nuclear HMBS gene (chr11q23.2-qter) and the mitochondrial MT-
TL1 (chrMT 3212–3319). Primers targeting the nuclear encoded HMBS gene (forward 
5’-TGAGGCGGATGCAGATAC-3’ and reverse 5’- CCCACCCACGGTAGTAATTC-3’ 
(Life technologies)) yielded a 201 bp amplicon quantitatively detected using a 
CY5 labelled probe (5’-[CY5]TATCAGCCAAGCCTCCGAAC[BHQ2]-3’ 
(Sigma Aldrich, St. Louis, United States of America)). Primers targeting the 
mitochondrial encoded MT-TL1 (forward 5’-CACCCAAGAACAGGGTTTGT-3’ 
and reverse 5’-TGGCCATGGGTATGTTGTTA-3’ (Life Technologies)) yielded a 
108 bp amplicon quantitatively detected using a HEX labelled probe (5’-[HEX]
TTACCGGGCTCTGCCATCT[BHQ1]-3’, (Sigma Aldrich)) [53]. Reactions included 
1x Absolute QPCR Mix containing SYBR Green and ROX (AB-1163 Life Technologies) 
in the presence of 100 nM mtDNA primers, 360 nM nDNA primers and 100 nM 
probes. The 45-cycle PCR was carried out at a 62°C annealing temperature and probe 
fluorescence was monitored using ROX, HEX, CY5 and FAM filters on Mx3000P or 
Mx3005P qPCR systems (Agilent Technologies, Waldbronn, Germany). Quantification cycle 
values (Cq [dRN]) were obtained using the adaptive baseline approach (MxPro v4.10) up 
to cycle 35 with fixed fluorescence thresholds at 0.004 dRn. Performance of singleplex 
PCR and multiplex PCR runs was comparable (Supplementary Table 3). Performance 
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of the assay at variable ratios of artificial HMBS (289 bp linear: ACA GAC GGG GTC 
CTT TCA TTC GAG GCT GGG CTG AGG CGG ATG CAG ATA CGG CCC CTT 
TGG GAA GAC ACG TTC CAC TTT TGA TTC ATA GGA GAG AGT ATC AGC 
CAA GCC TCC GAA CTG CAC ACA AAC GTC TTA GAA GTG CGC CTT CTT 
TTT GTG TTA TAG TGG TCT CCC AGC CAC AGC CAA CGC TCC AAG TCC 
CCA GCT GTG ACA CAC CTA CTG AAT TAC TAC CGT GGG TGG GAG GCC 
GCC GTG GGC CTT TCC ATT ACG AGC CTG CTT GCC GAG CCC TGG 
GCT TGT GCA C ) and artificial MT-TL1 (180 bp cloned in circular 2374 bp pMA-T 
vector: TAT CAT CTC AAC TTA GTA TTA TAC CCA CAC CCA CCC AAG AAC 
AGG GTT TGT TAA GAT GGC AGA GCC CGG TAA TCG CAT AAA ACT TAA 
AAC TTT ACA GTC AGA GGT TCA ATT CCT CTT CTT AAC AAC ATA CCC 
ATG GCC AAC CTC CTA CTC CTC ATT GTA CCC ATT CTA ATC GCA ATG 
GCA) was linear (Supplementary Table 4). DNA input of the breast cancer cell lines 
and the primary breast tumour specimens was standardized for 1 ng DNA per reaction. 
A calibration curve containing a pool of DNA isolates from independent fresh frozen 
tumours was taken along as internal control to monitor inter assay variation. Obtained 
Cq values were used to calculate the ratio of mitochondrial DNA opposed to nuclear 
DNA by the relative quantitation method (2^∆Cq [54]). Multiplying this ratio by the 
copy number of HMBS (obtained as described above) resulted in the number of mtDNA 
molecules per cell as mtDNA content. 
Gene expression analysis
Gene expression data of the cell lines was obtained from our previously described triplicate 
microarray data (Gene Expression Omnibus database accession number GSE41313 [52]) 
on the Human Genome HT_HG-U133_Plus_PM GeneChip 96-well arrays (Affymetrix). 
Data of all breast cancer cell lines were available with the exception of SUM225CWN. 
Gene expression data of the primary breast tumour specimens was obtained from our 
previously described microarray data (Gene Expression Omnibus database accession 
number GSE2034 [50] and GSE5327 [55]) on the Human Genome HG-U133a 
GeneChip 96-well arrays (Affymetrix). Subtype classification was based on expression of 
the intrinsic gene set defined by Perou et al [56]. Cell line DU4475 could not be classified 
to a subtype group and was therefore excluded from the intrinsic subtype analysis. For 
individual genes, levels based on log2 transformed distances to the geometric mean for 
each probe set were obtained for probe IDs 201131_s_at (CDH1), 203440_at (CDH2), 
219121_s_at (ESRP1), 210495_x_at (FN1), 203936_s_at (MMP9), 219480_at (SNAI1), 
213139_at (SNAI2), 203085_s_at (TGFB1), 213943_at (TWIST1) and 201426_s_at 
(VIM). The tumour infiltrating lymphocyte classification as low TIL and high TIL was 
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based on the immune signature probe-set by Massink et al [44]. Classification as low 
hypoxia response and high hypoxia response was based on the expression of the hypoxia-
related gene signature as described before by Chi et al [57].
Statistical analyses
All analyses included the average mtDNA content obtained from the duplicate analysis 
for each individual sample. Data distribution was tested using Skewness-Kurtosis tests for 
normality. Numerical correlations between RNA expression levels and mtDNA content 
were investigated using the Spearman rank correlation and corrected for multiple testing 
using the false discovery rate controlling procedure [58]. Categorical comparisons of 
the intrinsic subtypes or grouped clinical variables and mtDNA content were employed 
using either Mann-Whitney U-tests (two groups) or Kruskal-Wallis one-way analysis 
of variance (multiple groups). When appropriate, we performed Cuzick’s test for trend 
across ordered categorical variables. Kaplan-Meier survival plots and log-rank tests were 
used to assess the differences in time to distant metastasis between mtDNA content 
groups. Proportional hazard analyses for distant metastasis-free survival were performed 
using Cox proportional-hazards regression methods. We stratified for estrogen receptor 
status and censored for 10 years clinical follow-up (most patients are redirected to their 
general practitioner at that point in time) to maintain proportionality (test of proportional 
hazards assumption using the Schoenfeld residuals P > 0.05). Univariate analysis was 
done on the individual clinicopathological variables, multivariable analysis included all 
clinicopathological variables and mtDNA content. All statistical tests were two-sided, and 
P values smaller than 0.05 were considered as statistically significant. Clinical variables 
were statistically analysed in Stata version 13.1 (StataCorp LP, College Station, United 
States of America). Other analyses were performed using Spotfire 7.0.0 (TIBCO, Palo 
Alto, United States of America). 
Supplementary data
Supplementary data for this article are available online at Oncotarget 
(http://www.oncotarget.com). 
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In this study, we aimed to explore whether low levels of mitochondrial 
DNA (mtDNA) content in the primary tumour could predict better 
outcome for breast cancer patients receiving anthracycline-based therapies. 
We hypothesized that tumour cells with low mtDNA content are more 
susceptible to mitochondrial damage induced by anthracyclines, and thus 
are more susceptible to anthracycline treatment. We measured mtDNA 
content by a quantitative PCR approach in 295 primary breast tumour 
specimens originating from two well-defined cohorts: 174 lymph node-
positive patients who received adjuvant chemotherapy and 121 patients 
with advanced disease who received chemotherapy as first-line palliative 
treatment. The chemotherapy regimens given were either anthracycline-
based (FAC/FEC) or methotrexate-based (CMF). In both the adjuvant 
and advanced setting, we observed increased benefit for patients with low 
mtDNA content in their primary tumour, but only when treated with 
FAC/FEC. In multivariable Cox regression analysis for respectively distant 
metastasis-free survival and progression-free survival, the hazard ratio for 
the FAC/FEC treated mtDNA low group in the adjuvant setting was 0.46 
(95% confidence interval (CI) 0.24-0.89, P = 0.020) and in the advanced 
setting 0.49 (95% CI 0.27-0.90, P = 0.022) compared to the FAC/FEC 
treated mtDNA high group. We did not observe these associations in the 
patients treated with CMF. In our two study cohorts, breast cancer patients 
with low mtDNA content in their primary tumour have better outcome 
from anthracycline-containing chemotherapy. The frequently observed 
decrease in mtDNA content in primary breast tumours may be exploited 
by guiding chemotherapeutic regimen decision-making.
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Introduction
Mitochondria are cellular organelles involved in multiple cellular processes, but best 
known for efficient ATP generation through oxidative phosphorylation. Mitochondria 
contain their own genomic entity termed mitochondrial DNA (mtDNA) encoding 
proteins essential for the oxidative phosphorylation system, and ribosomal RNAs and 
transfer RNAs functioning in the mitochondrial translation apparatus. Multiple mtDNA 
molecules can reside within a single mitochondrion and multiple mitochondria can 
reside within a single cell [1-3], making the total number of mtDNA molecules per cell 
(mtDNA content) variable. In general, the mtDNA content per cell is dependent on the 
tissue’s energy demands [4]. 
In tumours, the mtDNA content is often changed compared to non-neoplastic 
adjacent tissue [5]. For breast cancer specifically, there is a decline in mtDNA content: 
approxi mately three-quarter of primary breast tumour specimens have a decreased mtDNA 
content when compared to their nearby normal mammary epithelium [5-13]. We recently 
reported an association of worse 10-year distant metastasis-free survival for node-negative 
primary breast cancer patients who did not receive any (neo-)adjuvant systemic treatment 
with low mtDNA content in their primary tumours, showing the impact of mtDNA 
content on tumour aggressiveness [14]. However, how these findings influence response 
to systemic therapy in breast cancer patients is unknown. 
The anthracyclines doxorubicin and epirubicin are currently the most frequently used 
agents in breast cancer treatment. However, despite multiple efforts to find predictors for 
anthracycline sensitivity, up to date no evidence-based biomarkers are applied clinically 
in neither early nor metastatic breast cancer. Several markers have been postulated to 
predict benefit from adjuvant anthracycline-based chemotherapy, including TOP2A gene 
amplification or protein expression, ERBB2 (HER2) amplification, TOP2A and ERBB2 
co-amplification, chromosome 17 polysomy (CEP17), TIMP1 protein expression, FOXP3 
protein expression or TP53 protein expression, but none of them have been recommended 
for clinical use [15]. Anthracyclines induce severe oxidative stress [16] and are known 
to accumulate in mitochondria, where they can intercalate mtDNA [17] and damage 
mtDNA [18]. In in vitro model systems, reduced mtDNA content increases sensitivity 
to doxorubicin [13, 19]. We hypothesize that tumour cells with low mtDNA content are 
more susceptible to mitochondrial damage induced by anthracyclines than cells with high 
mtDNA content, and thus are more susceptible to anthracycline treatment. Before the 
introduction of anthracycline-based chemotherapy, methotrexate-based regimens were 
most often applied in breast cancer [20]. The working mechanism of this compound is 
not directly at the DNA level, but it is an anti-metabolite, ultimately leading to inhibition 
of DNA synthesis. Since methotrexate induces only low levels of oxidative stress [16], we 
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do not expect differences in its efficacy in tumour cells with either low or high mtDNA 
content.
In this retrospective study, we aimed to explore if low levels of mtDNA content in 
the primary tumour can predict better outcome for patients receiving anthracycline-based 
therapies, but not for patients receiving methotrexate-based therapies. 
Results
mtDNA content in primary breast tumours
In total, we analysed primary tumour DNA from 295 breast cancer patients derived 
from two cohorts: node-positive patients receiving either FAC/FEC or CMF adjuvant 
chemotherapy treatment (adjuvant cohort), and patients receiving either FAC/FEC or 
CMF first-line palliative chemotherapy treatment for their recurrent disease (advanced 
cohort). We obtained mtDNA content in these DNA extracts by multiplex real time 
quantitative PCR (qPCR) targeting a nuclear-encoded and a mitochondrial-encoded 
gene, and included a correction for sample-specific somatic copy number variation of 
the nuclear-encoded gene as obtained by qPCR. 
In the adjuvant cohort of 174 patients, the median mtDNA content was 758 mtDNA 
molecules per cell (interquartile range (IQR) 506), in the advanced cohort of 121 patients 
the median mtDNA content was 694 mtDNA molecules per cell (IQR 402). Because 
mtDNA content was not normally distributed within both cohorts (both Shapiro-Wilk P 
< 0.001), we dichotomized each cohort based on the median mtDNA content, resulting 
in mtDNA low and mtDNA high groups. No differences were observed with respect 
to the chemotherapeutic regimens given between the mtDNA low and mtDNA high 
groups in both the adjuvant and the advanced cohorts (Fisher’s exact P = 0.4 and P = 
0.5, respectively) (Supplementary Table 5).
mtDNA content in association with clinicopathological variables
Next, we evaluated the association between mtDNA content and clinicopathological 
variables. In the adjuvant cohort, no statistically significant associations were observed 
between mtDNA content and age at diagnosis, menopausal status at diagnosis, nodal 
status (number of nodes positive), primary tumour size (T-stage), primary tumour 
Genomic Grade Index (GGI), estrogen receptor (ER), progesterone receptor (PR) and 
HER2 status (Fisher’s exact P > 0.05) (Table 1). In the advanced cohort, no statistically 
significant associations were observed between mtDNA content and age at recurrence, 
menopausal status at recurrence, nodal status, primary tumour size, primary tumour 
GGI, PR status, HER2 status, dominant relapse site, disease-free interval and treatment 
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with consolidation therapy (Fisher’s exact P > 0.05) (Table 2), but ER-positive primary 
tumours were more prevalent in the mtDNA low group (Fisher’s exact P = 0.018).
mtDNA content in association with patient outcome
In the adjuvant cohort, patients treated with adjuvant FAC/FEC showed a significant longer 
distant metastasis-free survival (DMFS) when their primary tumour had low mtDNA 
content compared to patients with a high tumour mtDNA content (Log Rank P = 0.015) 
(Figure 1A). The median length of DMFS in the mtDNA low and mtDNA high groups 
were respectively 85 months (95% CI 40-NA) and 34 months (95% CI 26-69). The 
Table 1 Association between mtDNA content and clinicopathological variables of node-positive patients 
receiving either FAC/FEC or CMF adjuvant chemotherapy treatment (adjuvant cohort).
Characteristic
mtDNA low 
n (%)
mtDNA high 
n (%) P
Age (at diagnosis)
≤ 40
> 40-50
> 50
27 (31.0%)
43 (49.4%)
17 (19.5%)
19 (21.8%)
53 (60.9%)
15 (17.2%)
0.3
Menopausal status (at diagnosis)
Pre
Post
80 (92.0%)
7 (8.0%)
74 (85.1%)
13 (14.9%)
0.2
Tumour size
T1 (≤ 2 cm)
T2 (2-5 cm)
T3/4 (> 5 cm)
unknown
24 (29.3%)
43 (52.4%)
15 (18.3%)
5
13 (15.3%)
54 (63.5%)
18 (21.2%)
2
0.1
Nodal status
1-3
> 3
53 (60.9%)
34 (39.1%)
47 (54%)
40 (46%)
0.4
Grade (GGI)
1
2
3
unknown
15 (19.7%)
27 (35.5%)
34 (44.7%)
11
11 (15.7%)
32 (45.7%)
27 (38.6%)
17
0.5
ER status
Negative
Positive
24 (27.6%)
63 (72.4%)
24 (27.6%)
63 (72.4%)
1
PR status
Negative
Positive
unknown
24 (29.6%)
57 (70.4%)
6
27 (33.3%)
54 (66.7%)
6
0.7
HER2 status
Balanced
Amplified
unknown
64 (82.1%)
14 (17.9%)
9
59 (83.1%)
12 (16.9%)
16
1
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Figure 1 Kaplan-Meier survival curves as a function of mtDNA content for DMFS in patients receiving FAC/
FEC (A) or CMF (B) adjuvant chemotherapy, and for PFS in patients receiving FAC/FEC (C) or CMF (D) first-line 
chemotherapy for their recurrent disease.
Table 2 Association between mtDNA content and clinicopathological of patients receiving either FAC/FEC or 
CMF first-line chemotherapy treatment for their recurrent disease (advanced cohort).
Characteristic
mtDNA low 
n (%)
mtDNA high 
n (%) P
Age (at recurrence)
≤ 45
> 45-55
> 55 
14 (23.3%)
25 (41.7%)
21 (35.0%)
20 (32.8%)
15 (24.6%)
26 (42.6%)
0.1
Menopausal status  (at recurrence)
Pre
Post
30 (50.0%)
30 (50.0%)
31 (50.8%)
30 (49.2%)
1
Tumour size
T1 (≤ 2 cm)
T2 (2-5 cm)
T3/4 (> 5 cm)
unknown
17 (28.8%)
32 (54.2%)
10 (16.9%)
1
17 (28.3%)
30 (50.0%)
13 (21.7%)
1
0.8
Nodal status
0
1-3
> 3
17 (28.3%)
15 (25.0%)
28 (46.7%)
25 (41.0%)
13 (21.3%)
23 (37.7%)
0.3
Grade (GGI)
1
2
3
unknown
8 (15.1%)
14 (26.4%)
31 (58.5%)
7
5 (8.5%)
22 (37.3%)
32 (54.2%)
2
0.3
ER status
Negative
Positive
26 (43.3%)
34 (56.7%)
40 (65.6%)
21 (34.4%)
0.018
PR status
Negative
Positive
38 (63.3%)
22 (36.7%)
41 (67.2%)
20 (32.8%)
0.7
HER2 status
Balanced
Amplified
unknown
38 (71.7%)
15 (28.3%)
7
46 (76.7%)
14 (23.3%)
1
0.7
Dominant relapse site
Soft tissue
Bone
Visceral
5 (8.3%)
8 (13.3%)
47 (78.3%)
6 (9.8%)
11 (18.0%)
44 (72.1%)
0.8
Disease-free interval
≤ 1 year
> 1-3 years
> 3 years
19 (31.7%)
29 (48.3%)
12 (20.0%)
26 (42.6%)
28 (45.9%)
7 (11.5%)
0.3
Hormonal consolidation therapy
No
Yes
unknown
44 (74.6%)
15 (25.4%)
1
47 (77.0%)
14 (23.0%)
0.8
Chapter_3_Marjolein.indd   40 22-12-2018   11:56:29
C
ha
pt
er
 3
mtDNA content as a predictive marker in breast cancer   |   41 
+
+
+
+ +
+
+
+
++
+
+
+
+
+
+
+
+
+ +
++
+
++
++
+
+
++
+
L
o
g 
R
an
k 
P
 =
 0
.0
12
0.
00
0.
25
0.
50
0.
75
1.
00
0
12
24
36
48
60
72
84
96
10
8
12
0
T
im
e 
[m
o
n
th
s]
Survival probability (DMFS)
m
tD
N
A
 h
ig
h
m
tD
N
A
 lo
w
A
dj
uv
an
t 
FA
C
/F
E
C
 c
h
em
o
th
er
ap
y
57
52
37
26
24
19
13
10
10
8
5
62
61
52
40
36
36
31
22
17
17
14
m
tD
N
A
 lo
w
m
tD
N
A
 h
ig
h
0
12
24
36
48
60
72
84
96
10
8
12
0
T
im
e 
[m
o
n
th
s]
N
um
b
er
 a
t 
ri
sk
A
+
+
+
+
+
+
+
+
+
+
+
L
o
g 
R
an
k 
P
 =
 0
.7
0.
00
0.
25
0.
50
0.
75
1.
00
0
12
24
36
48
60
72
84
96
10
8
12
0
T
im
e 
[m
o
n
th
s]
Survival probability (DMFS)
   
   
m
tD
N
A
 h
ig
h
m
tD
N
A
 lo
w
A
dj
uv
an
t 
C
M
F
 c
h
em
o
th
er
ap
y
31
26
19
18
16
12
10
9
9
7
6
25
22
18
16
12
9
9
9
8
6
6
m
tD
N
A
 lo
w
m
tD
N
A
 h
ig
h
0
12
24
36
48
60
72
84
96
10
8
12
0
T
im
e 
[m
o
n
th
s]
N
um
b
er
 a
t 
ri
sk
B
+
+
+
+
P
et
o
 P
 =
 0
.0
22
0.
00
0.
25
0.
50
0.
75
1.
00
0
3
6
9
12
15
18
T
im
e 
[m
o
n
th
s]
Survival probability (PFS)
m
tD
N
A
 h
ig
h
 
m
tD
N
A
 lo
w
F
ir
st
−
lin
e 
FA
C
/F
E
C
 c
h
em
o
th
er
ap
y
41
25
20
14
8
6
5
36
30
23
18
14
12
7
m
tD
N
A
 lo
w
m
tD
N
A
 h
ig
h
0
3
6
9
12
15
18
T
im
e 
[m
o
n
th
s]
N
um
b
er
 a
t 
ri
sk
C
++
P
et
o
 P
 =
 0
.3
0.
00
0.
25
0.
50
0.
75
1.
00
0
3
6
9
12
15
18
T
im
e 
[m
o
n
th
s]
Survival probability (PFS)
m
tD
N
A
 h
ig
h
m
tD
N
A
 lo
w
F
ir
st
−
lin
e 
C
M
F
 c
h
em
o
th
er
ap
y
20
14
11
7
5
3
1
24
15
7
7
4
4
2
m
tD
N
A
 lo
w
m
tD
N
A
 h
ig
h
0
3
6
9
12
15
18
T
im
e 
[m
o
n
th
s]
N
um
b
er
 a
t 
ri
sk
D
Chapter_3_Marjolein.indd   41 22-12-2018   11:56:29
42   |   Chapter 3
5-year DMFS in the mtDNA low and mtDNA high groups were respectively 59% (95% 
CI 48-73) and 41% (95% CI 30-57). In univariable Cox regression analysis for DMFS, 
the mtDNA low group compared to the mtDNA high group has a hazard ratio (HR) of 
0.57 (95% CI 0.36-0.9, P = 0.017) (Table 3). Also in multivariable Cox regression analysis 
corrected for the base model including traditional prognostic factors, the patients in the 
low mtDNA content group had a longer DMFS compared to the mtDNA high group 
(HR 0.46, 95% CI 0.24-0.89, P = 0.020) (Table 3). However, also in the adjuvant cohort, 
patients treated with adjuvant CMF showed an equal distant metastasis probability in the 
mtDNA low and mtDNA high groups (Log Rank P = 0.7) (Figure 1B). The median length 
Table 3 Univariable and multivariable Cox regression analysis for DMFS of node-positive patients receiving 
FAC/FEC adjuvant chemotherapy (adjuvant cohort).
Characteristic
Univariable Multivariable
events/n HR (95% CI) P events/n HR (95% CI) P
Age (at diagnosis)
≤ 40
> 40-50
> 50
24/33
39/66
10/19
1
0.67 (0.40-1.11)
0.48 (0.23-1.01)
0.1
0.054
19/25
23/44
10/17
1
0.34 (0.17-0.67)
0.78 (0.33-1.85)
0.002
0.6
Menopausal status (at diagnosis)
Pre
Post
66/108
7/10
1
0.96 (0.44-2.10) 0.9
46/78
6/8
1
0.93 (0.33-2.60) 0.9
Tumour size
T1 (≤ 2 cm)
T2 (2-5 cm)
T3/4 (> 5 cm)
14/28
43/68
14/19
1
1.70 (0.93-3.12)
2.16 (1.02-4.55)
0.09
0.043
12/21
31/53
9/12
1
1.15 (0.54-2.45)
1.67 (0.62-4.49)
0.7
0.3
Nodal status
1-3
> 3
41/73
32/45
1
1.48 (0.93-2.36) 0.1
1
1.39 (0.76-2.55) 0.3
Grade (GGI)
1
2
3
7/16
24/38
28/44
1
1.84 (0.79-4.28)
2.03 (0.88-4.64)
0.2
0.1
6/13
22/34
24/39
1
1.37 (0.50-3.74)
1.21 (0.44-3.34)
0.5
0.7
ER status
Negative
Positive
22/34
51/84
1
0.76 (0.46-1.26) 0.3
17/26
35/60
1
1.68 (0.55-5.13) 0.4
PR status
Negative
Positive
22/32
44/74
1
0.64 (0.38-1.07) 0.1
20/30
32/56
1
0.41 (0.13-1.25) 0.1
HER2 status
Balanced
Amplified
48/85
12/14
1
2.54 (1.33-4.85) 0.004
42/74
10/12
1
2.04 (0.92-4.54) 0.1
mtDNA
High
Low
39/56
34/62
1
0.57 (0.36-0.90) 0.017
26/38
26/48
1
0.46 (0.24-0.89) 0.020
In the multivariable model, analysis was limited to 86 patients (52 events) with no missing values.
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of DMFS in the mtDNA low and mtDNA high groups were respectively 49 months (95% 
CI 41-NA) and 57 months (95% CI 22-NA). The 5-year DMFS in the mtDNA low and 
mtDNA high groups was respectively 46% (95% CI 30-71) and 44% (95% CI 29-66). 
In univariable Cox regression analysis for DMFS, the mtDNA low group compared to the 
mtDNA high group has a HR of 0.88 (95% CI 0.46-1.69, P = 0.7).
In the advanced cohort, in logistic regression analysis for overall response, patients 
treated with first-line FAC/FEC for their recurrent disease in the mtDNA low group 
had an odds ratio (OR) of 2.48 (95% CI 0.97-6.61, P = 0.06) compared to patients in 
the mtDNA high group (Table 4). These patients with a low primary tumour mtDNA 
content had a significant longer progression-free survival (PFS) compared to patients 
with high mtDNA content in their primary tumour (Peto P = 0.022) (Figure 1C). The 
median length of PFS in the mtDNA low and mtDNA high groups were respectively 
9.20 months (95% CI 6.44-16.39) and 5.91 months (95% CI 2.99-9.13). In univariable 
Cox regression analysis for PFS, the mtDNA low group compared to the mtDNA high 
group has a HR of 0.6 (95% CI 0.36-1.0, P = 0.048) (Table 5). Also in multivariable 
Cox regression analysis corrected for the base model including also traditional predictive 
factors, the patients in the low mtDNA content group had a longer PFS compared to the 
mtDNA high group with a HR of 0.49 (95% CI 0.27-0.90, P = 0.022) (Table 5). For 
the patients treated with first-line CMF for their recurrent disease, in logistic regression 
analysis for overall response the mtDNA low group had an OR of 0.48 (95% CI 0.14-
1.57, P = 0.2) (Table 4). No significant differences were observed between these two 
groups in their probability to disease progression (Peto P = 0.3) (Figure 1D), with a 
median PFS of 3.91 months (95% CI 2.37-9.03) and 6.24 months (95% CI 3.09-13.11) 
in the mtDNA low and mtDNA high groups respectively. In univariable Cox regression 
analysis for PFS, the HR of the mtDNA low group compared to the mtDNA high group 
was 1.14 (95% CI 0.61-2.13, P = 0.7).
Table 4 Overall response rate of patients receiving either FAC/FEC or CMF first-line chemotherapy for their 
recurrent disease (advanced cohort).
mtDNA low 
n (%)
mtDNA high 
n (%) OR (95% CI) P
First-line FAC/FEC
Non-responders
Responders
10 (27.8%)
26 (72.2%)
20 (48.8%)
21 (51.2%) 2.48 (0.97-6.61) 0.06
First-line CMF
Non-responders
Responders
14 (58.3%)
10 (41.7%)
8 (40.0%)
12 (60.0%) 0.48 (0.14-1.57) 0.2
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Discussion
In this retrospective study, we measured mtDNA content in primary breast tumours and 
demonstrate that patients with low mtDNA content in their tumours have increased 
benefit from anthracycline-based chemotherapies (FAC/FEC), in both the adjuvant and 
advanced disease-setting. We hypothesized that tumour cells with low mtDNA content 
are more susceptible to mitochondrial damage induced by anthracyclines, and thus are 
more susceptible to anthracycline treatment. A previous study reported similar findings: 
for 27 patients receiving anthracycline-based adjuvant chemotherapy [13], the 5-year 
Table 5 Univariable and multivariable Cox regression analysis for PFS of patients receiving FAC/FEC first-line 
chemotherapy for their recurrent disease (advanced cohort).
Characteristic
Univariable Multivariable
events/n HR (95% CI) P events/n HR (95% CI) P
Age (at recurrence)
≤ 45
> 45-55
> 55 
19/24
26/30
18/23
1
1.15 (0.64-2.09)
0.97 (0.51-1.85)
0.6
0.9
17/21
24/28
17/21
1
1.74 (0.77-3.93)
0.85 (0.25-2.88)
0.2
0.8
Menopausal status (at recurrence)
Pre
Post
37/44
26/33
1
0.85 (0.51-1.40) 0.5
33/39
25/31
1
0.90 (0.35-2.35) 0.8
Dominant relapse site
Soft tissue
Bone
Visceral
5/5
8/10
50/62
1
0.13 (0.04-0.42)
0.18 (0.06-0.48)
<0.001
<0.001
5/5
7/9
46/56
1
0.07 (0.02-0.28)
0.17 (0.05-0.55)
<0.001
0.003
Disease-free interval
≤ 1 year
> 1-3 years
> 3 years
25/26
28/37
10/14
1
0.73 (0.42-1.26)
0.65 (0.31-1.36)
0.3
0.3
24/25
24/32
10/13
1
1.06 (0.55-2.04)
0.85 (0.33-2.15)
0.9
0.7
ER status
Negative
Positive
38/43
25/34
1
0.58 (0.35-0.96) 0.036
35/40
23/30
1
1.21 (0.56-2.63) 0.6
PR status
Negative
Positive
45/52
18/25
1
0.69 (0.40-1.20) 0.2
42/48
16/22
1
0.85 (0.33-2.14) 0.7
HER2 status
Balanced
Amplified
44/55
14/16
1
1.31 (0.71-2.39) 0.4
44/54
14/16
1
1.07 (0.52-2.17) 0.9
Hormonal consolidation therapy
No
Yes
51/53
12/23
1
0.21 (0.11-0.40) <0.001
46/48
12/22
1
0.16 (0.07-0.36) <0.001
mtDNA
High
Low
36/41
27/36
1
0.60 (0.36-1.00) 0.048
35/40
23/30
1
0.49 (0.27-0.90) 0.022
In the multivariable model, analysis was limited to 70 patients (58 events) with no missing values.
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disease-free survival (tumour recurrence) was 84% in the mtDNA low group opposed to 
50% in the mtDNA high group, and this difference was not observed in 24 patients who 
did not receive adjuvant chemotherapy. However, these cohorts had only small numbers 
of patients, were heterogeneous regarding prognosis (i.e. lymph node status), and it was 
not reported if these patients received adjuvant hormonal treatment to improve outcome. 
In this study, we measured mtDNA content in nearly 300 primary breast tumours of two 
well-defined cohorts: lymph node-positive patients receiving only adjuvant chemotherapy 
as systemic treatment for their disease, and patients with disease recurrence receiving 
chemotherapy as first-line palliative treatment.
We measured mtDNA content using a multiplex qPCR approach where the 
mitochondrial-encoded locus lies outside of the common deletion region [21]. Also, 
we included a correction for copy number variation of the nuclear-encoded reference 
locus to minimize a bias in mtDNA content determination due to tumour-related local 
genomic aberrations. By including a minimal tumour cell percentage of 50% (the fraction 
of tumour cell nuclei within the cryosection) we aimed to minimize the contribution 
of non-tumour cells (i.e. stromal and immune cells) to the final mtDNA content. It is 
important to note that we evaluated the mtDNA content in the primary tumour specimens 
without comparing it to the tumour-adjacent normal mammary epithelium, and thus do 
not know whether the specimens with low mtDNA content have this due to variation 
of germline origin, or whether it is truly a somatic reduction in mtDNA copy number. 
In several other studies, mtDNA content in breast tumours has been compared with 
adjacent normal mammary tissue. In these studies, a somatic reduction of mtDNA was 
observed in ~70% of the cases [5-13], which makes it highly likely that those samples 
with a low mtDNA content in our dataset largely reflect the tumour-specific mtDNA 
content and is not due to germline origin.
Besides the stage in the disease trajectory, there are some differences between the 
two cohorts used in this study. The patient cohort receiving adjuvant chemotherapy was 
a younger cohort compared to the patients in the advanced cohort, with the majority of 
the patients being pre-menopausal. Also, the ER-positive cases were underrepresented in 
the advanced cohort compared to the general breast cancer population (approx. 75%), 
likely because ER-positive patients received (also) hormonal therapy (i.e. tamoxifen) 
and were thus excluded from our selection. In this advanced cohort, we observed an 
association between mtDNA content and ER status, with more ER-positive cases in the 
mtDNA content low group (Table 2). In both the adjuvant cohort of lymph node-positive 
patients, and in our previous study with lymph node-negative patients [14] or in other 
studies [7, 9, 12], no association between mtDNA content and ER status was observed. 
In addition, in the advanced cohort there were some differences between patients treated 
with first-line CMF or with first-line FAC/FEC: patients receiving CMF were older 
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(Fisher’s exact P = 0.031, Supplementary Table 7) and received less often consolidation 
therapy (Fisher’s exact P = 0.048, Supplementary Table 7). Also, similar to what we 
have done in the past for biomarker studies in the advanced setting, mtDNA content 
was measured in the primary tumour and not in the recurrent site. To our knowledge, it 
remains to be elucidated if the mtDNA content level in the recurrence site is similar to 
the primary tumour. Despite this, we did observe the hypothesized association between 
low mtDNA content and PFS in patients receiving first-line FAC/FEC chemotherapy, 
and this association was independent of established clinicopathological variables affecting 
outcome. We did not observe a statistically significant association with overall response 
(complete remission, partial remission or stable disease > 6 courses) within this group, 
but post-hoc power calculation with the current findings (72% response in mtDNA low, 
51% response in mtDNA high, Table 4) indicates that our power is currently 45%. The 
objective response – which does not include patients with stable disease but only those 
with complete and partial remission or progressive disease and thus only takes into account 
the two extremes – in logistic regression analysis for the mtDNA low group compared 
to the mtDNA high group gives an OR of 4.11 (95% CI 1.27-15.17, P = 0.02) in the 
FAC/FEC group, and an OR of 0.6 (95% CI 0.12-3.00, P = 0.23) in the CMF group, 
however these patient numbers are very small (Supplementary Table 3). A total number 
of 166 patients will be necessary to elucidate with 80% power if there is a difference in 
overall response to first-line FAC/FEC in the mtDNA low and mtDNA high group. 
Several markers have been described to predict benefit from adjuvant anthracycline-
based chemotherapy, including ERBB2 (HER2) [22], TIMP1 [23] and TOP2A [24]. None 
of these three markers showed the postulated association with outcome in our cohorts of 
adjuvant or first-line FAC/FEC treated patients (Supplementary Table 10), neither did 
we observe a correlation between mtDNA content and these markers (Supplementary 
Table 11).
The retrospective nature of this study did not allow us to include patients receiving 
taxane-based chemotherapy, nowadays often used to treat breast cancer as well. Similar to 
the methotrexate-based regimen, taxanes induce only low levels of oxidative stress [16] and 
do not work directly at the DNA level. Thus, we do not expect differences in efficacy in 
tumours with low or high mtDNA content. Specifically, we reason that tumour cells with 
low mtDNA content possess a vulnerability to drugs affecting mitochondria. It would be 
interesting to assess the outcome of patients with low or high tumour mtDNA content 
when treated with regimen containing chemotherapeutics that induce either mild (such as 
taxanes) or moderate oxidative stress (such as platins or alkylating agents), or the sequential 
combination of regimen. But given the common use of taxanes in breast cancer patients 
and the retrospective nature of our study, validation of our findings as well as exploring 
the impact of mtDNA content on outcome of taxane-treated patients is warranted. 
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In conclusion, where it was previously shown that a low mtDNA content in primary 
breast cancer tumours is associated with a worse prognosis [14], our study here in two 
well-defined cohorts indicates that breast cancer patients with low mtDNA content in 
their primary tumour have better outcome from anthracycline-containing chemotherapy, 
in the adjuvant as well as in the advanced setting. We suggest that the frequently 
observed decrease in mtDNA content in breast tumours may be exploited by guiding 
chemotherapeutic regimen decision-making. Larger (prospective) cohorts of uniformly 
treated patients are necessary to validate our results and to determine the clinical relevance 
of mtDNA content quantification in cancer.
Materials and methods
Study cohort and sampling
DNA extracts from an earlier retrospective study [25] were selected from our bio-bank at 
the Erasmus MC (Supplementary Figure 1). Tissue specimens from our selection were 
collected during 1979-1995. The study was approved by the medical ethics committee of 
the Erasmus MC (MEC 02.953) and conducted in accordance to the Code of Conduct 
of Federation of Medical Scientific Societies in the Netherlands, and thus provided 
patient records were anonymized and de-identified prior to analysis. We adhered to the 
Reporting Recommendations for Tumour Marker Prognostic Studies (REMARK) [26]. 
Follow-up and tumour response were defined based on the criteria by the International 
Union Against Cancer (Geneva, Switzerland) [27] and the European Organization for 
Research and Treatment of Cancer [28] as described previously [25]. Estrogen receptor 
(ER) status, progesterone receptor (PR) status, and ERBB2 (HER2) amplification were 
determined as described before (resp. [29, 30] and [31]). The RT-qPCR Genomic Grade 
Index (GGI) was determined as described previously [32], which we used as an alternative 
grading system for histological grading according to Bloom-Richardson since this grading 
was unavailable for nearly 30% of the samples.
For the adjuvant cohort (REMARK diagram in Supplementary Figure 1A), a total 
of 528 DNA extracts were available from fresh frozen primary breast tumour specimens 
originating from female patients with lymph node-positive disease (N1 or N2) without 
distant metastasis at primary diagnosis (M0). None of the patients received neoadjuvant 
therapy. We selected only samples from patients receiving as adjuvant systemic treatment 
either cyclophosphamide / methotrexate / 5-fluorouracil (CMF) or 5-fluoracil / anthracycline 
/ cyclophosphamide (FAC or FEC) and did not receive adjuvant hormonal treatment (n = 
307) (patient characteristics of complete set in Supplementary Table 1). Note that at the 
time of tumour collection, only patients with node-positive disease but not node-negative 
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disease received adjuvant systemic chemotherapy in the Netherlands. Next, we selected 
based on uniformity in the DNA extraction method only the samples extracted with the 
DNeasy Tissue kit (Qiagen, Venlo, The Netherlands, performed as described by supplier) (n 
= 289). To minimize stromal cell contamination, we selected for an invasive tumour cell 
percentage of at least 50% in the specimen (n = 176). One patient ineligible in retrospect 
was excluded. Thus, mtDNA content was examined in a total of 175 patients. For one 
patient, a qPCR amplification signal was absent. In the final cohort of 174 patients, 56 
received CMF and 118 received FAC/FEC adjuvant systemic therapy. At the end of follow-
up, 111 events (distant metastasis) were observed within the group of these 174 patients.
For the advanced cohort (REMARK diagram in Supplementary Figure 1B), a 
total of 231 DNA extracts from fresh frozen primary disease resection specimen were 
available from female patients who received chemotherapy as first-line treatment for 
disease recurrence (loco-regional or distant metastasis). We selected only those samples 
originating from patients receiving either CMF or FAC/FEC as first-line chemotherapy 
regimen (n = 206) (patient characteristics of complete set in Supplementary Table 2). 
We again only selected patients based on uniformity in the DNA extraction method (only 
the samples extracted with the DNeasy Tissue kit (Qiagen), performed as described by 
supplier) (n = 197) and with an invasive tumour cell percentage of at least 50% in the 
specimen (n = 126). Five patients were excluded: no clinical data was available for four 
patient samples, and one patient who did not receive axillary lymph node dissection was 
ineligible in retrospect. Thus, mtDNA content was examined in a cohort of 121 patients, 
of which 44 received CMF and 77 received FAC/FEC first-line chemotherapy. A total 
of 29 (24%) patients received hormonal consolidation therapy during follow-up and 
for one patient it was unknown if she had been treated with consolidation therapy. Of 
the 121 patients, none (0%) received neoadjuvant therapy and 34 (28%) received prior 
adjuvant chemotherapy (7 CMF, 17 FAC/FEC and 9 cyclophosphamide monotherapy). 
Overall response was defined as described previously [25], and a total of 69 patients 
responded to chemotherapy (5 with complete remission, 38 with partial remission, 26 
with stable disease > 6 courses) and 51 patients showed no response to chemotherapy 
(36 with progression, 15 with stable disease ≤ 6 courses) (Supplementary Table 3). For 
one patient the type of response was ambiguous. In our analysis, we right-censored at 18 
months follow-up because of low numbers of patients at risk. At the end of follow-up, 
104 events (progression) were observed within the group of 121 patients.
mtDNA content
Mitochondrial DNA content was determined as described previously [14]. Briefly, 
a multiplex real-time quantitative PCR was used which amplifies nuclear HMBS 
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(chr11q23.2-qter) and mitochondrial MT-TL1 (chrMT 3212–3319). ROX normalized 
quantification cycle values (Cq [dRn]) were obtained from duplicate runs on the MX3000 
or MX3005P qPCR systems (Agilent Technologies, Waldbronn, Germany) by the adaptive 
baseline approach (MxPro v4.10) up to cycle 35 with fixed fluorescence thresholds at 
0.004 dRn. We quantified in 1 ng DNA the ratio of mitochondrial DNA opposed to 
nuclear DNA by the relative quantitation method (2^ΔCq [54]) using the obtained Cq 
values. Multiplying this ratio by the copy number of HMBS (obtained as described below) 
resulted in the number of mtDNA molecules per cell as mtDNA content. A calibration 
curve containing a pool of DNA extracts from a different set of fresh frozen tumours 
was taken along as internal control to monitor the performance of the PCR reactions 
(Supplementary Table 4). Also, no template reactions were taken along in each run and 
never resulted in an obtained Cq value.
Copy number analysis
Copy number variation of the nuclear encoded HMBS gene – which served as a reference 
to obtain mtDNA content – was obtained using qBiomarker Copy Number assays 
(Qiagen) VPH000-0000000A (multi-copy reference) and VPH111-0594782A (HMBS 
target) as described by the supplier. Briefly, HMBS and the multi-copy reference were 
quantified using SYBR-green based real-time quantitative PCR in 4 ng of DNA. The 
multi-copy reference is a stable sequence that is minimally affected by local genomic 
changes, because it appears in the human genome over 40 times. ROX normalized Cq 
values were obtained as described above but with fixed fluorescence thresholds at 0.2 
dRn. In 4 ng of DNA, using the 2^ΔΔCq calibrator genome method, the predicted copy 
number of HMBS was obtained for each individual tumour and corrected for tumour cell 
percentage. A calibration curve containing a pool of DNA extracts from a different set 
of fresh frozen tumours was taken along as internal control to monitor the performance 
of the PCR reactions (Supplementary Table 4), of which the dilution containing 4 ng 
of DNA was used as the calibrator for copy number calculations. Two cell line samples 
were taken along as high (MDA-MB-468) and low (MDA-MB-134VI) controls for copy 
number variation, which gave results with respectively median 3.3 (min 2.5 – max 4.5) 
and median 0.9 (min 0.7 – max 1.0) HMBS copies/cell (n = 12 runs). Also, no template 
reactions were taken along in each run and never resulted in an obtained Cq value.
Statistical analysis
All analyses included the average mtDNA content obtained from the duplicate analysis for 
each individual sample. Data distribution was tested using Shapiro-Wilk test for normality. 
Categorical comparisons of grouped clinical variables and the mtDNA content groups were 
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employed using Fisher’s exact test. The association with response rate to chemotherapy 
was analysed with a logistic regression model to calculate odds ratios (ORs) and 95% 
conﬁdence intervals (95% CIs). Kaplan-Meier survival plots were used to visualize the 
differences in time to distant metastasis (adjuvant setting) or time to progression (advanced 
setting) between mtDNA content groups (dichotomized). In the adjuvant cohort the 
log-rank test was used to compare survival probability. In the advanced cohort the Peto & 
Peto modification of the Gehan-Wilcoxon test was used to compare survival probability 
because most events occurred early on in this cohort. Proportional hazard analyses for 
distant metastasis-free survival (adjuvant setting) or progression-free survival (advanced 
setting) were performed using Cox regression methods to calculate hazard ratios (HRs) 
and their 95% CIs. Univariable analysis was done on the individual variables, for the 
multivariable analysis we used a base model (including traditional clinicopathological 
variables [23, 33]) and mtDNA content. In regression analyses, the Wald statistic was 
used to calculate corresponding P values. Proportionality over time was monitored for 
each Cox regression using the Schoenfeld residuals with the assumption tested using 
Chi-squared test, and was never violated (P > 0.05). All statistical tests were two-sided, 
and P values smaller than 0.05 were considered as statistically significant. Analyses were 
performed using R, version 3.2.3. 
Supplementary data
Supplementary data for this article are available online at Clinical Cancer Research 
(http://clincancerres.aacrjournals.org/). 
Chapter_3_Marjolein.indd   50 22-12-2018   11:56:29
C
ha
pt
er
 3
mtDNA content as a predictive marker in breast cancer   |   51 
References
1. Robin, E.D. and R. Wong, Mitochondrial DNA molecules and virtual number of mitochondria per 
cell in mammalian cells. J Cell Physiol, 1988. 136(3): p. 507-513.
2. Wiesner, R.J., J.C. Ruegg, and I. Morano, Counting target molecules by exponential polymerase 
chain reaction: copy number of mitochondrial DNA in rat tissues. Biochem Biophys Res Commun, 
1992. 183(2): p. 553-539.
3. Legros, F., et al., Organization and dynamics of human mitochondrial DNA. J Cell Sci, 2004. 
117(13): p. 2653-2662.
4. Lee, H.C. and Y.H. Wei, Mitochondrial biogenesis and mitochondrial DNA maintenance of 
mammalian cells under oxidative stress. Int J Biochem Cell Biol, 2005. 37(4): p. 822-834.
5. Reznik, E., et al., Mitochondrial DNA copy number variation across human cancers. Elife, 2016. 5: 
e10769.
6. Mambo, E., et al., Tumor-specific changes in mtDNA content in human cancer. Int J Cancer, 2005. 
116(6): p. 920-924.
7. Yu, M., et al., Reduced mitochondrial DNA copy number is correlated with tumor progression and 
prognosis in Chinese breast cancer patients. IUBMB Life, 2007. 59(7): p. 450-457.
8. Tseng, L.M., et al., Mitochondrial DNA mutations and mitochondrial DNA depletion in breast 
cancer. Genes Chromosomes Cancer, 2006. 45(7): p. 629-638.
9. Fan, A.X., et al., Mitochondrial DNA content in paired normal and cancerous breast tissue samples 
from patients with breast cancer. J Cancer Res Clin Oncol, 2009. 135(8): p. 983-989.
10. Barekati, Z., et al., Methylation profile of TP53 regulatory pathway and mtDNA alterations in 
breast cancer patients lacking TP53 mutations. Hum Mol Genet, 2010. 19(15): p. 2936-2946.
11. McMahon, S. and T. LaFramboise, Mutational patterns in the breast cancer mitochondrial genome, 
with clinical correlates. Carcinogenesis, 2014. 35(5): p. 1046-1054.
12. Bai, R.K., et al., Mitochondrial DNA content varies with pathological characteristics of breast cancer. 
J Oncol, 2011. 2011: 496189.
13. Hsu, C.W., et al., Mitochondrial DNA content as a potential marker to predict response to 
anthracycline in breast cancer patients. Breast J, 2010. 16(3): p. 264-270.
14. Weerts, M.J.A., et al., Mitochondrial DNA content in breast cancer: Impact on in vitro and in vivo 
phenotype and patient prognosis. Oncotarget, 2016. 7: p. 29166-29176.
15. Harris, L.N., et al., Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women 
With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice 
Guideline. J Clin Oncol, 2016. 34(10): p. 1134-1150.
16. Conklin, K.A., Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. 
Integr Cancer Ther, 2004. 3(4): p. 294-300.
17. Ashley, N. and J. Poulton, Mitochondrial DNA is a direct target of anti-cancer anthracycline drugs. 
Biochem Biophys Res Commun, 2009. 378(3): p. 450-455.
18. Khiati, S., et al., Mitochondrial topoisomerase I (top1mt) is a novel limiting factor of doxorubicin 
cardiotoxicity. Clin Cancer Res, 2014. 20(18): p. 4873-4881.
19. Mei, H., et al., Reduced mtDNA copy number increases the sensitivity of tumor cells to chemotherapeutic 
drugs. Cell Death Dis, 2015. 6: e1710.
20. Early Breast Cancer Trialists’ Collaborative, G., Effects of chemotherapy and hormonal therapy for 
early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet, 
2005. 365(9472): p. 1687-1717.
21. Cortopassi, G.A. and N. Arnheim, Detection of a specific mitochondrial DNA deletion in tissues of 
older humans. Nucleic Acids Res, 1990. 18(23): p. 6927-6933.
22. Gennari, A., et al., HER2 status and efficacy of adjuvant anthracyclines in early breast cancer: a 
pooled analysis of randomized trials. J Natl Cancer Inst, 2008. 100(1): p. 14-20.
Chapter_3_Marjolein.indd   51 22-12-2018   11:56:29
52   |   Chapter 3
23. Schrohl, A.S., et al., Tumor tissue levels of Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and 
outcome following adjuvant chemotherapy in premenopausal lymph node-positive breast cancer 
patients: A retrospective study. BMC Cancer, 2009. 9: 322.
24. Du, Y., et al., The role of topoisomerase IIalpha in predicting sensitivity to anthracyclines in breast 
cancer patients: a meta-analysis of published literatures. Breast Cancer Res Treat, 2011. 129(3): p. 
839-848.
25. Liu, J., et al., The 29.5 kb APOBEC3B deletion polymorphism is not associated with clinical outcome 
of breast cancer. PLoS One, 2016. 11(8): e0161731.
26. McShane, L.M., et al., Reporting recommendations for tumor marker prognostic studies (REMARK). 
J Natl Cancer Inst, 2005. 97(16): p. 1180-1184.
27. Hayward, J.L., et al., Assessment of response to therapy in advanced breast cancer: a project of the 
Programme on Clinical Oncology of the International Union Against Cancer, Geneva, Switzerland. 
Cancer, 1977. 39(3): p. 1289-1294.
28. European Organization for Research and Treatment of Cancer, B.C.C.G., Manual for clinical 
research and treatment in breast cancer (4th edition). 2000, Excerpta Medica Almere, the 
Netherlands. p. 116-117.
29. Foekens, J.A., et al., Prognostic value of estrogen and progesterone receptors measured by enzyme 
immunoassays in human breast tumor cytosols. Cancer Res, 1989. 49(21): p. 5823-5828.
30. Foekens, J.A., et al., Relationship of PS2 with response to tamoxifen therapy in patients with recurrent 
breast cancer. Br J Cancer, 1994. 70(6): p. 1217-1223.
31. van Agthoven, T., et al., Relevance of breast cancer antiestrogen resistance genes in human breast 
cancer progression and tamoxifen resistance. J Clin Oncol, 2009. 27(4): p. 542-549.
32. Toussaint, J., et al., Improvement of the clinical applicability of the Genomic Grade Index through a 
qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics, 
2009. 10: 424.
33. Schrohl, A.S., et al., Primary tumor levels of tissue inhibitor of metalloproteinases-1 are predictive of 
resistance to chemotherapy in patients with metastatic breast cancer. Clin Cancer Res, 2006. 12(23): 
p. 7054-7058.
Chapter_3_Marjolein.indd   52 22-12-2018   11:56:29
C
ha
pt
er
 3
mtDNA content as a predictive marker in breast cancer   |   53 
Chapter_3_Marjolein.indd   53 22-12-2018   11:56:30
54   |   Chapter 3
CHAPTER 4
Ile
Ala
Ar
g
Asn
Asp
Cys
Gl
u
G
ln
Gly
H
is
Leu
Le
u
Ly
s
M
et
Phe
Pro
Se
r
Ser
Thr
Trp
Tyr
Val
RNR1
RN
R2
ND
1
ND2
ND
3
N
D
4
ND4
L
N
D
5
ND6
CO1
CO
2
CO
3
ATP6
ATP8
CYB
Chapter_3_Marjolein.indd   54 22-12-2018   11:56:30
Mitochondrial RNA expression and 
variants in association with  
clinical parameters in primary 
breast cancers
Marjolein J.A. Weerts | Marcel Smid | John A. Foekens | 
Stefan Sleijfer | John W.M. Martens
Cancers 2018, 10(12):500
Chapter_4_Marjolein.indd   55 22-12-2018   11:55:29
The human mitochondrial DNA (mtDNA) encodes 37 genes, including 
thirteen proteins essential for the respiratory chain, and two ribosomal RNAs 
and twenty-two transfer RNAs functioning in the mitochondrial translation 
apparatus. The total number of mtDNA molecules per cell (mtDNA 
content) is variable not only between tissue types, but also between tumours 
and their normal counterparts. For breast cancer specifically, tumours tend 
to be depleted in their mtDNA content compared to adjacent normal 
mammary tissue. Additionally, various studies have shown that primary 
breast tumours harbour somatic variants in their mtDNA. A decrease 
in mtDNA content or the presence of somatic variants could indicate a 
reduced mitochondrial function within breast cancer. In this explorative 
study we aimed to further understand the genomic changes and expression 
of the mitochondrial genome within breast cancer, by analysing RNA 
sequencing data of primary breast tumour tissue specimens of 344 cases. 
We demonstrate that somatic variants detected at the mtRNA level are 
representative for the somatic variants in the mtDNA. We also show that 
the number of somatic variants within the mitochondrial transcriptome is 
not associated with the mutational processes impacting the nuclear genome, 
but is positively associated with age at diagnosis. Finally, we observe that 
mitochondrial expression is related to ER status. We conclude that there is 
a large heterogeneity in somatic mutations of the mitochondrial genome 
within primary breast tumours, and differences in mitochondrial expression 
among breast cancer subtypes. The exact impact on metabolic differences 
and clinical relevance deserves further study.
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Introduction
Mitochondria are small organelles involved in multiple cellular processes. They are most 
renowned for their role in energy production, since they contain their own circular 
genomic entity encoding proteins essential for the respiratory chain and thereby for 
generating cellular ATP via oxidative phosphorylation. The human mitochondrial DNA 
(mtDNA) is gene-dense consisting of ~16,569 base pairs encoding 37 genes: thirteen 
proteins, and two ribosomal RNAs and twenty-two transfer RNAs functioning in the 
mitochondrial translation apparatus. Polycistronic transcription of mtDNA is initiated 
at the non-coding D-loop region, and the resultant precursor transcripts are processed by 
excision of the transfer RNA genes (“tRNA punctuation model” [1]) generating individual 
mitochondrial transfer RNA, ribosomal RNA and messenger RNA transcripts. The total 
number of mtDNA molecules per cell (mtDNA content) is variable between tissue types, 
and interestingly also between tumours and their normal counterparts [2]. For breast 
cancer specifically, tumours tend to be depleted in their mtDNA content compared to 
adjacent normal mammary tissue [2-10], and mtDNA content in breast tumours positively 
correlates with the expression of mtDNA-encoded genes [11]. Decreased content and 
expression of mtDNA could indicate a reduced mitochondrial function within breast 
cancer, in line with the Warburg hypothesis [12] limiting energy production largely to 
glycolysis. Recently, we have shown mtDNA content to be associated with breast cancer 
patient outcome [13, 14], underlining the clinical relevance of mitochondria in breast 
cancer. 
Apart from mtDNA content, the significance of somatic mtDNA variants within 
(breast) cancer is still subject to debate, where the whole spectrum of neutral accumulation, 
positive selection (advantage) and negative selection (disadvantage) have been postulated. 
Various studies have shown that primary breast tumours harbour somatic variants in 
their mtDNA [8, 15, 16], with approximately 70% of the specimens containing at least 
one single nucleotide variant (SNV, range 1 – 7) and 10% containing at least one small 
insertion/deletion (INDEL, range 0 – 3). However, these variants do not appear at 
particular ‘hot-spot’ positions on the mitochondrial genome, raising doubts about their 
clinical relevance.
To better understand nucleotide changes in and expression of the mitochondrial 
genome within primary breast tumours, we investigated here transcriptomic sequencing 
data within the ICGC consortium [17] and explored how these findings correlate with 
clinical parameters, providing more insight into the mitochondrial genome as potential 
biomarker and its clinical relevance in breast cancer. 
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Results
We evaluated RNA sequencing data of 344 primary breast tumour specimens. After 
mapping of sequencing reads against the human reference genome, median 15% (IQR 
10-23%) of the uniquely mapped reads were assigned to the mitochondrial contig, 
resulting in median 9,889x read depth (IQR 5,333) of mtDNA.
Somatic variants in mtRNA
Variant calling resulted in a total of 9,063 single nucleotide variants (SNVs) on 1,600 
positions and 84 small insertions or deletions (INDELs) on 38 positions of the mitochon-
drial genome within the 344 cases (Figure 1). Since INDELs were only a minority, our 
Figure 1 Variants in the mitochondrial RNA of 344 primary breast tumour cases. 
Position on the mitochondrial genome (circle) and their variant allele frequency (increasing % from inner-to-outer) of all 
variants identified in the 344 cases. Somatic or germline origin in respectively closed black or open grey circles. Genes and 
their direction of transcription (arrows) in red (+ strand) or blue (-strand). Note that variants on position 2617 (known 
RNA – DNA differences) are not shown.
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focus was on the SNVs only. We defined SNVs as somatically acquired tumour variants 
when not associated with the individual’s haplotype (n = 7,235 excluded, 80%) or with 
heteroplasmic allele frequency of ≤ 95% (n = 917 excluded, 10%). Also, we defined the 
va riants at position 2617 (r.2617a>u and r.2617a>g, present in respectively n = 340 and 
n = 101 cases) as not tumour-specific because 1) they have been described previously as 
RNA-DNA differences in blood cells of non-cancer patients [18, 19] and 2) we confirmed 
their presence in a transcriptomic dataset of normal specimens of various tissue types 
including breast tissue [20] (Supplementary Table 4). After these exclusions, a total of 
470 somatic variants on 429 positions were identified.
Our dataset has overlapping cases (n = 165) with the dataset published by Ju et al. 
[15] concerning somatic mitochondrial variants in tumour and matched normal specimens 
at the DNA level. This allowed us to directly compare called variants between the two 
datasets (see also Supplementary File) to evaluate presence, classification and allele 
frequency of variants. Since variants at position 2617 are known RNA-DNA differences 
(see above) and indeed not called in the DNA dataset, these were not included in this 
comparison. A total of respectively 3,997 and 4,009 SNVs were called at the RNA and 
DNA level within the primary tumour specimens of the 165 cases. The majority of the 
variants were called at both the RNA and DNA level (n = 3,889, respectively 97.3% and 
97.0%), whereas a small fraction was only called at either the RNA or the DNA level 
(respectively n = 108 (2.7%) and n = 120 (3.0%) variants) (Figure 2). Of the variants 
detected at both the RNA and DNA level, only a few (n = 10, 0.3%) had a discrepancy 
in classification as either ‘somatic’ or ‘germline’ (Figure 2). Also, good consistency was 
observed in allele frequency at the RNA and DNA level (linear fit coefficient of 0.92 for 
all variants and 0.96 for somatic tumour variants). From this we concluded that presence, 
Figure 2 Classifi cation of variants detected in the mitochondrial RNA and in the mitochondrial DNA of 165 
primary breast tumour cases.
Venn-diagram depicting classifi cation of variants as either somatic (black) or germline (grey) at the RNA level and the 
DNA level.
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classification and allele frequency of variants was consistent between the RNA and the 
DNA level (as elaborated on in Supplementary File).
We then continued to further decipher the somatic mtRNA variants in our dataset (n 
= 470 in n = 344 cases). The variant allele frequency of the somatic variants was distributed 
with a peak at the lower and at the upper end of allele frequencies (Supplementary Figure 
S1). There was no correlation between the variant allele frequency and the percentage 
of invasive tumour cells in the evaluated specimen (Spearman correlation coefficient 
rho = 0.03, P = 0.5). The detected somatic variants were distributed along the entire 
mitochondrial genome (Figure 1), with 40 (8.5%) variants located in the tRNA genes, 69 
(14.7%) in rRNA genes, 85 (18.1%) in the D-loop, 1 (0.2%) in the non-coding regions, 
and 275 (58.5%) in the mRNA genes of which 212 (77.1%) had a nonsynonymous effect 
on the coding amino acid (Figure 3). However, relative to their genomic size (9.0% tRNA 
genes, 15.1% rRNA genes, 6.8% D-loop, 0.4% non-coding and 68.7% mRNA genes) 
more variants were present in the D-loop and fewer in the mRNA genes (Fisher exact P 
< 0.001). Also in comparison to the germline variants (variants that were associated with 
the haplogroup of that individual or with an allele frequency > 95%, n = 8,152) there 
was a difference in genomic distribution (Fisher’s exact P < 0.001) with fewer somatic 
variants in the D-loop but more in the tRNA and mRNA genes, and an enrichment for 
somatic nonsynonymous mRNA variants (Figure 3). The positions of somatic variants 
were much more conserved among species compared to the germline variants (Mann-
Whitney test P < 0.001), as measured by the fraction of species that harbour the reference 
Figure 3 Genomic distribution of mitochondrial RNA variants of 344 primary breast tumour cases.
Genomic distribution is depicted for somatic (left) or germline (right) variants in either non-coding (purple), the D-loop 
(orange), tRNA (red), rRNA (blue) or mRNA (green) regions of the mitochondrial genome. The percentage of total is 
indicated at the top of the bars. The percentage of substitutions in the mRNA regions with either a synonymous or non-
synonymous effect is indicated within the mRNA bar (light green). Note that variants at position 2617 (known RNA 
– DNA differences) are not included.
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sequence at that position (Conservation Index of respectively median (IQR) 0.93 (0.36) 
and 0.76 (0.69)). A total of 69 (15%) somatic variants were recurrent and positioned 
on 28 mitochondrial positions. Majority of the somatic variants (95%) represented the 
typical replication-coupled mtDNA substitution pattern with predominantly C > T and 
T > C transitions as described previously [15, 16, 21] in a nucleotide context similar to 
the germline variants (Figure 4). However, compared to the detected germline variants 
the ratio between C > T and T > C variants is shifted (Fisher exact P < 0.001) with an 
increased number of C > T transitions among the somatic variants (Figure 4).
In the entire cohort, there are 112 (33%) cases with 0 somatic variants, 97 (28%) 
with 1 somatic variant, and 135 (39%) with more than 1 somatic variant (range 2 to 7). 
Of the cases with more than 1 somatic variant, 82 (61%) had a difference > 20% allele 
frequency between variants, indicative for (sub-)clonality. 
Somatic mitochondrial variants in relation to somatic variants in the nuclear genome
Next, to gain more insight into the relation between the mutational processes shaping 
mtDNA and nDNA, we associated the amount of somatic mtRNA variants with the 
number of somatic variants induced by the known major mutational patterns shaping the 
nDNA. For this purpose, we obtained for the overlapping cases (n = 268) the number of 
nDNA variants as published by Nik-Zainal et al. [17]. There was no statistically significant 
association between the number of somatic mtRNA variants and the total number of 
somatic variants in the nuclear DNA (Spearman correlation coefficient rho = 0.01, P 
= 0.8). Next, we combined per case the number of variants in nDNA associated with 
the mutational processes as described by Nik-Zainal et al. [17]: age-related (signatures 
1 and 5), APOBEC-related (signatures 2 and 13) and homologous-recombination 
deficiency-related (signatures 3 and 8) processes. No statistically significant associations 
were observed between the number of somatic mtRNA variants and any of these three 
mutational processes (all Kruskal-Wallis P > 0.2). Note that only two samples within 
the dataset contained variants associated with mismatch-repair deficiency (signatures 6, 
20 and 26), and none of samples contained variants associated with the signatures of 
unknown aetiology (signatures 17, 18 and 30), as a consequence of which these specific 
subgroups could not be evaluated. 
Mitochondrial gene expression
To estimate the expression and transcript processing of the mitochondrial genome for 
each case, transcripts per million (TPM, log2-transformed) were calculated for the 
entire mtDNA and each mitochondrial-encoded gene individually. Expression of the 
entire mtDNA – normalized against the nuclear genome and thus evaluated as driven by 
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mtDNA content and transcription rate – was high and showed minor variability among 
the 344 cases (median 19.9210 TPM, IQR 0.0045). Within the 37 mitochondrial-
encoded genes – normalized within the mitochondrial genome and thus evaluated as 
driven by processing of the polycistronic transcripts – the levels for genes encoding 
tRNAs were lowest (median 12.52 TPM, IQR 1.32), followed by mRNAs (median 
15.37 TPM, IQR 0.31) and rRNAs (median 16.83 TPM, IQR 0.48). Most variability 
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Figure 5 Correlation matrix of expression of all 37 mitochondrial-encoded genes of 344 primary breast tumour 
cases.
Correlation matrix depicting the Spearman correlation between all 37 mitochondrial-encoded genes (text of tRNA genes 
in red, rRNA genes in blue, mRNA genes in green). Colour intensity and the size of the circle are proportional to the 
correlation coefficients. 
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was observed in levels of tRNAs. Also, distinct correlation clusters were observed between 
the expression levels of the genes encoding mRNAs, tRNAs and rRNAs, where among 
genes a positive correlation was present per gene-type, but between different gene-types 
a negative correlation was present (Figure 5). No correlation was observed between the 
number of mtRNA variants and expression of the entire mtDNA (Spearman correlation 
coefficient rho = -0.02, P = 0.7). 
Association with clinicopathological parameters
Lastly, we explored how these findings correlate with relevant clinical parameters. We 
analysed the number of somatic mtRNA variants (grouped variable as 0 variants, 1 variant 
and >1 variant per tumour, Table 1) and the expression of the entire mitochondrial 
contig (continuous variable, Table 1) in relation to traditional clinicopathological 
variables including age at diagnosis (n = 291 cases), tumour size (T-stage) (n = 216 cases), 
Table 1 Association between number of somatic tumour mtRNA variants or expression of the entire mtDNA and 
clinicopathological variables.
mtRNA somatic variants mtRNA expression
Variable No. of cases
0 
variants
1 
variant
>1 
variants P median (IQR) TPM P
Age
56 (28-85)
unknown
291 (100%)
53
53 (17) 55 (23) 61 (24)
0.022a
0.11c
0.049d
Tumour size
T1 (≤ 2 cm)
T2 (> 2-5 cm)
T3 (> 5 cm)
unknown
76 (35.2%)
109 (50.5%)
31 (14.4%)
128
33.8%
47.9%
18.3%
25.0%
64.1%
10.9%
44.4%
42.0%
13.6%
0.07b
19.9202 (0.0043)
19.9207 (0.0045)
19.9223 (0.0047)
0.051a
Grade
I
II
III
unknown
24 (8.5%)
111 (39.4%)
147 (52.1%)
62
9.9%
40.7%
49.5%
12.2%
35.1%
52.7%
5.1%
41.0%
53.8%
0.4b
19.9202 (0.0037)
19.9216 (0.0044)
19.9209 (0.0049)
0.1a
ER
Negative
Positive
unknown
81 (27.8%)
210 (72.2%)
53
21.7%
78.3%
31.2%
68.8%
30.3%
69.7%
0.3b
19.9196 (0.0050)
19.9216 (0.0041)
< 0.001a
PR
Negative
Positive
unknown
102 (35.4%)
186 (64.6%)
56
31.5%
68.5%
40.5%
59.5%
35.0%
65.0%
0.5b
19.9204 (0.0048)
19.9215 (0.0042)
0.006a
For each subgroup within the clinicopathological variable, the number of cases and either the fraction of patients 
within the mtRNA somatic variant groups (0, 1 or more than 1) or the mtRNA expression (TPM, log2 transformed) is 
indicated. a Kruskal-Wallis (multiple groups) or Mann-Whitney (two groups) P value. b Fisher exact P value. c Spearman 
correlation coefficient. d Spearman correlation P value.
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pathological grade (n = 282 cases), estrogen receptor (ER) status (n = 291 cases) and 
progesterone receptor (PR) status (n = 288 cases). Due to the low numbers of patients 
with HER2-amplified (n = 2 cases) and presenting with metastases at primary diagnosis 
(n = 3 cases), these clinicopathological variables were not evaluated. Age at diagnosis 
was statistically significant associated with both the number of somatic mtRNA variants 
(Kruskal-Wallis P = 0.022) and expression of the entire mtDNA (Spearman correlation 
coefficient rho = 0.11, P = 0.049), where a higher age corresponded to more somatic 
mtRNA variants and higher expression of the entire mtDNA. Also, a highly statistically 
significant association was observed between expression of the entire mtDNA and 
hormone receptor status (as evaluated at the protein level), with increased mtDNA 
expression in the ER-positive and in the PR-positive tumours (respectively Mann-
Whitney U test P < 0.001 and P = 0.006). In fact, also a significant correlation was 
observed between expression of the entire mtDNA and RNA expression of ESR1 or PGR 
(respectively Spearman correlation coefficient rho = 0.19 P < 0.001 and rho = 0.17 P = 
0.001, n = 344 and n = 342 cases).
Discussion
In this work, we explored genomic changes in and expression of the mitochondrial genome 
within primary breast tumours, and their correlation with clinicopathological variables. 
Within our breast tumour dataset, the fraction of reads mapping to the mitochondrial 
contig of the reference genome (median 15%) is in line with previous findings in non-
tumorous breast samples: within the Illumina Body Tissue Atlas ~15% of the sequencing 
reads mapped to the mitochondrial genome (n = 1) [22], and within the Genotype-
Tissue Expression (GTEx) Consortium ~15-20% of the transcriptional output was of 
mitochondrial origin (n = 27) [23]. This indicates that although the expression of the 
mitochondrial genome has been shown to be decreased in breast tumours compared to 
tumour-adjacent normal mammary tissue [11], the extent to which this occurs is less 
extreme than observed among tissue types (e.g. a much lower fraction of mitochondrial 
reads in blood (< 5%) or much higher fraction in kidney (>50%) [23]). Nevertheless, we 
observed an association between expression of the entire mtDNA and ER status (measured 
at protein-level), with marginally higher expression in ER-positive tumours and a similar 
observation for PR status (protein-level) (Table 1). In addition, also RNA expression 
of ESR1 and PGR was positively correlated with expression of the entire mitochondrial 
contig. The relation between expression of mtDNA and clinicopathological parameters 
has not been evaluated by others, but when we associated the data reported by Reznik et al 
[11] on mtRNA expression within the TCGA-BRCA dataset (n = 656 cases) we observe a 
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similar correlation for ER status (Kruskal-Wallis P = 0.006, Supplementary Table 5) and 
none for the other clinicopathological variables (all P > 0.05 Supplementary Table 5). 
In pre-clinical models, there appears to be a link between ER and mitochondrial activity: 
exposure to estrogens increases mitochondrial expression and oxygen consumption in ER-
positive [24, 25] but not in ER-negative breast cancer cells [25]. Similarly, ER-negative 
breast cancer cell lines show lower mitochondrial respiration and a stronger dependency 
on glycolysis in comparison to ER-positive breast cancer cells [26]. Unfortunately, 
measurements on mitochondrial activity comparing ER-positive and ER-negative clinical 
specimens are to our knowledge not reported in the literature, and thus the effect of 
differences in ESR1 levels on mitochondrial activity in primary breast tumours remains 
currently unknown. Interestingly, uptake values of fluorodeoxyglucose (FDG) in positron 
emission tomography (PET) – a visualization of glucose uptake reflecting the increased 
rate of glycolysis in the tumour – appears to be higher in ER-negative cases [27-33], 
indicative that indeed metabolic differences are present between the subtypes. Additional 
studies should be performed to identify if there are differences in mitochondrial function 
among breast cancer subtypes and the potential clinical relevance of these findings, such 
as predictive and prognostic potential.
We also observed distinctive clustering of tRNA genes, which is in line with the 
tRNA punctuation model: when processing the polycistronic transcripts, tRNA genes 
are excised and due their small size (< 75 base pairs) tRNAs are more likely to be lost 
during the RNA extraction and/or library preparation procedures, whereas the mRNA 
and rRNA genes are retained (> 200 base pairs). Notably, we did not observe differences in 
this distinct pattern between the ER-positive and the ER-negative cases (Supplementary 
Figures S2 and S3), and thus the processing of the polycistronic transcripts does not 
seem to differ between these two subtypes. 
Our findings on the number, genomic distribution, and substitution pattern of 
mtDNA variants within the mitochondrial transcriptome are in line with previous 
studies on variants within the mitochondrial genome in other cancer types [8, 15, 16, 
21, 34, 35] (see also Supplementary File). We observe an increased number of somatic 
variants in the D-loop and fewer in mRNA genes than expected by genomic size, which 
might be explained by the gene-dense constitution of mtDNA: variants in the D-loop 
potentially have less destructive effects whereas variants in the mRNA genes might have 
detrimental effects on the function of the oxidative phosphorylation system, and thus 
will be selected against. However, compared to germline variants in our dataset there are 
fewer variants in the D-loop and more in the tRNA and mRNA genes, and enrichment 
for nonsynonymous variants. This might be explained by the typical mutation pattern 
shaping mtDNA, which has been shaping the germline variants and thus the trivial 
positions have already been altered, as suggested by Ju et al [15]. In line with this, the 
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conservation of variants among species – the fraction of species that harbour the reference 
sequence at that position – was much higher for somatic variants than for the germline 
variants, which can be explained by the same hypothesis. Adding to this, compared to 
the detected germline variants there is an increased number of C > T transitions among 
the somatic variants (Figure 4).
Adjusting variant allele frequency to account for sample purity (percentage of 
tumour cells within the specimen) is often applied for nuclear-encoded genes to obtain 
information on the allele frequency of variants in the tumour cells. However, this is 
not possible for mtDNA variants in tumour tissue specimens: the number of mtDNA 
molecules per cell largely varies among cell types and thus the non-tumour cells present 
in the specimen do not have the regular two copies as the nuclear genome would have, 
but contain multiple mtDNA copies of an unknown number. As a result, whereas allele 
frequency of variants could give information on possible constraints on variants, we did 
not perform analysis on it since it is impossible to estimate the actual allele frequency of 
variants in the mitochondria of tumour cells. Nevertheless, we show that majority of the 
samples with more than 1 somatic variant harbour a difference in variant allele frequency 
between variants, indicative for (sub-)clonality. This corresponds to the hypothesis that 
mtDNA variants are either expanded or lost [36] and that the mutations occur separated 
in time [15].
Also noteworthy is that with the current methodologies applied by us and by others 
– namely the use of non-micro dissected tumour specimens and blood as matched normal 
DNA – we cannot be completely sure that the detected somatic mtDNA mutations are 
tumour-specific. First, tumour tissue specimens consist of multiple cell types, including 
the tumour cells but also non-neoplastic cells such as immune cells and cells from the 
mammary epithelium, all with variable mtDNA content. Secondly, (somatic) mtDNA 
variant heteroplasmy patterns can differ within an individual across tissues [37-40]. Thus, 
the somatic variants were either acquired in the tumour, the normal somatic epithelium, 
or even in other cell types present within the specimen.
We did not observe associations between the number of somatic mtRNA variants and 
the three major mutational processes shaping the nDNA within breast tumours. This is 
in line with the hypothesis that mutations within the mitochondrial genome are mainly 
due to fidelity of the mitochondrial polymerase [41] and thereby hardly due to exogenous 
factors [15]. Accordingly, in our evaluation of associations with clinicopathological 
parameters we observed a statistically significant association between the number of 
mtRNA somatic variants and age at diagnosis. Previous work on somatic variants at 
the DNA level also revealed a correlation with older age of diagnosis (n = 381 [15] and 
n = 58 cases [34]). Previous work in a small cohort also showed associations between 
number of somatic variants in mtDNA and higher TNM and higher histological grade 
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(n = 58 cases [34]), which we did not observe. Please note that there are differences in 
the composition of the cohorts; our dataset does not exactly represent the breast cancer 
population as seen in daily practice, with an underrepresentation of ERBB2-amplified 
cases (Supplementary Table 1). 
By using data at the RNA level, we intended to minimize the interference of NUMTs 
with evaluation of mtDNA expression and variant calling, since their expression in the 
nucleus is negligibly low [11, 42]. Especially in defining heteroplasmic mtDNA variants 
in DNA data, NUMTs have been shown to be a complicating issue with non-identical 
positions misinterpreted as heteroplasmic variants [43-47]. Note that we do observe a 
few heteroplasmic variants at the DNA-only level (Supplementary File). However, using 
data at the RNA level comes with the trade-off that only variants in expressed regions are 
detected and thus variants in non-expressed regions are missed. Since mtDNA is a gene-
dense entity, we estimate that the number of missed variants should be low. Indeed, in 
our direct comparison of samples with variants at the RNA and DNA level, we show that 
this is maximally ~3% of the variants (DNA-only variants). Similar to these findings, the 
comparison by Stewart et al [16] on somatic variants at the RNA and DNA level showed 
7 of the 130 variants (5%) detected at only the DNA level within their set of 100 breast 
cancer specimens. Another trade-off using RNA is the additional step to generate cDNA, 
which might induce false positive calls by mistakes of the reverse transcriptase. Again based 
on our direct comparison of samples with variants at the RNA and DNA level, the number 
of false positives is maximally 3% of the detected variants (RNA-only variants). Though, 
besides false positives, these RNA-only variants might actually be RNA-DNA differences 
for example caused by RNA-editing [48], or true variants not called at the DNA level. 
To conclude, in this explorative study on the role of mtRNA in breast cancer, we 
found that somatic variants at the DNA level are reflected at the RNA level with no 
hotspot mutations and great heterogeneity across tumours. We confirm that the number 
of somatic variants within the mitochondrial transcriptome is not associated with the 
mutational processes shaping the nuclear genome but instead, is associated with age of 
diagnosis. Furthermore, we show that mitochondrial expression is related to ER status. 
The exact consequence of the observed differences in mtRNA expression and the detected 
somatic variants on metabolism and clinical outcome warrants further study.
Materials and methods
Data
We studied all patients with RNA sequencing data within the ICGC BASIS consortium, of 
which the cohort has been described previously [17] and data deposited in the European-
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Genome Phenome Archive (accession code EGAS00001001178). Briefly, for a total of 
348 primary breast tumours we generated duplex-specific nuclease-based RNA sequencing 
data. Four samples were excluded from analyses due to potential cross-contamination (see 
below). We did not apply a threshold on tumour cell percentage within the specimen 
for inclusion in this study. Clinicopathological data and the nuclear somatic mutation 
catalogue were obtained from the Supplementary Tables as provided by Nik-Zainal et al 
[17]. Expression levels of ESR1, PGR (quantile normalized FPKM, log2 transformed) 
were obtained as described previously [49]. A complete dataset on all variables used in 
our analyses is provided in Supplementary Table 1. In addition, we used publically 
available RNA sequencing data of twelve human tissue specimens obtained via a similar 
sequencing approach [20], that has been deposited in NCBI’s Gene Expression Omnibus 
(GEO) (accession code GSE45326). Also, we used the mtDNA variants called by Ju et 
al [15] from whole-genome or whole-exome sequencing data of DNA from the primary 
breast tumour specimens and matched normal tissue specimens as provided in their 
Supplementary Tables.
Bioinformatics
Sequencing reads were aligned using STAR v2.4.2.a [50] against the Genome Reference 
Consortium Human Build 38 (GRCh38, GenBank assembly GCA_000001405.15), 
which contains as the mitochondrial contig the revised Cambridge Reference Sequence 
(rCRS). Only non-duplicated uniquely mapped reads on mtDNA were used for 
further analysis, to avoid the potential use of improper assigned nuclear insertions of 
mitochondrial origin (NUMTs, mitochondrial pseudogenes). Note that RNA expression 
of NUMTs has been shown to be absent or negligibly low [11, 42]. Total read depth was 
estimated based on the read length (75 nucleotides) and mtDNA size (16,569 nucleotides). 
FeatureCounts v 1.4.6 [51] was used to count mapped reads using mtDNA as the meta-
feature and each genomic region (13 mRNAs, 22 tRNAs, 2 rRNAs) as the features, 
allowing multi-overlapping reads (-O) because of the polycistronic nature of mitochondrial 
RNA transcripts. We normalized read counts to transcripts per million (TPM) for the 
entire mitochondrial contig (mtDNA read counts versus total read counts assigned to 
genes in GRCh38, defined as entire mtDNA levels) and for each mitochondrial-encoded 
gene (gene read counts versus total mtDNA read counts, defined as <gene> levels). In this 
way, the TPM for the entire mtDNA represents the total amount of mtRNA influenced 
by both mtDNA content, transcription rate and transcript stability, whereas the TPM 
for each mitochondrial-encoded gene represents the variation in gene expression driven 
by processing of the polycistronic transcripts and transcript stability [52]. A complete 
dataset of all expression levels is provided in Supplementary Table 2. Variants alternative 
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to rCRS were called using GATK HaplotypeCaller 3.4-46-gbc02625 [53] using default 
settings (including downsampling_type = BY_SAMPLE, downsample_to_coverage = 500, 
standard_min_confidence_threshold_for_calling = 20). In this way, maximum depth of 
coverage is controlled at each locus, resulting in a more even coverage of variants between 
the samples. Hard-filtering was applied to the called variants for quality by depth (QD 
> 2), alternative depth (AD of ALT > 10) and strand odds ratio (variants with allele 
frequency ≤ 95% i.e. heteroplasmic variants: SOD < 4 for SNVs and SOD < 10 for 
INDELs; variants with allele frequency > 95% i.e. (near) homoplasmic: no filtering). In 
this way, the allele frequency of detected variants was high and confident enough to be 
a true variant and likely no sequencing errors or PCR mistakes. In addition, after visual 
inspection of variants (Integrative Genomics Viewer [54, 55]), potential false positive 
calls in challenging regions were excluded: positions surrounding the homopolymer 
region 301-315 (“D310”), positions 512-513 due to a repetitive sequence, alternative 
C calls at positions 16182-16183 and 16189 due to polyC sequences, and alternative A 
at positions 4264, 5513 and 12138-12139 due to polyA sequences. A complete dataset 
of all remaining variants is provided in Supplementary Table 3. All remaining single 
nucleotide variants were used in a nucleotide BLAST against the human reference sequence 
(NCBI’s nucleotide web blast, https://blast.ncbi.nlm.nih.gov) with the surrounding 
reference sequence (30 bases 5’ and 30 bases 3’) to uncover potential NUMT events, but 
none were recovered. The conservation index (45 species conservation) for the protein-
coding genes, tRNAs and rRNAs were obtained via SNV Query in Mitomaster [56]. 
The haplotype of each case was estimated by using the heteroplasmic and homoplasmic 
variants in HaploGrep v2 [57]. Sample cross-contamination was estimated using only the 
heteroplasmic variants (allele frequency ≤ 95%) in haplotype assignment. This identified 
four samples with heteroplasmic contamination of another haplotype, therefore these 
samples were excluded from analyses. Sample mismatch between cases with variants called 
in both RNA (our dataset) and DNA (dataset Ju et al [15]) sequencing data (n = 168) 
was estimated by haplotyping based on all near-homoplasmic variants (allele frequency 
> 95%), and comparison of the obtained haplogroup. Mismatch was observed for 13 
patients, but after manual inspection specificity could be confirmed for 10 patients by 
the presence of private variants. Two patients with a clear mismatch, and one patient 
ambiguous in mismatch, were excluded from the RNA-DNA comparison analyses (n = 
165 remaining).
Statistics
Performed statistical tests are reported in the results section. All statistical tests were 
two-sided, and P values smaller than 0.05 were considered as statistically significant. 
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Outliers data points in boxplots are defined as Q1-1.5*IQR or Q3+1.5*IQR. Analyses 
were performed in R version 3.3.2 (https://cran.r-project.org). Data analyses included 
usage of the following packages: the set of tidyverse, ggcorplot, SomaticSignatures [58] 
and VennDiagram [59]. 
Supplementary data
Supplementary data for this article are available online at Cancers 
(https://www.mdpi.com/journal/cancers). 
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The use of blood-circulating cell-free DNA (cfDNA) as ‘liquid-biopsy’ is 
explored worldwide, with hopes for its potential in providing prognostic or 
predictive information in cancer treatment. In exploring cfDNA, valuable 
repositories are biobanks containing material collected over time, however 
these retrospective cohorts have restrictive resources. In this study, we 
aimed to detect tumour-specific mutations in only minute amounts of 
serum-derived cfDNA by using a targeted next generation sequencing 
(NGS) approach. In a retrospective cohort of ten metastatic breast cancer 
patients, we profiled DNA from primary tumour tissue (fresh frozen), 
tumour-adjacent normal tissue (formalin-fixed paraffin embedded), and 
three consecutive serum samples (frozen). Our presented workflow includes 
comparisons with matched normal DNA or in silico reference DNA to 
discriminate germline from somatic variants, validation of variants through 
the detection in at least two DNA samples of an individual, and the use 
of public databases on variants. By our workflow, we were able to detect a 
total of four variants traceable as circulating tumour DNA (ctDNA) in the 
sera of three of the ten patients.
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Introduction
Blood-circulating nucleic acids are extracellular (cell-free, cf ) residing DNA or RNA 
molecules (cfDNA or cfRNA) that likely originate from apoptotic or necrotic cells, or 
are actively released [1]. In cancer patients, cfDNA may harbour somatically derived 
tumour-specific mutations reflecting the genomic characteristics of an individual’s cancer, 
such as single nucleotide variants or structural rearrangements [2, 3]. The use of cfDNA 
as a so-called ‘liquid-biopsy’ is being explored worldwide, with hopes for its potential 
in providing prognostic or predictive information. In exploring the potential of cfDNA 
in oncology, valuable repositories are biobanks containing material collected over time. 
However, these retrospective cohorts have restrictive resources, including suboptimal 
specimen preservations such as formalin fixed and paraffin embedded (FFPE) specimens or 
limiting amounts of DNA available for profiling, challenging the analysis of these cohorts. 
In this study, we aimed to detect tumour-specific mutations in only minute amounts 
of serum-derived cfDNA. We present a NGS workflow using a custom 45 gene sequencing 
panel on the Ion PGM system applied to a retrospective cohort of ten metastatic breast 
cancer patients. This workflow includes comparisons with FFPE matched normal DNA 
from tumour-adjacent histologically normal mammary epithelium or in silico reference 
DNA to discriminate germline from somatic variants. To evaluate the detection of variants 
in minute quantities of DNA, we initially compared, for two patients, the performance 
of our method on standard amounts of primary tumour DNA with minute counterparts. 
Finally, for all ten patients, we identified variants in their primary tumour DNA (standard 
DNA quantities) and three consecutive serum samples (minute DNA quantities) 
Results
Performance of the custom amplification-based targeted NGS panel
Using our custom panel we sequenced a total of forty-six DNA samples, derived from 
fresh frozen (FF) primary breast carcinoma specimens (tumour), FF serum (cfDNA) 
and FFPE tumour-adjacent normal mammary epithelial specimens (matched normal). 
Primary tumour (n = 10) and matched normal (n = 6) DNA samples were analysed 
using standard amounts of DNA input. The cfDNA samples (n = 30) were analysed 
using minute amounts of DNA input (median 387 pg, interquartile range IQR 265-445 
pg) as well as two replicates of primary tumour DNA for two patients (n = 4) (250 pg).
For performance assessment, we analysed the following parameters of the data. Before 
mapping we analysed 1) read length distribution and 2) per sequence GC content of the 
generated reads. After mapping against the reference genome we analysed 3) read for each 
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amplicon, 4) percentage of reads mapped to the targeted regions relative to all mapped 
reads and 5) read depth of those mapped reads. Finally, after calling single nucleotide 
variants deviant from the reference genome we analysed 6) the percentage of bases called 
at the required read depth. 
First, the distribution in read length of the reads of each sample was compared to the 
expected distribution in read length based on amplicon size of the panel (Supplementary 
Figure S1A). The highest peak of read length was at the expected 120 base pairs (bp) for 
the primary tumour DNA sequenced at standard and at minute amounts as well as for 
the cfDNA sequenced at minute amounts, whereas the matched normal DNA had its 
highest peak at 90 bp (Kruskal Wallis P < 0.001). Second, we analysed the GC content 
of the reads for each sample (Supplementary Figure S1B). The highest peak for GC 
content was at the expected 50% for the primary tumour DNA sequenced at standard 
and minute amounts and the cfDNA sequenced at minute amounts, whereas the matched 
normal DNA had the highest peak at 40% (Kruskal Wallis P = 0.002). Third, we analysed 
the amplicon performance for each sample type by the median reads per amplicon. The 
required read depth of at least 20x was obtained for 3019/3106 (97.2%) amplicons 
in matched normal DNA. The required read depth of at least 100x was obtained for 
2973/3106 (95.7%) in the primary tumour DNA at standard amounts, 2953/3106 
(95.1%) at minute amounts, and 2947/3106 (94.9%) for cfDNA at minute amounts. 
A total of 66/3106 amplicons (2.1%) did not reach the required read depths in all four 
sample types covering regions in 25 genes. Fourth, we determined the percentage of 
reads mapped to the targeted regions relative to all mapped reads. This percentage was 
for matched normal DNA sequenced at standard amounts (90.4%, IQR 76.2-93.1%) 
approximately 5% less compared to primary tumour DNA sequenced at standard amounts 
(95.7%, IQR 95.6-95.8%) or cfDNA sequenced at minute amounts (94.5%, IQR 94.3-
94.7%) (Mann Whitney both P < 0.001). This percentage was for cfDNA approximately 
1% less than primary tumour DNA sequenced at standard amounts (Mann Whitney P 
< 0.001). The percentage of mapped reads at the targeted regions did not differ between 
primary tumour DNA sequenced at minute (95.2%, IQR 95.2-95.3%) and standard 
amounts (Mann Whitney P = 0.8). Fifth, the median read depth of matched normal DNA 
(351x, IQR 139-756x) was lower than that of either primary tumour DNA sequenced 
at standard amounts (899x, IQR 527-1377x) or cfDNA sequenced at minute amounts 
(891x, IQR 530-1385x) (Mann Whitney P = 0.001 and P < 0.001). The median read 
depth of either cfDNA or primary tumour DNA sequenced at minute amounts was 
comparable to primary tumour DNA sequenced at standard amounts (Mann Whitney P 
= 0.6 and P = 0.1, respectively). Finally, after mapping of the sequencing reads, we called 
single nucleotide variants deviant from the reference genome to reveal germline single 
nucleotide polymorphisms (SNPs) and somatically acquired tumour-specific variants. Of 
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the called variants, the variant frequency was calculated as the fraction of variant reads 
over the total reads at that genomic position. Based on our criterion of 10 or more variant 
reads, matched normal material – intended to detect germline SNPs at 50% or 100% 
variant frequency – required a read depth of at least 20x. The percentage of bases at a 
depth of at least 20x was median 94.6% (IQR 91.8%-97.1%) in the matched normal 
DNA. Other material – intended to detect tumour specific somatic variants – required 
a read depth of at least 100x. In the primary tumour DNA and cfDNA the percentage 
of bases at a depth of at least 100x was respectively median 95.4% (IQR 95.0%-95.9%) 
and 95.0% (IQR 93.8%-95.8%). 
Taken together, these findings imply that DNA sequenced at standard or at minute 
amounts results in comparable amounts and quality of data, but that sequencing material 
derived from FFPE preserved specimens – as is our matched normal material – resulted 
in less read depth and biased data with respect to length and GC content of the reads.
Defining the somatic origin of variants
To discriminate between SNPs and somatic variants in the primary tumour and cfDNA, 
we had FFPE-preserved tumour-adjacent normal mammary epithelium available for six of 
the ten patients. After calling single nucleotide variants deviant from the reference genome, 
an unexpected high and variable number of variants was detected in the matched normal 
DNA: a median of 1754 variants (IQR 78-4311 variants), as opposed to a median of 
50 variants (IQR 46-54 variants) in the six corresponding primary tumour DNAs. The 
variants detected in matched normal DNA showed an enrichment for C > T transitions 
in their substitution spectrum, comprising median 86.0% (IQR 57.7-96.5%) of the total 
detected variants within a sample (Figure 1A, red). This is different than the distribution 
for SNPs in the human exome (i.e. 6.7% C > A, 8.9% C > G, 52.2% C > T, 4.4% T 
> A, 24.4% T > C and 3.5% T > G [4]) or that of the FF primary tumour material 
(Supplementary Figure S2B). Variants in matched normal DNA are only expected 
to represent hetero- and homozygous SNPs at variant frequencies of 50% and 100% 
respectively. The C > T transitions in these FFPE specimens often had variant frequency 
far below 50% in most samples (Supplementary Figure S2A). Therefore, we explored 
the effect of excluding from our matched normal FFPE-derived DNA all called variants 
which had variant frequencies below expected frequency for heterozygosity. Exclusion 
of variants below 35% variant frequency in these samples greatly reduced the number 
of reported variants to a median of 48 (IQR 41-297 variants) per sample. However, for 
P4 and P5, the number of variants detected remained unacceptable high after exclusion 
of variants below 35% variant frequency (resp. 379 and 543, Figure 1B) prompting us 
to omit all the data of those two matched normal samples for discrimination between 
Chapter_5_Marjolein.indd   81 22-12-2018   10:09:06
82   |   Chapter 5
germline SNPs and somatic tumour variants. For the other four patients, the variants 
detected in matched normal DNA after ≤ 35% variant frequency curations were considered 
germline SNPs. 
Next, we aimed to define the somatic or germline origin of variants detected in the 
primary tumour material of the ten patients. Alignment to the reference genome revealed 
a total of 486 alternative variants in all ten primary tumours with a median of 50 variants 
(IQR 45-54 variants) per individual tumour. The subsequent identification of somatically 
acquired variants in tumour material involves the exclusion of germline SNPs from the 
called variants. Conventionally, SNPs detected in matched normal DNA are used for 
this purpose (see above). Correction for germline SNPs reported in the curated matched 
normal DNA left us with 17, 6, 11 and 11 putative somatic variants in the primary 
Figure 1 Substitution spectra of variants called relative to the reference genome in DNA derived from formalin 
fixed paraffin embedded (FFPE) matched normal specimens. 
A: The contribution of the six possible base substitutions (C > A in blue, C > G in black, C > T in red, T > A in grey, T > 
C in green and T > G in pink) are depicted for each of six patients (P1 to P6) relative to the total variants in that sample. 
The total number of detected variants is depicted at the right end of the bars. B: A threshold removing variants with 
variant frequencies below 35% was applied to FFPE preserved matched normal specimens. The resulting substitution 
spectra (as in A) are depicted for each of the six patients (P1 to P6).
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tumour of P1, P2, P3 and P6, respectively (Table 1). However, no suitable matched 
normal DNA for germline SNP detection was available for the remaining six patients. 
As an alternative approach, we explored the in silico Virtual Normal methodology [5]. 
This methodology applies the contextual information of variants reported in the public 
domain by not only taking into account the surrounding reference sequence, but also 
neighbouring variants. We compared the conventional method using matched normal 
DNA (MN) with the in silico method using Virtual Normal genomes (VN) for the four 
patients of which suitable matched normal material was sequenced (Figure 2). The 
concordance in classification as germline SNPs i.e. present in both the MN and VN, or 
as somatic variants i.e. absent from both the MN and VN, is in total median 81% of the 
variants detected in the primary tumours (Figure 2, black and blue). Absent from the 
MN but present in the VN were 15% of the variants (Figure 2, yellow) and 3% of the 
variants were absent from the VN but present in the MN (Figure 2, grey).
Figure 2 Defining somatic origin of variants using matched normal DNA (MN) or virtual normal genomes (VN) 
as reference. 
Annotation of variants detected in the primary tumours of the four patients of who matched normal was accessible (P1, 
P2, P3 and P6) are depicted relative to the total variants in that sample. In here, variants absent from both the VN and 
MN in black, variants present in both VN and MN in blue, variants absent in the VN but present in the MN in grey, 
and variants present in the VN but absent from the MN in yellow. The total number of detected variants is depicted at 
the right end of the bars. 
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Taken together, we defined putative somatic variants in tumour DNA as follows. 
If matched normal material was available, occurrence of a tumour variant in this MN 
identifies variants as germline SNP. Additionally, irrespective the availability of matched 
normal material, in silico annotation using the VN genomes classifies variants as SNP 
when present in at least one VN genome. Applying the above to all variants of the ten 
primary tumours left us with 33 putative somatic variants recurrent at 26 distinct locations 
in the genome. Per individual tumour, a median of 2 (IQR 2-3) putative somatic variants 
were detected (Table 1, Supplementary Table S1).
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Table 1 Variant detection in primary tumour and serum-derived cfDNA specimens.
Patient Specimen Variants
Variants 
in MN
Variants 
in VN
Somatic 
variants
Confirmed 
somatic variants
P1
Primary tumour 48 31 44 2 1
cfDNA (serum T1) 46 29 42 2 2
cfDNA (serum T2) 53 29 46 5 2
cfDNA (serum T3) 77 30 47 28 1
P2
Primary tumour 45 39 43 1 1
cfDNA (serum T1) 49 40 45 3 1
cfDNA (serum T2) 46 40 44 1 1
cfDNA (serum T3) 47 39 44 2 1
P3
Primary tumour 55 44 48 3 3
cfDNA (serum T1) 57 45 49 4 3
cfDNA (serum T2) 56 43 48 4 3
cfDNA (serum T3) 55 44 48 3 3
P4
Primary tumour 36 NA 34 2 1
cfDNA (serum T1) 33 NA 32 1 1
cfDNA (serum T2) 33 NA 32 1 1
cfDNA (serum T3) 35 NA 34 1 1
P5
Primary tumour 52 NA 49 3 3
cfDNA (serum T1) 50 NA 47 3 3
cfDNA (serum T2) 51 NA 48 3 3
cfDNA (serum T3) 51 NA 48 3 3
P6
Primary tumour 59 48 56 2 1
cfDNA (serum T1) 58 49 56 1 1
cfDNA (serum T2) 59 50 57 1 1
cfDNA (serum T3) 58 49 56 1 1
P7
Primary tumour 45 NA 35 10 8
cfDNA (serum T1) 45 NA 34 11 7
cfDNA (serum T2) 50 NA 36 14 6
cfDNA (serum T3) 43 NA 34 9 8
P8
Primary tumour 51 NA 45 6 3
cfDNA (serum T1) 49 NA 45 4 4
cfDNA (serum T2) 49 NA 45 4 4
cfDNA (serum T3) 48 NA 45 3 3
P9
Primary tumour 54 NA 52 2 2
cfDNA (serum T1) 54 NA 52 2 1
cfDNA (serum T2) 55 NA 54 1 1
cfDNA (serum T3) 70 NA 54 16 1
P10
Primary tumour 41 NA 39 2 1
cfDNA (serum T1) 111 NA 42 69 0
cfDNA (serum T2) 54 NA 40 14 0
cfDNA (serum T3) 44 NA 39 5 1
Number of variants (columns) in each specimen for each of the ten patients (rows). The columns indicate 1) total variants 
detected, 2) variants in the indicated specimen also detected in the matched normal specimen (if available), 3) variants 
in the indicated specimen also present in at least one Virtual Normal genome, 4) variants classified as somatic variant 
(criteria in manuscript) and 5) somatic variants in the indicated specimen also confirmed in at least one additional 
patient-matched specimen.
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Detection of variants in minute material
To evaluate the feasibility of detecting variants in minute quantities of DNA, we compared 
the sequence output of our targeted sequencing panel on primary tumour DNA as standard 
and minute sequencing input. To this end, we sequenced for two individual patients 
one standard as 10 ng input and two minute counterparts as 250 pg input. In the first 
patient, we detected a total of 48 variants in the primary tumour sequenced at standard 
amounts and 46 and 49 variants in the two replicates sequenced at minute amounts 
(P1, Table 2). In the second patient, we detected a total of 45 variants in the primary 
tumour sequenced at standard amounts and 79 and 50 variants in the two replicates 
sequenced at minute amounts (P2, Table 2). Using the variants detected in the standard 
primary tumour DNA as predicted positives, the variant detection in minute replicates 
has a sensitivity of 96.8% (IQR 3.1%) and a false discovery rate of 9% (IQR 14.4%). 
The high discovery rate implies false positive variants generated as a result of sequencing 
minute quantities. Indeed, a high number of variants is detected in only a single minute 
replicates sample and are present at a low variant frequency (Figure 3A). To overcome 
these false positives, we aimed at the confirmation of a variant in an additional sample, 
which means we require a variant to be detected in at least two samples of an individual 
patient. A total of 44 variants were detected in both minute replicate samples for both 
P1 and P2. When we apply this confirmation-approach, a sensitivity of 91.7% (P1) and 
97.8% (P2), and a false discovery rate of 0% (P1 and P2) were obtained. We next explored 
if the additional PCR cycles for the minute quantities introduced biases, such as a shift in 
variant frequency or allelic dropouts. For this, we selected variants in the primary tumour 
Table 2 Variant detection in primary tumour specimen replicates at standard or minute input.
Patient Replicate Variants
Variants 
in MN
Variants 
in VN
Somatic 
variants
Somatic 
variants 
in 1/3
Somatic 
variants 
in 2/3
Somatic 
variants 
in 3/3
P1
Standard 48 31 44 2 0 1 1
Minute (A) 46 29 41 3 1 1 1
Minute (B) 49 30 44 3 2 0 1
P2
Standard 45 39 43 1 0 0 1
Minute (A) 79 39 46 32 31 0 1
Minute (B) 50 38 45 5 4 0 1
Number of variants detected (columns) in each replicate for each of the two patients of primary tumour specimen 
sequenced at standard and minute amounts (rows). The columns indicate 1) total variants detected, 2) variants in 
the indicated replicate also detected in the matched normal (MN) specimen (if available), 3) variants in the indicated 
replicate also present in at least one Virtual Normal (VN) genome, 4) variants classified as somatic variant (criteria in 
manuscript), 5) somatic variants in only the indicated replicate (one out of three) 6) somatic variants in the indicated 
and in one additional replicate (two out of three) and 7) somatic variants in the indicated and in all additional replicates 
(two out of three).
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defined as germline by their presence in the VN genomes and with a variant frequency 
between 45-55% (heterozygotes, n = 46) or above 95% (homozygotes, n = 26). In the 
primary tumours sequenced at standard quantities, the median variant frequency is for 
heterozygotes 49.4% (IQR 3.57%) and for homozygotes 99.7% (IQR 0.74%). In the 
minute replicates, a larger variation is visible for those selected variants: for heterozygotes 
a median variant frequency of 49.2% (IQR 8.7%) (Brown-Forsythe Levene-type test P 
< 0.001) and for homozygotes 99.7% (IQR 1.5%) (Brown-Forsythe Levene-type test P 
= 0.08). However, we did not observe any allelic dropouts (a shift in variant frequency 
from 45-55% to <5% or >95%, or from >95% to <5%) (Supplementary Figure S3A).
Last, for standard and minute replicates of the primary tumours, we defined the 
putative somatic variants for both patients (as described above). In the primary tumour 
Figure 3 Detection of (somatic) variants in standard and minute primary tumour replicate samples. 
A: The variant frequency in percentages of variants detected in a single replicate (1, white), in two out of three replicates 
(2, grey) or in all three replicates (3, black) of the two analysed patients. Recurrent somatic variants at unique genomic 
positions are connected by lines to visualize variant frequency between replicates. B: The variant frequency in percentages 
of somatic variants detected in a single replicate (1, white), in two out of three replicates (2, grey) or in all three replicates 
(3, black) of the two analysed patients. Recurrent somatic variants at unique genomic positions are connected by lines to 
visualize variant frequency between replicates. 
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DNA sequenced at standard input we detected a total of 2 and 1 somatic variants in P1 
and P2, respectively. Of those variants, we validated in the minute replicates 2/2 (100%) 
(Minute A) or 1/2 (50%) (Minute B) somatic variants in P1 and 1/1 (100%) (Minute 
A) or 1/1 (100%) (Minute B) somatic variants in P2 (Figure 3B). Thus, one of the 
three somatic variants was detected in one of the two minute replicates and therefore not 
detected by sequencing minute amounts. 
Taken together, by sequencing only minute input quantities the majority of variants 
are detected however with a more variable variant frequency. The confirmation of variants 
in an additional patient-matched sample is necessary to minimize false discoveries, and 
this is therefore included in our workflow.
Sequencing minute cfDNA as tumour surrogate
Besides the primary tumours, we sequenced three consecutive serum-derived cfDNA 
samples at minute quantities for each of the ten patients, in which we defined the putative 
somatic variants (as described above). In the ten primary tumours we detected 33 putative 
somatic variants with median 2 (IQR 2-3) per individual, in the thirty sera we detected 
219 putative somatic variants with median 3 (IQR 1-5) per cfDNA sample (Table 1). 
Because we included the confirmation of variants in an additional patient-matched 
sample, we first compared the putative somatic variants detected in each cfDNA sample 
with the matching primary tumour of each individual (Figure 4). A total of 24 putative 
somatic variants were present in at least one cfDNA sample and the matching primary 
tumour. On the other hand, there were 2 putative somatic variants confirmed in multiple 
matching cfDNA samples of an individual that were absent from the matching primary 
tumour (Figure 4, purple). Collectively, we were able to identify median 1 (IQR 1-3) 
putative somatic variants per cfDNA sample by confirmation in at least one additional 
patient-matched sample (Table 1). These 26 variants have potential as informative 
tumour-surrogate markers.
As a final step, we carefully inspected these variants to be able to use them as 
informative tumour surrogates (Table 3). First, we inspected the frequency of the variant. 
The contribution of non-tumour DNA is expected to be different between primary 
tumour specimen and cfDNA, and thus it would be unlikely for a somatic variant to 
have a cfDNA variant frequency similar to the variant frequency in the primary tumour 
specimen. Second, we employed public databases as in silico repositories for additional 
information about the detected variants, including databases on cancer driver genes [6], 
variants in relation to human health [7], germline polymorphisms [8-11] and functional 
consequences of the observed substitution [12]. Third, to make sure the variant had not 
been filtered out in other patient-matched samples, we inspected the detected somatic 
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Figure 4 Detection of somatic variants in primary tumour and serum-derived cfDNA specimens. 
The variant frequency in percentages of somatic variants detected in the primary tumour (PT) and three consecutive 
cfDNA samples (either T1, T2 or T3) of the ten patients in the study. Recurrent somatic variants at unique genomic 
positions are connected by lines to visualize variant frequency between replicates. Somatic variants detected in the 
primary tumour and confirmed in one, two or three patient-matched cfDNA sample in respectively white, grey or black. 
Somatic variants absent from the primary tumour but detected in two cfDNA sample in purple. 
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present in PT and one cfDNA present in PT and two cfDNA
present in PT and three cfDNA absent from PT and present in two cfDNA
variants in the original variant call files without any of the applied filtering steps of all 
the patient-matched samples. By using these three criteria, 22 variants are considered 
as non-informative (Table 3). The remaining four variants – AKAP9 c. 1686T>G in 
P1, PIK3CA c.3140A>T and SMAD4 c.1059C>A in P7, TP53 c.520C>T in P9 –are 
considered informative tumour surrogates traceable as ctDNA by our targeted sequencing 
approach (Table 3). These four variants were validated by conventional Sanger sequencing, 
and/or independent re-sequencing (Supplementary Figure S4).
Discussion
We aimed at developing an easily implementable targeted NGS approach to detect 
tumour-specific somatic variants in only minute amounts of cfDNA, to apply this to 
retrospective cohorts with specimens collected over time. These cohorts often have 
restrictions, such as limited amounts available and suboptimal preservation of specimens. 
To have a comprehensive coverage of somatic variants, we designed an amplicon panel 
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targeting exonic regions of 45 genes frequently mutated in breast, colon, prostate and 
ovarian cancer. Because of the small amplicon length in its design, this panel is suitable for 
the sequencing of fragmented DNA such as apoptotic cfDNA and degraded FFPE-derived 
DNA. Using this panel, we generated deep sequencing data of primary tumour DNA 
and minute amounts of serum-derived cfDNA samples of ten metastatic breast cancer 
patients from a retrospective cohort. We focused on the detection of single nucleotide 
substitutions in the sequencing data, because its detection is well-defined and it is the 
most prevalent mutation type in breast cancer [13]. 
The only source of germline DNA was FFPE-preserved tumour specimen from which 
we were able to obtain adjacent healthy tissue for six of the ten patients. We observed 
a variable number of artefacts in these FFPE-derived DNA samples. False discovery of 
particularly C > T transitions is known for FFPE-derived DNA samples [14-17], where 
cytosine residues are progressively de-aminated into uracil and upon amplification read 
as thymidine residues (C > U > T). This phenomenon is also evident in GC content of 
the generated reads, where for the matched normal specimens a decrease in GC content 
(i.e. C > T transition) is observed (Supplementary Figure S1B). The specimens were 
collected between 25 and 37 years ago, which may partially explain the suboptimal quality 
of these samples. For the detection of germline SNPs, the detection threshold of at least 
35% on variant frequency was sufficient to eliminate the majority of the preservation-
induced artefacts such as the C > T substitutions in four of the six cases. When material 
is not intended to only call germline SNPs but also lower frequency variants, i.e. in 
FFPE preserved tumour specimens, alternative strategies to eliminate FFPE-induced 
deamination products prior to sequencing – such as enzymatic treatment of the DNA 
samples or the use of proof-reading polymerases – are likely required [15, 17, 18]. 
As a next step, we aimed to define somatically acquired tumour-specific variants. The 
conventional approach uses matched normal DNA to make the distinction between somatic 
variants and germline SNPs in tumour material. However, when matched normal DNA is 
not of optimal quality – such as long-term FFPE preservation – the discrimination between 
germline SNPs and somatic variants becomes challenging. When artefacts are present in 
the matched normal data, there is a minor risk of erroneous categorization of tumour-
specific variants as SNPs in the tumour material. Especially since the C > T transition is 
also often observed in somatic mutation profiles of cancer specimens [19]. Also, there is 
a major risk of classifying a germline SNP as somatic variant in tumour material when it 
is not detected in matched normal DNA. This seems to occur frequently for P1 (Figure 
2): the addition of an alternative approach to discriminate between somatic and germline 
variants by using VN genomes [5] results in a large fraction of variants absent from the 
matched normal but present in the VN genomes. Also the fraction of variants present in 
both the matched normal and the VN genomes is small for P1. This indicates that some 
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germline variants had been missed in the poor quality matched normal DNA. The in silico 
approach using VN genomes thus removed additional variants which had been missed by 
taking only the matched normal approach. By combining our matched normal material 
and VN genomes, we identified the putative somatic variants in the tumour genomes of 
the ten patients described here. As an additional control for our classification as germline 
or somatic variant, we reason that tumour cell content of primary tumour specimen or 
the tumour-derived cfDNA fraction is never 100%, and thus that somatic variants cannot 
display a variant frequency close to 100%. Indeed, none of the variants with a variant 
frequency above 95% were classified as somatic (Supplementary Figure S5A and S5B).
By sequencing only minute quantities, we observed in a few samples some unexpected 
high numbers of variants i.e. in a primary tumour sample sequenced at minute amounts 
(P2 Minute A, Table 2) and also a few serum-derived cfDNA samples sequenced at 
minute amounts (P1 serum T3, P9 serum T3, P10 serum T1, Table 1). Theoretically, 
polymerase introduced artefacts – with a mutation rate of high-fidelity polymerases in 
the order of one mutation per a million bases – can reach approximately 300 variants 
per targeted amplification (worst-case scenario with 21 PCR cycle amplification of a 139 
bp amplicon). However, these randomly introduced artefacts should not exceed variant 
frequencies above 1.5% for minute quantities (a single artefact in 250 pg representing 36 
diploid cells [20]) and 0.05% for standard quantities (a single artefact in 10 ng representing 
1429 diploid cells), which is both below the 2% threshold used by the variant caller. 
However, we did observe a larger variation in variant frequency when using only minute 
input amounts for the primary tumour minute replicates (Supplementary Figure S3A) 
and also for the cfDNA samples (Supplementary Figure S3B). Amplification bias and 
variability in length of the fragmented DNA might skew the amplification of specific 
DNA fragments and thus variant frequency of detected variants [21]. We were unable to 
discover the exact reason why an increase in detected variants occurred in a few samples, 
and thus confirmation of detected variants is necessary. Commonly, validation of variants 
is achieved by independent re-analysis of the DNA sample. However, in retrospective 
cohorts this is not always possible due to restrictive sources of DNA. As an alternative, we 
suggest the confirmation of variants through the detection in at least two DNA samples 
of an individual patient. Because our cfDNA samples originate from consecutive serum 
draws, this means we might miss variants such as those occurring only during a specific 
stage in the disease trajectory. Also, we are aware that an obvious drawback of using only 
minute quantities of cfDNA is false negative detection. We can expect variants – especially 
low frequent variants – to be missed just by chance because of using minute fractions 
representing forty times fewer molecules than the standard input. 
Thus, we were able to detect multiple putative somatic variants in primary tumour 
material as well as their corresponding serum-derived cfDNA samples. As a final step, 
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we further inspected these variants whether they truly represent informative tumour 
surrogates. First, we compared variant frequency between patient-matched samples. The 
fraction of tumour-derived cfDNA is expected to be only a few percentages [22], whereas 
the primary tumour specimens are expected to have high tumour cell content. Therefore, 
somatic variants at around 50% variant frequency in both the primary tumour as well as 
the cfDNA are likely heterozygous SNPs; somatic variants at a low variant frequency in 
both the primary tumour as well as the cfDNA are potential artefacts. Somatic variants 
with a clearly different variant frequency between the primary tumour and cfDNA, or 
between consecutive cfDNA draws at different disease stages (e.g. disease recurrence), are 
indicative for true somatic variants traceable as ctDNA. Second, we took an advantage 
of public databases on variants. However, we observe conflicting annotation, i.e. variants 
being reported as both germline SNP but also as a tumour-specific somatic mutation in 
public databases (Table 3). Thus, this information should be taken with caution. Third, 
we verified if – due to stringent threshold settings – the detected variants had not been 
filtered out in patient-matched samples. Based on these three aspects we defined if the 
variant detected in cfDNA are to be used as an informative tumour surrogate (Table 3). 
A limitation by using only minute quantities of cfDNA is the detection limit in the 
order of 2% variant frequency (250 pg represents approximately 36 diploid cells [20] thus 
allowing the detection of 1 mutant copy in 72 wildtype copies), whereas tumour-specific 
cfDNA can be present at variant frequencies as low as 0.001% [22]. Also, the retrospective 
serum samples used in this study are likely contaminated with DNA from non-tumour 
cells such as lysed leukocytes [23], and thus the fraction of tumour-derived cfDNA is 
expected to be low. We are aware that the preservative in the blood collection tube (i.e. 
cloth activator or anti-coagulant), and processing procedure of the blood-derivative (i.e. 
time-to-processing and sedimentation speed), has a great influence on the cfDNA quantity 
[24-27], and because this affects the fraction of tumour-derived cfDNA it should be kept 
in mind when analysing cfDNA. Also, this makes comparison with other findings in 
literature quite complex. Previous studies have assessed cfDNA in metastatic breast cancer 
using methods varying from multi-gene to single mutation approaches including targeted 
or exome NGS, Sanger sequencing, digital (droplet) PCR, and BEAMing, most often in 
plasma samples. In comparison, our detection rate of 30% (3/10 patients with tumour-
specific cfDNA) is at the low side compared to the reported detection rate of 50%-100% 
in studies with a similar approach (profiling multiple genes in both the primary tumour 
and the cfDNA [28-32]). We attribute this difference to the use of minute quantities 
and thus our ability to detect variants at or above 2% VAF, since in the above mentioned 
studies approximately 30% of the reported tumour-specific variants in metastatic breast 
cancer have a frequency below 2%. In addition, we designed our gene-panel for the most 
frequently mutated genes, but variants not included in the panel will not be detected.
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Taken together, in a retrospective cohort with only limited amounts of serum-derived 
cfDNA available, using our developed workflow, we were able to retrace in cfDNA somatic 
variants detected in the primary tumour and also somatic variants not detected in the 
primary tumour for three of the ten patients (30%). We conclude that the presented 
approach enables specific detection of tumour-specific somatic variants above 2% variant 
frequency in minute amounts of cfDNA and can be used to discover tumour surrogate 
markers to explore the potential of cfDNA in oncology.
Materials and methods
Specimens
Retrospectively collected specimens from metastatic breast cancer patients were obtained 
from our biobank. Selection was based on availability of fresh frozen primary tumour 
and serum samples at three different time points during treatment for metastatic disease 
and stored at -80°C. The consecutive serum samples were collected at start of first line 
tamoxifen therapy (T1), during therapy (T2) and at disease progression (T3). For 
some cases haematoxylin stained microscopic sections of the routine formalin fixed and 
paraffin embedded primary tumour was available, of which macro-dissected adjacent 
normal epithelial mammary tissue yielded matched normal specimen [33]. The study 
was approved by the medical ethics committee (MEC 02.953) and performed according 
to the Code of Conduct of Medical Scientific Societies (www.federa.org/codes-conduct). 
In the Netherlands, according to the Code of Conduct, informed consent is not required 
for retrospective analysis of bio specimens retrieved during standard of care procedures.
DNA extraction
Primary tumour DNA was extracted using the phenol chloroform method from pulverized 
FF specimens [34]. Matched normal DNA was extracted using Chelex 100 resin (Bio-Rad, 
Veenendaal, the Netherlands) as described previously [33]. CfDNA was extracted after 
external lysis of the serum (400 µL) using the automated MagNA Pure Compact Nucleic 
Acid Isolation Kit I (Roche Diagnostics, Almere, the Netherlands) [35]. Extracted DNA 
was quantified using the Qubit® 2.0 fluorometer (Thermo Fisher Scientific, Landsmeer, 
the Netherlands).
Amplicon-based targeted next-generation sequencing
Ion semiconductor sequencing on the Ion Torrent Personal Genome Machine (PGM) 
was performed with an Ion AmpliSeq custom Panel applying consumables, kits, software 
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packages and protocols of the manufacturer (Thermo Fisher Scientific). In short, adapter-
ligated libraries were constructed using the AmpliSeq Library kit 2.0 using 3106 amplicons 
designed for small regions (63 to 139 nucleotides insert size) targeting 45 cancer-related 
genes [35]. Gene selection was based on the most frequently mutated driver genes in 
breast, colon, prostate and ovarian cancer as revealed by extensive genomic analysis 
deposited in the COSMIC database and interrogates for 39 genes all coding exons and 
for 6 genes only those exons harbouring hotspot mutations (Supplementary Table S2), 
covering a total of 14159 COSMIC mutations. For sequencing of minute amounts, 
the recommended DNA starting input of 10 ng was reduced to approximately 250 pg 
(range 165.6-573.6 pg). For samples below 10 ng DNA input, adapter-ligated library 
preparation was adjusted from the standard 17 PCR cycles to 20 or 21 PCR cycles. 
After purification with AMPure XP beads (Beckman Coulter, Woerden, the Netherlands), 
library quantity was determined using the Ion Library Quantitation kit and diluted to a 
final concentration of 8 pM. Template was emulsion PCR-prepared using the Ion PGM 
Template OT2 200 kit on the Ion OneTouch 2 system and confirmed using the Ion 
Sphere quality control kit. Template-positive Ion Sphere Particles were enriched using 
DynaBeads MyOne Streptavidin C1 on the Ion OneTouch ES instrument and barcoded 
samples were sequenced on the Ion Torrent PGM for 500 flows using the Ion PGM 
Sequencing Kit v2.0 on an Ion 318v2 chip. 
Bioinformatics and statistics
Data from the PGM runs were processed initially using the Ion Torrent platform-specific 
pipeline software Torrent Suite to generate sequence reads, trim adapter sequences, filter, 
and remove poor signal-profile reads. Quality control of generated reads was performed 
using the Torrent Suite Software v4.0 with the “Coverage Analysis” plug-in and using 
FastQC [36]. Initial variant calling compared to the reference genome hg19 (build 37) 
was generated using Torrent Suite Software v4.0 with the “variant caller v4.0” plug-in. 
To be able to detect low frequency variants with minimal false negative calls we used the 
Somatic - Low Stringency Optimized settings. To correct for panel-specific sequencing 
errors, we removed all variants detected in >90% of the analysed samples. Further analyses 
were conducted on single nucleotide variants in exonic regions only, a variant read depth 
of at least 10x, a quality score of at least 20 and with a minimal strand bias threshold of 
0.9. We applied to matched normal material – intended to detect germline SNPs at 50% 
or 100% variant frequency – a criterion of a at least 20x read depth. Other material – 
intended to detect tumour specific somatic variants – required a read depth of at least 
100x. The Virtual Normal methodology was applied using the Galaxy tool in the DTLS 
tool shed, using the ‘Diversity and 1000G (479 genomes)’ virtual normal set. Annotation 
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of the variants was performed by a custom pipeline including ANNOVAR [37], the 
Catalogue Of Somatic Mutations In Cancer [6] (COSMIC) version 67, ClinVar [7], the 
Genome of the Netherlands [11] (GoNL) version 7.0.0.59, Database of Single Nucleotide 
Polymorphisms [8] (dbSNP) build ID 137 (non-flagged), 1000 Genomes [10] (1000G) 
version 2012april_all, and the Exome Variant Server [9] (ESP) version 6500si_all. Variants 
assigned as somatic were examined visually using Integrative Genomics Viewer (IGV) 
software. Statistical comparisons were performed by the indicated tests in R version 3.2.3. 
Supplementary data
Supplementary data for this article are available online at Scientific Reports 
(https://www.nature.com/srep/). 
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Large variation exists in mitochondrial DNA (mtDNA) not only between 
but also within individuals. Also in human cancer, tumour-specific mtDNA 
variation exists. In this work, we describe the comparison of four methods 
to extract mtDNA as pure as possible from frozen tumour tissue. Also, 
three state-of-the-art methods for sensitive detection of mtDNA variants 
were evaluated. The main aim was to develop a procedure to detect low-
frequent single-nucleotide mtDNA-specific variants in frozen tumour 
tissue. We show that of the methods evaluated, DNA extracted from cytosol 
fractions following exonuclease treatment results in highest mtDNA yield 
and purity from frozen tumour tissue (270-fold mtDNA enrichment). 
Next, we demonstrate the sensitivity of detection of low-frequent single-
nucleotide mtDNA variants (≤ 1% allele frequency) in breast cancer cell 
lines MDA-MB-231 and MCF-7 by single-molecule real-time (SMRT) 
sequencing, UltraSEEK chemistry based mass spectrometry, and digital 
PCR. We also show de novo detection and allelic phasing of variants by 
SMRT sequencing. We conclude that our sensitive procedure to detect low-
frequent single-nucleotide mtDNA variants from frozen tumour tissue is 
based on extraction of DNA from cytosol fractions followed by exonuclease 
treatment to obtain high mtDNA purity, and subsequent SMRT sequencing 
for (de novo) detection and allelic phasing of variants.
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t
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Introduction
The past decades, extensive genomic analysis of tumour specimens using massive parallel 
sequencing by large sequencing consortia (e.g. https://www.icgc.org/icgc and http://
cancergenome.nih.gov/) have revealed the major somatic drivers of human cancer, that 
have been reported in numerous studies. However, the small circular genome of the 
mitochondria has been largely ignored in such analyses. The human mitochondrial 
DNA (mtDNA) consists of ~16,569 base pairs encoding 37 genes: two ribosomal RNAs 
and twenty-two transfer RNAs functioning in the mitochondrial translation apparatus 
and thirteen proteins essential for oxidative phosphorylation. The total number of 
mtDNA molecules per cell varies between cell types from a few up to several thousand, 
and depends on both the number of mitochondria per cell as well as the number of 
mtDNA molecules per mitochondrion [1-3]. Similar to chromosomal DNA in the 
nucleus (nDNA), mtDNA may contain rare or polymorphic variants. Currently nearly 
10,000 variable positions within mtDNA are reported in public databases [4]. When 
variation is acquired, genetically different mtDNA molecules can reside within a single 
cell, referred to as heteroplasmy (that is, > 0% and < 100% allele frequency per cell). 
Importantly, heteroplasmic patterns can differ within an individual across tissues [5-8]. 
Despite inherited and somatically acquired variants in mtDNA being associated with 
multiple human diseases [9], the exact significance of somatic mtDNA variants in cancer 
remains controversial [10, 11]. 
Recently, taking advantage of publically available data from the large sequencing 
consortia, a handful of papers reported on the catalogue of somatic mitochondrial variants 
in multiple tumour types [12-14]. However, a complicating issue in the genomic analysis 
of mtDNA is the presence of sequences of mitochondrial origin in the nDNA (termed 
nuclear insertions of mitochondrial origin, NUMTs). NUMTs have likely originated 
from joining mtDNA/RNA fragments to nDNA ends during double strand break repair 
[15, 16] and are found in nearly all eukaryotes that contain mtDNA. This process may 
occur at any moment during lifetime [17] as well as during tumour evolution [18]. There 
are fixed NUMTs present in virtually every human genome – and thus reported in the 
human reference genome – inserted millions of years ago, but also more recent NUMT 
insertions have been described [19]. Unfortunately, due to their sequence similarity to 
mtDNA, NUMTs can interfere with accurate variant detection and thus investigation 
of mitochondrial heteroplasmy [16, 19-23]. Estimations based on the human reference 
genome indicate that for each 175 base pairs mtDNA segment an average of 9.5 NUMT 
copies are present in the human nDNA [24], but this number may likely be higher [19]. 
In addition, since the insertion of the mitochondrial genome is an ongoing process, this 
number is even larger in tumour cells since they also contain all somatic insertions events 
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of NUMTs [18]. In addition, in tumour cells the processes shaping nDNA [25, 26] are 
substantially different from the one that shapes the mtDNA [13], resulting in somatic 
variants in NUMTs and complicating accurate mtDNA heteroplasmy detection even 
further for tumour cells.
Consequently, the large variation in mtDNA between and within individuals as well 
as the presence of NUMTs demands a highly specific and sensitive detection of mtDNA 
variants, especially for low-frequent tumour-specific variants. In the study described 
here, we aimed to develop a sensitive procedure to detect low-frequent single-nucleotide 
mtDNA variants in frozen tumour tissue. Multiple efforts in developing methods for 
extraction of pure mtDNA exist [27-34]. These include methods using commercial 
kits or (laborious) ultracentrifugation to obtain pure mitochondria, and techniques 
to enrich for mtDNA by either the isolation technique or enzymatic degradation of 
nDNA. Unfortunately, the majority of previous studies focused on either cultured cells 
or cells from the blood and not on more physically and biochemically complex structures 
formed by tissue specimens. Thus, the application of these techniques to frozen tumour 
tissue specimens – an important source to assess tumour cell characteristics – has not 
been shown to date. Therefore, we compared four easily implementable procedures to 
extract mtDNA as pure as possible from frozen tumour tissue. Also, we evaluated three 
state-of-the-art techniques for the detection of low-frequent mtDNA-specific variants: 
Pacific Biosciences’ SMRT sequencing [35], UltraSEEK chemistry [36] and digital PCR. 
Results
Procedure to obtain mtDNA-enriched DNA extracts from frozen tumour tissue
To obtain mtDNA as pure as possible from frozen tumour tissue, our first focus was on the 
most optimal isolation procedure to extract mtDNA with minimal carry-over of nDNA. 
For this, we extracted DNA from fresh frozen primary tumour specimens using four easily 
implementable methods, and compared the yields via quantification of the percentage 
of mtDNA (Figure 1A) and total amount of dsDNA (Figure 1B). A silica-based total 
cellular DNA extraction method (I) used as reference for yield resulted in median 863 ng 
(interquartile range IQR 94 ng) dsDNA of which 0.1% (IQR 0.0%) mtDNA. A method 
(II) based on alkaline extraction – commonly used to extract plasmid DNA and thus 
designed to extract circular DNA [28, 30, 32, 33] – yielded median 144 ng (IQR 140 ng) 
dsDNA with 0.5% (IQR 0.6%) mtDNA. Extracting DNA from isolated mitochondria 
(III) [34] yielded median 825 ng (IQR 529 ng) dsDNA with 0.2% (IQR 0.1%) mtDNA. 
A selective lysis method (IV) that starts with the disruption of the plasma membrane to 
release the cellular components [29, 37] followed by sedimentation of cell nuclei, and 
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DNA extracted from the remaining cytosol fraction yielded median 403 ng (IQR 321 
ng) dsDNA with 1.0% (IQR 0.8%) mtDNA. Note that a similar trend was obtained by 
these methods using frozen cultured cells as input (Supplementary Figure 1A/B). From 
these results, it is evident that the best isolation procedure to extract mtDNA from frozen 
tumour tissue is method IV – DNA from cytosol fractions – with the highest mtDNA 
percentage and sufficient dsDNA yield. To increase the mtDNA fraction, we applied 
an enzymatic exonuclease reaction to degrade specifically linear nDNA. This greatly 
increased the percentage of mtDNA in DNA extracts from cytosol fractions, from median 
1% (IQR 0.8%) to median 27% (IQR 40%) (Figure 1C). This result was also obtained 
when using DNA from frozen cultured cells as input material (Supplementary Figure 
1C). Exonuclease treatment on total cellular DNA extracts increased the percentage of 
mtDNA as well, but not to the same extent as for DNA extracts from cytosol fractions, 
and total dsDNA yield was lower (Supplementary Figure 2). Concluding, the preferred 
procedure to obtain mtDNA as pure as possible from fresh frozen tumour tissue is to 
extract DNA from cytosol fractions followed by exonuclease treatment.
Approach for sequencing of mtDNA
Next we explored sequencing methods for the detection of mtDNA variants. First, whole 
genome sequencing-by-synthesis (SBS) was applied to total cellular DNA extracts (method 
Figure 1 Comparison of methods for mtDNA extraction from fresh frozen tumour specimens.
Cryosections originating from ten frozen tumour specimens (biological replicates) were subjected to different extraction 
procedures including (I) a total cellular DNA extraction method, (II) a method based on alkaline extraction, (III) a 
method extracting DNA from isolated mitochondria and (IV) a selective lysis method extracting DNA from cytosol 
fractions. For each method, the percentage of mtDNA (A) and total amount of dsDNA (B) was quantified. Also, DNA 
extracts from cytosol fractions originating from ten frozen tumour specimens were subjected to exonuclease-based 
enrichment and the percentage of mtDNA quantified, with for each specimen the mtDNA percentage before and after 
treatment connected by lines (C). Boxplots represent median, inter quartile range (IQR) and 1.5 × IQR.
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I) and DNA extracts from cytosol fractions (method IV), both without and with additional 
enrichment for mtDNA by exonuclease treatment. As expected, the cell line DNA extract 
from cytosol fraction treated with exonuclease yielded the highest percentage of aligned 
reads to mtDNA (86%), whereas the other methods yielded much lower percentages (< 
25%) (Supplementary Table 1). The DNA extract from cytosol fraction treated with 
exonuclease derived from fresh frozen tumour tissue yielded a percentage of aligned reads 
to mtDNA in line with the PCR-based mtDNA percentage (respectively 12% and 10%). 
Thus, despite the relatively high fraction of 10% mtDNA, a major proportion of reads were 
derived from nuclear DNA. The observed spread in mtDNA percentage in exonuclease 
treated method IV extracts from frozen tumour tissue (Figure 1C) will therefore lead 
to a variable proportion of mtDNA reads using whole genome SBS. To circumvent this 
variability, we decided to explore a targeted approach for sequencing mtDNA. 
For this, nine primer sets covering the complete mtDNA were evaluated for their 
specificity to mtDNA, as in silico BLAST search showed that the primers did not match 
to known NUMT sequences in the reference genome. Specificity of the nine primer 
sets was confirmed by the absence of PCR products in two mtDNA-depleted cell lines 
(Supplementary Figure 3), allowing mtDNA-specific sequencing of the nine amplicons 
using single-molecule real-time (SMRT) sequencing. This method is able to generate 
long reads, covering each amplicon in a single read. To obtain an estimate of sequencing 
output and to evaluate variants detected by the whole genome SBS and targeted SMRT 
sequencing approaches, we compared for the two approaches the sequencing output of 
MDA-MB-231 DNA extracts from cytosol fraction treated with exonuclease. Whole 
genome SBS generated a total of 800,504 reads of 100 nucleotides (of which 87% 
duplicated reads) and after alignment resulted in an evenly distributed coverage of median 
201x (IQR 2, range 13 - 404). The 2,727 reads of 1,738 - 2,836 base pairs by targeted 
SMRT sequencing displayed more variable coverage among the amplicons with median 
282x (IQR 132, range 87 - 761) (Supplementary Figure 4). The more variable coverage 
in targeted SMRT sequencing was mainly due to regions where amplicons overlapped, 
causing an increase in coverage (Supplementary Figure 4). Both sequencing approaches 
detected all 29 positions with a documented alternative allele in MDA-MB-231 against 
rCRS at homoplasmic levels (> 99% allele frequency). Also additional heteroplasmic 
variants were detected, with no major differences observed between the two sequencing 
approaches (Supplementary File). Given the lower output in read depth per number of 
generated reads by whole genome SBS sequencing – due to a loss of reads which map to the 
nuclear genome – and the risk of introducing NUMTs hampering downstream analysis, 
we continued sequencing experiments using the targeted SMRT sequencing approach.
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Sensitive detection of low-frequent mtDNA variants
To detect low-frequent single-nucleotide variants in mtDNA, we evaluated three 
approaches: SMRT sequencing, UltraSEEK chemistry and digital PCR. As a source of 
mtDNA we used breast cancer cell lines MDA-MB-231 and MCF-7. A total of respectively 
29 and 13 variants alternative to rCRS have been documented in the mtDNA of MDA-
MB-231 (also see above) and MCF-7, with a total of 28 positions containing a different 
allele between the two cell lines. To determine detection limits empirically, we prepared 
mixtures of the cell lines – considering MDA-MB-231 as the mutant variant – to generate 
samples with allele frequencies of 0%, 0.001%, 0.01%, 0.1%, 1% and 10% variant. 
The mixture samples were subjected to the three detection methods, and we evaluated 
their ability to detect the mutant variant. By SMRT sequencing, we obtained a median 
coverage of 4,060x per sample (IQR 4,842x, range 648 – 34,263x) (see Supplementary 
Table 1 Limit of detection for low-frequent mtDNA variants by SMRT sequencing, UltraSEEK and digital PCR.
Position 
Mutant 
(MDA-MB-231)
Wildtype 
(MCF-7)
Limit of detection per method
SMRT UltraSEEK Digital PCR
153 G A ≥0.1% na na
195 C T ≥0.1% na na
1719 A G ≥0.1% na na
2706 G A ≥0.1% na na
6221 C T ≥1.0% ≥1.0% na
6371 T C ≥1.0% ≥0.1%* na
6776 T C ≥0.1% na na
7028 T C ≥0.1% na na
8506 C T ≥0.1% ≥1.0% na
9966 G A ≥0.1% na na
11719 A G ≥0.1% na na
12084 T C ≥0.1% ≥0.1% na
12705 T C ≥0.1% na na
13966 G A ≥0.1% ≥0.1% ≥0.01%
14470 C T ≥0.1% ≥0.1% na
14766 T C ≥0.1% na na
15310 C T ≥0.1% ≥0.1%* ≥0.1%
15380 A G ≥0.1% na na
16093 C T ≥0.1% na na
16184 C T ≥0.1% na na
16223 T C ≥0.1% na na
16265 G A ≥0.1% na na
16278 T C ≥0.1% na na
Detection of the mutant variant allele (MDA-MB-231 genotype) in the lowest mutant fraction mixture indicated per 
position per method (empirical limit of detection). For the UltraSEEK and digital PCR method this was limited to 
respectively 7 and 2 positions due to requirement of generating dedicated PCR primers. na = not analysed. * = detected 
in 1 out of 3 replicate samples.
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Table 2 Allele frequency of the heteroplasmic de novo variants detected in six cell line mixtures by SMRT 
sequencing.
 
Position
 
Variant
 
Detected 
amplicona
 
Phased 
genotypeb
Cell line mixture (mutant fraction)
0% 0.001% 0.01% 0.1% 1% 10%
76 T A, B Wildtype 24.06* 24.75* 24.44* 24.75* 24.35* 21.01*
15806 A A Wildtype 7.09 7.29 7.07 7.12 7.58 6.22
1062 A B Wildtype 1.29 1.34 1.24 1.33 1.20 1.37
10085 T F Wildtype 0.60 0.86 0.87 0.84 0.74 0.70
7029 T E Wildtype 0.49 0.48 nc 0.37 nc 0.47
14644 T I Wildtype 0.30 0.38 0.24 0.23 0.41 0.36
14817 T I Wildtype 0.29 0.23 0.33 0.34 nc nc
72 C A, B Wildtype 0.13* 0.12* 0.14* 0.14* 0.19* 0.08*
15897 A A Wildtype 0.12 0.09 0.16 0.10 nc 0.15
1398 C B Wildtype 0.08 nc 0.08 0.05 nc nc
39 T A, B Wildtype 0.06* 0.06* 0.03* 0.10* 0.08* 0.04*
5031 A D Wildtype 0.14 nc nc nc 0.17 nc
14751 T I Wildtype nc 0.15 nc 0.09 0.16 nc
15129 C I, A Wildtype nc 0.05* 0.05* nc nc nc
934 A B Wildtype nc 0.05 0.05 nc nc nc
564 A B Wildtype nc 0.05 nc 0.08 nc nc
12124 T G, H Wildtype nc 0.05* nc 0.04* 0.07* nc
103 A A, B Wildtype nc nc nc 0.01* nc nc
13680 T H, I Wildtype nc nc nc 0.03* nc nc
10607 T F, G Wildtype nc nc nc nc 0.06* nc
16391 A A Wildtype 0.07# nc nc nc nc nc
9808 T F Wildtype nc nc 0.08# nc nc nc
11778 A G Wildtype nc nc nc 0.06# nc nc
14607 A I Wildtype nc nc nc 0.06# nc nc
228 A B Wildtype nc nc nc 0.05# nc nc
9627 A F Wildtype nc nc nc 0.04# nc nc
9804 A F Wildtype nc nc nc 0.04# nc nc
15550 T A Wildtype nc nc nc 0.03# nc nc
15604 T A Wildtype nc nc nc 0.03# nc nc
16067 T A Wildtype nc nc nc 0.03# nc nc
16169 T A Wildtype nc nc nc 0.03# nc nc
664 A B Wildtype nc nc nc nc 0.09# nc
12818 A H Mutant nc nc nc 0.06+ 0.91+ 8.03+
16184 A A Mutant nc nc nc 0.07+ 0.41+ 6.89+
763 A B Mutant nc nc nc 0.06+ 0.61+ 6.16+
13623 T H, I Mutant nc nc nc nc nc 0.31*+
10406 A F, G Mutant nc nc nc nc nc 0.18*
6887 T E Mutant nc nc nc nc nc 0.88+
3714 G C Mutant nc nc nc nc nc 0.34#
16218 T A Mutant nc nc nc nc nc 0.22#
3697 A C Mutant nc nc nc nc nc 0.23#
1323 A B Mutant nc nc nc nc nc 0.14#
a = the amplicon (termed A to I) in which the variant was detected, which can be either one or two in the case of 
overlapping regions. b = the genotype of the variant as determined by allelic phasing (i.e. either MCF-7 considered 
wildtype or MDA-MB-231 considered mutant). nc = not called. * = variants that are detected in two overlapping 
amplicons and thus by two independent observations. + = variants that were detected in a sample containing 100% 
mutant material by both SMRT and SBS sequencing at a lower depth (Supplementary File). # = variants that can in 
theory be PCR errors because they were detected in only a single amplicon in a single sample.
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Table 2 for coverage per sample per amplicon). In the 0% variant allele sample (pure 
MCF-7), we confirmed all 13 positions with an alternative allele against rCRS [38] at > 
95% allele frequency. At 5/28 positions known to be different between the two cell lines, 
heteroplasmic variants were observed in all mixture samples (Supplementary Table 3), 
prompting us to omit these positions in further analysis for limit of detection. Thus, 
we explored 23 positions by SMRT sequencing and confirmed all variant alleles, with 
a detection limit of 0.1% for 21 positions and a detection limit of 1% for 2 positions 
(Table 1 and Supplementary Figure 6A). The UltraSEEK method employs amplification 
of the region(s) of interest by PCR and subsequent detection of the variant(s)-of-interest 
via a single-base extension using chain terminators labelled with a moiety for solid phase 
capture, allowing enrichment of product, and identification of the product using matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry [36]. By UltraSEEK, 
we explored 7 positions and detected all variant alleles at those positions, with a detection 
limit of 0.1% for 5 positions and a detection limit of 1% for 2 positions (Table 1 and 
Supplementary Figure 6B). In digital PCR, a sample is partitioned into many individual 
parallel probe-based PCR reactions, each reaction contains either one target molecule 
or none, allowing a “yes” or “no” answer for the target molecule containing the mutant 
and wildtype allele in each reaction. By digital PCR 2 positions were evaluated for the 
variant allele, and one variant allele was detected ≥ 0.01% allele frequency and the other 
≥ 0.1% allele frequency (Table 1 and Supplementary Figure 6C).
Detection of de novo mtDNA variants by SMRT sequencing
Since by SMRT sequencing the entire mtDNA was sequenced, we explored all alternative 
alleles that were called in the dataset of the six sample mixtures containing 0%, 0.001%, 
0.01%, 0.1%, 1% and 10% mutant variant frequency. A total of 132 variants were called at 
126 positions (some positions contained more than one alternative allele, Supplementary 
Table 3). Besides the documented homoplasmic variants for these two cell lines (35 
variants, including the 28 differing alleles described above and 7 concordant alleles), 97 
de novo variants were detected. Of those, 55 appeared as false positive calls in Integrative 
Genomics Viewer [39] since they were associated with homopolymer regions or were 
in close proximity to homoplasmic alternative variants (Supplementary Figure 5). Of 
the remaining 42 de novo variants, the allele frequency ranged from 0.01% to 24.8% 
(Table 2). To evaluate if those de novo variants are true positive variants or potential false 
positives, we assessed their validation within the dataset: independent observations of 
a variant in multiple mixtures, or independent observations of a variant in overlapping 
regions of the sequenced amplicons. Of the 42 de novo variants, 20 were present in 
multiple mixtures, whereas 22 were present in one mixture only (Table 2). Also, 5 had 
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Figure 2 Phasing of de novo variants with variants known to belong to either the wildtype (MCF-7) or mutant 
(MDA-MB-231) genotype, exemplifi ed by four Integrative Genomics Viewer (IGV) screenshots. 
A: In the 0.1% mutant sample, position  7029 (T, red) phases together with reads containing the wildtype (MCF-7) 
variant at position 6776 (C, blue) but not the mutant (MDA-MB-231) variants at positions 7028 (T, red) and 8506 
(C, blue). B: In the 10% mutant sample, position 10406 (A, green) phases together with reads containing the mutant 
(MDA-MB-231) variants at position 11719 (A, green) and 12084 (T, red) but not the wildtype (MCF-7) variant at 
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been detected in the mutant-only sample (100% MDA-MB-231) that was sequenced 
at lower depth by both SMRT and SBS sequencing (see Supplementary File). Ten de 
novo variants were detected in overlapping regions of the sequenced amplicons, and thus 
represent two independent observations within one sample (Table 2). This resulted in 
26 de novo variants that could be validated in our dataset, and thus true positive calls. 
A total of 16 de novo variants were detected in only a single amplicon in a single sample 
(Table 2), and can in theory be false positive calls (i.e. PCR errors or sequencing errors). 
These potential false positive variants had an allele frequency between 0.03% and 0.34%. 
Based on this, if validation of variants in either multiple samples or multiple amplicons 
is not possible, a conservative threshold on allele frequency for de novo variant detection 
of the SMRT sequencing approach would be ≥ 1.0% allele frequency.
Allelic phasing of mtDNA variants detected by SMRT sequencing
The long read length of SMRT sequencing enables to phase variants i.e. determine if 
they are present on the same read or on separate reads and thus if they originated from 
the same or another mtDNA molecule (Figure 2). By this, we could evaluate if variants 
phased together with the known homoplasmic variants of the wildtype (MCF-7) or of 
the mutant (MDA-MB-231) genotype. Of the 42 de novo variants, a total of 32 variants 
phased together with the wildtype genotype and not with the mutant genotype (Table 2). 
The variants with an allele frequency ≥ 0.5% in the wildtype-only mixture (0% mutant) 
were typically detected in all mixtures, whereas variants ≤ 0.5% allele frequency in the 
wildtype-only mixture were typically detected in the mixtures with only low mutant 
fractions (Table 2), hence the detection limit of the method. The remaining 10 de novo 
variants phased together with the mutant genotype and not with the wildtype genotype. 
Among those 10 variants that phased together with the mutant genotype, were the five 
that had also been detected in the mutant-only sample (100% MDA-MB-231) sequenced 
at lower depth by both SMRT and SBS sequencing (see Supplementary File). Also here, 
variants with a higher allele frequency in the mutant-only sample were typically detected 
position 9966 (A, green). Note that position 10406 is covered by two amplicons, and thus detected by two independent 
observations. C: In the 10% mutant sample, position 13623 (T, red) phases together with reads containing the mutant 
(MDA-MB-231) variants at position 12705 (T, red), 13966 (G, orange), 14470 (C, blue), 14766 (T, red) and 15310 
(C, blue) but not the wildtype (MCF-7) variants at position 13260 (C, blue) and 14319 (C, blue). Note that position 
13623 is covered by two amplicons, and thus detected by two independent observations. D: In the 0.1% mutant sample, 
position 15897 (A, green) phases together with reads containing the wildtype (MCF-7) variants at position 15380 (G, 
orange) and 16148 (T, red) but not the mutant (MDA-MB-231) variants at position 15310 (C, blue), 16093 (C, blue), 
16184 (A, green), 16189 (C, blue), 16223 (T, red), 16265 (G, orange) and 16278 (T, red). Horizontal is the DNA 
sequence, vertical the individual reads, and alignments sorted by base. Note that the position in IGV does not correspond 
to the rCRS position due to the use of an extended reference for alignment (see Materials and Methods). INDELs < 2 
bases are hidden for clarity.
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in the mixtures with high mutant fractions (Table 2), hence the detection limit of the 
method. Thus, by SMRT sequencing we were able to evaluate the origin of the 42 de 
novo variants, phased to either the wildtype or mutant genotype (Table 2).
Discussion
In this research, we aimed to develop a sensitive procedure to detect low-frequent 
single-nucleotide mtDNA variants from frozen tumour tissue. In assessing tumour cell 
characteristics, tissue specimens are an important source to detect tumour-specific variants. 
Especially when the focus is on low-frequent variants, frozen tissue is more suitable 
than formalin-fixed paraffin-embedded tissue since the latter is prone to deamination 
artefacts [40]. We started by establishing an extraction procedure to obtain mtDNA as 
pure as possible from frozen tumour tissue. The optimal method was DNA from cytosol 
fractions (method IV) treated with exonuclease, and resulted in a 270-fold mtDNA 
enrichment when compared to total cellular DNA extraction (27% versus 0.1% mtDNA 
yield, Figure 1). The method based on alkaline extraction that is normally applied to 
extract plasmid DNA has also been described by others for preparation of mtDNA-
enriched samples [28, 30, 32, 33]. In line with the work by Quispe-Tintaya et al [33], 
we find for frozen cultured cells a good mtDNA enrichment compared to total cellular 
DNA extraction (158-fold, Supplementary Figure 1). However, application to frozen 
tumour tissue resulted in only a 5-fold mtDNA enrichment (Figure 1) indicating that 
this method is less suited for frozen specimens. The method that extracts DNA from 
isolated mitochondria has also been described by others [34], for which we find for frozen 
cultured cells similar mtDNA enrichment levels compared to total cellular DNA extraction 
(3-fold, Supplementary Figure 1). However, again for frozen tumour tissue we observe 
lower mtDNA enrichment (2-fold, Figure 1). Note that, although the alkaline-based 
and mitochondria-based extraction methods were equivalent, different methods were 
applied to extract total cellular DNA in the above mentioned studies, and even among 
silica-based extraction methods mtDNA yield can be different [41, 42]. Importantly, 
DNA from cytosol fractions either with or without exonuclease treatment compared to 
total cellular DNA extraction did also show better results for cultured cells (resp. 33-fold 
and 760-fold enrichment, Supplementary Figure 1). Thus, generally, extraction methods 
that significantly enrich for mtDNA from frozen cultured cells (and possibly also blood 
cells) do not guarantee a proper enrichment for mtDNA from frozen tissue. 
A high fraction of mtDNA obtained within the DNA extract is vital to minimize 
the presence of NUMTs, which may lead to misinterpretation of mtDNA variants. 
Due to the variable number of mtDNA molecules per cell and the variable frequency of 
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NUMTs, estimating the potential misinterpretation with NUMTs is difficult and unique 
for each position in each individual. Since the generation of NUMTs is an ongoing 
process [17-19] estimating NUMT frequency is even more difficult for tumour cells 
since, they contain all private and all somatic NUMT events that have occurred during 
tumorigenesis and before that time. This is why we have chosen – and recommend – to 
analyse a mtDNA extract as pure as possible in SMRT sequencing. Exemplifying, in the 
case of 20x abundance of a NUMT (which is the case for numerous mtDNA regions [24]) 
in a cell type with 500 mtDNA molecules, it is possible to misinterpret the NUMT as 
a mtDNA variant with 8% heteroplasmy (2 x 20 / 500) in a total cellular DNA extract. 
Indeed, misinterpretation of non-identical mtDNA and NUMT positions is not a rare 
event and multiple examples have been highlighted in the literature [16, 20-23]. Therefore, 
obtaining a high mtDNA fraction corresponds to obtaining a high number of mtDNA 
molecules as opposed to nDNA molecules, decreasing the variant allele frequency of 
the NUMTs, thus diminishing the likelihood for misinterpretation: a 270-fold increase 
in mtDNA for the example mentioned above would result in suppressing the NUMT 
variant to 0.03% heteroplasmy (2 x 20 / 270 x 500). 
To detect low-frequent variants in mtDNA, we compared three state-of-the-art 
approaches. All three methods – SMRT sequencing, UltraSEEK, digital PCR – obtained 
100% sensitivity at 1% variant allele frequency (Table 1). Specifically, SMRT shows a 
sensitivity of 100% at 1% allele frequency, 91% at 0.1% allele frequency and 0% at 0.01% 
allele frequency. SMRT sensitivity mainly depends on the read depth: positions 6221 and 
6371 were sequenced less deep and had a detection limit of 1% (Supplementary Table 
3). UltraSEEK shows a sensitivity of 100% at 1% allele frequency, 71% at 0.1% allele 
frequency and 0% at 0.01% allele frequency. Digital PCR shows a sensitivity of 100% 
at 0.1% allele frequency, of 50% at 0.01% allele frequency and 0% at 0.001% allele 
frequency. Notably, whereas UltraSEEK and digital PCR are limited to the positions 
chosen beforehand, the SMRT sequencing approach is able to evaluate the entire mtDNA. 
Since to date no mutational hotspot regions have been described for mtDNA in primary 
tumour specimens [12-14], this is a valuable feature to study tumour-specific mtDNA 
variants. A limitation of all three methods is that they start with PCR amplification, and 
due to the large variation in mtDNA between and within individuals, primer binding 
sites can encounter variants that can bias PCR amplification. A whole genome sequencing 
method would enable a more unbiased approach, where a DNA sample is fragmented 
and subsequently sequenced independent of variants present in the sample. However – as 
shown by our results using whole-genome sequencing-by-synthesis (SBS) – this method 
requires deeper sequencing since a substantial part of the reads will be derived from nDNA. 
A bioinformatics approach would also be needed to filter reads originating from known 
NUMTs. In addition, the observed spread in mtDNA percentage in DNA extracts from 
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frozen tumour tissue (Figure 1) will lead to variability in the proportion of mtDNA reads 
between specimens when using a whole genome sequencing approach. This variability is 
likely due to biological variability in the number of mtDNA molecules within a cell or 
biochemical differences (e.g. fat or stromal content) between specimens, or due to technical 
variability in the multiplex qPCR assay. Samples with an extreme high mtDNA:nDNA 
ratio (and thus those greatly enriched for mtDNA) will have their mtDNA Ct value at the 
upper end whereas the nDNA Ct will be at the lower end, making the ratio estimation 
more variable because Ct estimations are less reliable. Also, the observed number of 
duplicated reads in SBS (87%) is within the expected range for single-end sequencing 
of the mitochondrial genome. Due to its small size, it contains only 16,569 starting 
positions for the 776,959 generated reads (Supplementary Table 1). When no variants 
or sequencing errors would be present within the reads, this would result in 97.9% of the 
reads appearing as duplicate reads. One could also use a targeted approach prior to SBS 
sequencing. Amplification of the complete mitochondrial genome in a single amplicon 
has been applied in SBS approaches, obtaining an error rate of 0.33% at a read depth of 
20,000x [43]. Sequencing such an amplicon by SMRT is not feasible with the current 
chemistry, since it would require a read length >80,000 base pairs (5 passes of ~16,569 base 
pairs). Our targeted approach to amplify mtDNA by primer sets to generate amplicons 
between 1,700 base pairs and 3,000 base pairs does allow for high quality SMRT reads 
(≥ 5 passes to create a consensus sequence, minimizing sequencing errors) covering the 
complete amplicon, and simultaneously minimizes the risk of NUMT amplification (87% 
of known NUMTs are mtDNA fragments ≤ 1,500 base pairs [22]). In addition, the used 
primer sets did not generate an amplification product in mtDNA-depleted counterparts 
of two cell lines (Supplementary Figure 3) nor products by in silico BLAST, affirming 
that known NUMTs are unlikely to interfere. A drawback is that template amplification 
by PCR can introduce errors that may result in false positive calls. To decrease this, the 
PCR used a high fidelity polymerase (error rate of ~10-7) and the number of PCR cycles 
was limited (15 + 5 cycli). This would theoretically mean that 98.5-97.5% of the generated 
products per amplicon are entirely error-free, or that each product contains 0.02 random 
errors. By setting alternative allelic calls to at least 5 independent high-quality reads we 
intent to minimize calling PCR errors. An alternative would be to employ molecular 
barcodes prior to PCR amplification, which will allow tracing PCR duplicates and thus 
yield more confident calls of the original molecules. Note that five of the de novo variants 
detected by SMRT present in only a single sample appeared on two amplicons and are 
thus independent observations and unlikely to be PCR errors (Table 2). For the de novo 
variants that appear in only one sample on one amplicon (n = 16) we cannot rule out that 
they are not PCR errors, despite their phasing with a particular genotype (Table 2). All 
those were low-frequent variants (allele frequency between 0.03% and 0.34%). Thus, given 
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the 100% sensitivity at 1% allele frequency, the SMRT approach is able to call variants 
reliable ≥ 1% allele frequency. To ascertain that variants below 1% allele frequency are 
true variants, validation is necessary by either independent re-sequencing (an additional 
sample, or in some cases in overlapping regions of amplicons within the same sample) or 
an orthogonal method. Both UltraSEEK and digital PCR prove suitable as orthogonal 
methods to confirm allelic calls, since they are both able to detect low-frequent variants. 
Analysis by UltraSEEK can be performed in multiplex (up to hundreds): the region(s) of 
interest are PCR amplified and subsequently the variant(s)-of-interest are detected via a 
single-base extension using chain terminators labelled with a moiety for solid phase capture, 
enrichment of product, and identification using matrix-assisted laser desorption/ionization 
time-of-flight mass spectrometry. However, both UltraSEEK and digital PCR are not 
suitable for de novo variant detection because they do need information on the variants-of-
interest beforehand. Also, primer design has to be done for each variant separately, which 
can be limiting due to design constraints. The sensitivity of UltraSEEK mainly depends 
on the number of molecules analysed, where 3 variant copies would suffice for detection 
(corresponding to at least 3,000 total copies for a 0.1% allele frequency). Analysis by 
digital PCR can be performed in multiplex (up to 4-8), with for each DNA molecule 
the region of interest is PCR-amplified and subsequently detected by specific probes on 
the variant-of-interest. Also in here, sensitivity mainly depends on the number of input 
molecules (minimal 2 variant copies of ≤ 20,000 total copies). The SMRT sequencing 
approach is as performant in terms of sensitivity (dependent on minimal 5 alternative 
reads) compared to these two methods, but is not limited to the necessity of knowing 
positions of variants-of-interest beforehand.
To conclude, our sensitive procedure to detect low-frequent single-nucleotide mtDNA 
variants from frozen tumour tissue is based on the extraction of DNA from cytosol fractions 
followed by exonuclease treatment to obtain high mtDNA yield, and subsequent SMRT 
sequencing for (de novo) detection and allelic phasing of variants. Orthogonal validation 
of variants can be done by either UltraSEEK (in the case of numerous variants) or digital 
PCR (in the case of a few variants). We conclude that the presented approach enables 
mtDNA-specific detection of de novo variants ≥ 1 % allele frequency.
Materials and methods
Specimens
Cell lines MDA-MB-231 and MCF-7 were cultured using RPMI (Invitrogen) sup-
plemented with FBS (10%) (Lonza), 100 U/mL penicillin (Invitrogen), 100 µg/mL 
streptomycin (Invitrogen) and 0.05 mg/mL gentamycin (Invitrogen). A mtDNA-depleted 
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MDA-MB-231 breast cancer cell line (MDA-MB-231-ρ0) was established by culturing 
MDA-MB-231 cells in the presence of 50 ng/µL ethidium bromide for 100 days in 
medium supplemented with uridine (0.05 mg/mL) (Sigma-Aldrich) and pyruvate (1 
mM) (Invitrogen). Frozen 143B and 143B-ρ0 osteosarcoma cell line pellets were kindly 
provided by dr. W.N.M. Dinjens (Department of Pathology, Erasmus MC). Fresh 
frozen primary breast tumour tissue specimens (resection material) were selected from 
the tumour biobank at the Erasmus MC (n = 10, stored in liquid nitrogen). The use of 
these patient materials was approved by the medical ethics committee of the Erasmus 
MC (MEC 02.953) and in accordance to the code of conduct of Federation of Medical 
Scientific Societies in the Netherlands. In the Netherlands, according to the Code of 
Conduct, informed consent is not required for retrospective analysis of bio-specimens 
retrieved during standard of care procedures.
DNA extraction and mtDNA enrichment
Input for frozen tumour tissue was standardized at 20 cryosections of 30 µm thickness, 
which resulted in an average input of 19.2 mg (range of 5.9 - 33.4 mg) tumour tissue 
per extraction. Input for cultured cells was standardized at 1 million frozen cells per 
extraction. Total cellular DNA was extracted using the NucleoSpin Tissue kit (Macherey-
Nagel) according to the supplier’s protocol (method I). Alkaline-based extraction was 
performed using the QIAprep Spin Miniprep kit (Qiagen), according to the supplier’s 
protocol (method II). Mitochondria were extracted using the Qproteome mitochondria 
isolation kit (Qiagen) according to the supplier’s protocol, and subsequently DNA was 
extracted using the NucleoSpin Tissue kit (above) (method III). To remove cell nuclei, 
samples were lysed using detergent that dissolves the cellular membrane (1 mL of 0.5x 
TBE containing 0.5% (v/v) Triton X-100 [37]) for 10 minutes, followed by sedimentation 
of the nuclei at 1020 x g for 10 minutes. From the remaining supernatant – the cytosol 
fraction – DNA was extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen) 
according to the suppliers’ protocol (method IV). In experiments to remove linear DNA, 
extracts (max. 100 ng DNA) were treated with 40 units of the ATP-dependent exonuclease 
PlasmidSafe (Epicentre) for 3 hours at 37°C. Exonuclease was heat-inactivated (30 minutes 
70°C) and the circular DNA was purified using ethanol precipitation (70% ethanol). 
DNA quantification and mtDNA purity assessment 
All DNA extracts were quantified using the Qubit dsDNA HS assay kit (Life Technologies) 
according to the suppliers’ protocol. Purity of mtDNA was assessed in duplicate runs of a 
multiplex qPCR assay targeting a nuclear and a mitochondrial encoded gene to calculate 
the ratio of mtDNA molecules opposed to nDNA molecules by the relative quantitation 
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method (2ΔCq) as described before [44]. The percentage of mtDNA in the DNA extract 
was quantified (Formula 1) based on the ratio mtDNA:nDNA molecules and the sizes 
of the mitochondrial reference genome (16,569 base pairs, NC_012920) and complete 
reference genome (haploid 3,088,269,805 base pairs, GRCh38). If no amplification 
signal for the nuclear encoded gene was obtained, the ratio mtDNA:nDNA was set to 
20,000,000 corresponding to a mtDNA percentage of 99%.
Formula 1  
Whole genome sequencing-by-synthesis (SBS)
Input DNA was mechanically sheared using focused-ultrasonicator (Covaris) to yield 
fragments of ~ 300 base pairs in length, which required the following shearing-time for 
different DNA extracts: 90 seconds for total cellular DNA, 120 seconds for total cellular 
DNA treated with exonuclease, 90 seconds for cytosol fraction DNA, 50 seconds for 
cytosol fraction DNA treated with exonuclease. Sequence library was created using the 
Thruplex DNA-seq sample preparation kit (Rubicon Genomics), using 0.1-7.7 ng sheared 
input DNA. Sequencing was performed on an Illumina HiSeq2500 sequencer using 
HiSeq Rapid v2 chemistry and yielding 100 nucleotides single-end reads. 
UltraSEEK
UltraSEEK assays were designed using the AgenaCx online assay design software which 
automatically selects the PCR and extension primers (Supplementary Table 4), and 
adds to each reaction control assays for PCR and capturing. All oligonucleotides were 
obtained from Integrated DNA Technologies and control oligo’s from Agena Bioscience 
GmbH. Reactions were performed as described before [36], using reagents obtained from 
Agena Bioscience. Briefly, PCR (45 cycles) was followed by shrimp alkaline phosphatase 
treatment and single base primer extension using biotinylated ddNTPs specific for the 
mutant alleles. After capture of the extended primers using streptavidin-coated magnetic 
beads, a cation-exchange resin was added for cleaning and 10-15 nl of the reaction was 
transferred to a SpectroCHIP® Array (a silicon chip with pre-spotted matrix crystals) using 
an RS1000 Nanodispenser (Agena Bioscience). Data were acquired via matrix-assisted laser 
desorption/ionization time-of-flight mass spectrometry using a MassARRAY Analyser 4 
(Agena Bioscience). After data processing, a spectrum was produced with relative intensity 
on the y-axis and mass/charge on the x-axis. Typer Analyser software was used for data 
analysis and report generation.
mtDNA percentage =                      * 100
ratio *  mitochondrial genome size
(ratio *  mitochondrial genome size) + nuclear genome size
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Digital PCR
Custom assays for two alternative variants were performed on the Quantstudio 3D digital 
PCR system (Thermo Fisher) according to the supplier’s protocol, with an adaption to the 
DNA input due to high mtDNA copy number. Reactions contained 20 pg of DNA in 
1x dPCR mastermix v2, 0.9 µM of each primer (Invitrogen) and 0.2 µM of each probe 
(Sigma) (Supplementary Table 4). After initial denaturation for 10 minutes at 96°C, 
the 40-cycle two-step PCR was performed at 30 seconds denaturation (98°C) and 120 
seconds annealing/extension (56°C), and followed by a final 2 minute extension (56°C). 
To calculate a variant frequency of the alternative variant, the threshold for signal dots 
was set to at least two dots. 
Single Molecule Real-Time (SMRT) sequencing
Amplicons covering the complete mtDNA [45, 46] (Supplementary Table 4) were 
generated in singleplex PCR reactions with initial denaturation for 3 minutes at 98°C, 
15 cycles of a three-step PCR with 10 seconds denaturation (98°C), 30 seconds annealing 
(67°C) and 90 seconds extension (72°C), and final extension (72°C) for 5 minutes. Each 
50 µL reaction contained 2.5 ng of template DNA and 1 unit of Hot-Start Q5 High 
Fidelity DNA polymerase (NEB) in 1x Q5 reaction buffer, 200 µM dNTPs and 0.5 µM 
of each 5’-M13 tailed primer (Invitrogen) (Supplementary Table 4). Specificity of the 
generated products was confirmed using microchip electrophoresis (DNA-12000 reagent 
kit, Shimadzu). Amplicons were equimolar pooled per sample and purified using AMPure 
PB paramagnetic beads (Pacific Biosciences) with a 0.6 beads:sample ratio according to 
the SMRTbell Template Prep Kit protocol and eluted in 10 mM Tris-HCl pH 8.5. 
The 5’-M13 universal sequence tail of the primers allowed barcoding of each sample by 
performing 5 amplification cycles of the three-step PCR as described above but with an 
annealing temperature of 58°C. Specificity of the generated products was confirmed using 
microchip electrophoresis (BioAnalyzer, DNA12000 or High Sensitivity DNA kit, Agilent). 
A final mix of barcoded fragments of all samples was obtained by equimolar pooling and 
subsequently purified using AMPure PB paramagnetic beads with a 0.6 beads:sample ratio. 
Concentration of the final mix was determined using the Qubit dsDNA HS assay kit, and 
SMRTbell library was generated according to the Amplicon Template Preparation and 
Sequencing guide (Pacific Biosciences). Sequencing was performed on Pacific Biosciences 
RSII with P6-C4 sequencing chemistry and 360 minutes movie-time or Sequel platforms 
with version 2 sequencing chemistry and 600 minutes movie-time. A total of twenty-two 
RSII and two Sequel SMRT cells were used to reach a read depth estimated at 3000x per 
sample. In addition, two RSII SMRT cells were used to reach an estimated 5000x for one 
sample (cell line mixture with 0.1% mutant allele frequency).
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Bioinformatics
Whole genome sequencing-by-synthesis (SBS) reads were trimmed and aligned using 
hisat2 [47] against the human reference genome GRCh38, after which the percentage 
of mtDNA was calculated (Formula 2). In addition, for evaluation of detected variants 
(Supplementary File), SBS reads were aligned against an extended version of rCRS 
(BWA-MEM version 0.7.15 default parameters [48]) and duplicate reads marked (Picard 
MarkDuplicates default parameters http://broadinstitute.github.io/picard/). We aligned 
the data against extended versions of rCRS (Supplementary Table 5) to compensate for 
mapping bias due to circularity of the mitochondrial genome.
Formula 2  
Single Molecule Real-Time (SMRT) sequencing RS bax.h5 files were converted to Sequel 
BAM files, of which circular consensus reads (CCS) were generated using the CCS2 
algorithm for each sample-specific barcode [49]. Next, a minimum quality threshold of 
99% and at least five passes of the SMRTbell were applied to select for highly accurate 
single-molecule reads. Selected CCS reads were trimmed (Cutadapt [50] for primers-
tails) and subsequently aligned against an extended rCRS (BWA- MEM version 0.7.15 
parameters -k17 -W40 -r10 -A1 -B1 -O1 -E1 -L0 [48]). We aligned the data against 
extended versions of rCRS (Supplementary Table 5) to compensate for mapping bias 
due to circularity of the mitochondrial genome. 
For the comparison between SBS and SMRT sequencing methods (Supplementary 
File), pileup files were generated (Bioconductor Rsamtools 1.26.2 pileup function with 
pileupParam min_base_quality=30, min_mapq=0, min_nucleotide_depth=0, min_
minor_allele_depth=0, distinguish_strands=TRUE, distinguish_nucleotides=TRUE, 
ignore_query_Ns=TRUE, include_deletions=FALSE, include_insertions=FALSE and in 
the case of SBS data flag isDuplicate=FALSE) and converted back to rCRS positions. For 
evaluation of detection limit and de novo variant detection for SMRT data, pileup files 
were generated as described above but with a more stringent threshold on the minimal 
number of alternative allele reads (min_nucleotide_depth=5) to minimize detection of 
potential PCR errors (see Supplementary File). All detected variants were manually 
inspected in the Integrative Genomics Viewer (IGV, Broad Institute) [39]. Phasing of 
variants was done by manual inspection of every read containing the detected alternative 
variant and evaluating the other detected alternative variants present on that read.
MDA-MB-231 and MCF-7 mitochondrial sequences were obtained from the 
NCBI GenBank (resp. AB626609.1 and AB626610.1, deposited after resequencing 
percentage reads of mitochondrial origin =     * 100
aligned reads on chrM
aligned reads on GRCh38
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by Imanishi et al [38]) and blasted against rCRS to obtain the homoplasmic mtDNA 
positions alternative to the reference sequence for these two cell lines (NCBI’s nucleotide 
web blast, https://blast.ncbi.nlm.nih.gov).
Data availability
Sequencing datasets can be accessed as BAM files (.bam) from the European Nucleotide 
Archive under accession number PRJEB23243. 
Supplementary data
Supplementary data for this article are available online at Scientific Reports 
(https://www.nature.com/srep/). 
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The use of blood-circulating cell-free DNA (cfDNA) as a ‘liquid-biopsy’ 
in oncology is being explored for its potential as a cancer biomarker. 
Mitochondria contain their own circular genomic entity (mitochondrial 
DNA, mtDNA), up to even thousands of copies per cell. The mutation rate 
of mtDNA is several orders of magnitude higher than that of the nuclear 
DNA. Tumour-specific variants have been identified in tumours along the 
entire mtDNA, and their number varies among and within tumours. The 
high mtDNA copy number per cell as well as the high mtDNA mutation 
rate makes it worthwhile to explore the potential of tumour-specific cf-
mtDNA variants as cancer marker in the blood of cancer patients. We used 
single-molecule real-time (SMRT) sequencing to profile the entire mtDNA 
of nineteen tissue specimens (primary tumour and/or metastatic sites, and 
tumour-adjacent normal tissue) and nine cfDNA samples, originating from 
eight cancer patients (5 breast, 3 colon). For each patient, tumour-specific 
mtDNA variants were detected and traced in cfDNA by SMRT sequencing 
and/or digital PCR to explore their feasibility as cancer biomarker. As a 
reference, we measured other blood-circulating biomarkers for these patients, 
including driver mutations in nuclear-encoded cfDNA and cancer-antigen 
levels or circulating tumour cells. Four of the twenty-four (17%) tumour-
specific mtDNA variants were detected in cfDNA, however at much lower 
allele frequencies compared to mutations in nuclear-encoded driver genes 
in the same samples. Also, extensive heterogeneity was observed among 
the heteroplasmic mtDNA variants present in an individual. We conclude 
that there is limited value in tracing tumour-specific mtDNA variants in 
blood-circulating cfDNA with the current methods available.
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Introduction
Mitochondria are organelles within our cells responsible for a variety of functions, including 
energy production and initiating apoptosis. Their small circular genome (mitochondrial 
DNA, mtDNA) encodes for proteins essential in the oxidative phosphorylation system 
and the transfer RNA and ribosomal RNA molecules of the mitochondrial translation 
apparatus. Within a single cell, multiple copies of mtDNA exist (mtDNA content), but 
due to its small size the mtDNA represents only a minor fraction of the total cellular 
DNA (< 0.1%). In general, cells with high energy demand (e.g. muscle cells) have a 
higher mtDNA content than cells with lower energy demand (e.g. blood cells) [1]. In 
human cancer, changes in mtDNA content have been reported when tumour specimens 
are compared to their normal counterparts [2]. The polyploid nature of mtDNA invokes 
the concept of only a single (homoplasmy) or two or more mitochondrial genotypes 
(heteroplasmy) within a cell. It has been shown that heteroplasmy patterns within 
an individual can differ between tissues, even in an allele-specific manner [3-6]. Also 
within cancer, tumours harbour mtDNA that is genetically different to their normal 
counterparts, either at a homo- or heteroplasmic level, and their number and position vary 
among tumours [7-9]. Interestingly, since the mutation rate of mtDNA is several orders 
of magnitude higher than that of nuclear DNA (nDNA) [10], it is very informative to 
assess phylogenetic distance not only intra- and inter-species, but also inter-individual.
Within oncology, the use of blood-circulating cell-free DNA (cfDNA) as a ‘liquid-
biopsy’ is being explored for its potential as a screening tool, to establish prognosis, or 
as a marker for response to treatment. The origin of cfDNA is mainly from apoptotic 
cells, hence its typical fragmentation pattern representing DNA cleavage between 
nucleosomes or chromatosomes (~146-166 base pairs and multiples thereof ) [11]. The 
physical characteristics of cf-mtDNA have not been studied as extensively as its nuclear 
counterpart. Since mtDNA is packed into nucleoids [12], which are not fragmented 
during apoptosis [13], the fragmentation pattern as seen for nDNA does not apply to 
mtDNA. Indeed, the majority of the cf-mtDNA in human plasma appears associated with 
particles of at least 0.45 µm in diameter [14] and a fraction of it is severely fragmented 
down to at least 30 base pairs [15-18]. If not fragmented, the circular nature of mtDNA 
might render it less susceptible to enzymatic cleavage and thus more stable within the 
circulation. The total amount of cfDNA is often increased in cancer patients compared to 
healthy individuals, for both DNA from the nucleus as well as mtDNA [16, 19-23]. The 
detection of tumour-specific cfDNA is aided by the aberrations present in the cancer’s 
genome, and thus by the detection of tumour-specific mutations within the cfDNA. A 
few studies have attempted to detect mtDNA variants in blood-derived cfDNA [4, 24-29] 
or other bodily fluids [24, 30-33]. However, in the studies on blood-derived cf-mtDNA, 
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used methods were either not very sensitive (i.e. conventional Sanger sequencing), or 
the variants were not truly tumour-derived (i.e. already present in matched normal 
specimens). Also, quantitative variant allele frequencies were not reported in all assessed 
samples, making interpretation of these results difficult. Nevertheless, the combination 
of a high copy number per cell, a high mutation rate and potentially high stability within 
the circulation make it worthwhile to explore the potential of tumour-specific variants 
in cf-mtDNA as a cancer biomarker.
In this study, we used a targeted Single-Molecule Real-Time (SMRT) sequencing 
approach to profile the entire mtDNA of the primary tumour and/or metastatic sites, 
tumour-adjacent normal tissue and cfDNA of eight cancer patients. We have recently 
shown that the SMRT sequencing approach is able to reliably detect unknown variants 
≥ 1.0% allele frequency and to trace known low-frequent variants down to at least 0.1% 
allele frequency [34]. In our cohort we observed tumour-specific mtDNA variants for 
each patient, and explored the feasibility to trace these tumour-specific variants in cf-
mtDNA as a cancer biomarker. 
Results
We sequenced the entire mtDNA of nineteen tissue specimens and nine cfDNA samples 
originating from eight cancer patients, including at least one tumour and one cfDNA 
sample for each patient. For four tissue specimens (primary tumour of P1, P2 and P3, 
and normal tissue of P1), we performed independent re-sequencing of another (nearby) 
section of the specimen. For one patient (P1), a total of five consecutive cfDNA samples 
were profiled for mtDNA variants by dPCR. The study cohort consisted of two cancer 
types – breast and colon cancer – at variable disease stages. Patient characteristics are 
summarized in Table 1. After haplotyping the mtDNA of each specimen for each 
individual to make sure that samples were matched correctly (Supplementary Figure 
1), the heteroplasmic mtDNA variants present in each sample were evaluated. 
Heterogeneity in heteroplasmic mtDNA variants between tumour and normal tissue
In the tumour and normal tissue specimens, the number of heteroplasmic mtDNA 
variants ranged from 0 up to 14 per specimen (Table 1), with allele frequencies between 
0.2% and 99.4% (Figure 1) (Supplementary Table 3). Good concordance was observed 
in detected variants between different sections of a specimen (P1, P2 and P3, Figure 
1), with two of the eighteen variants missed due to coverage and thus limit of detection 
(6255G>A at 0.8% allele frequency in P1 normal mammary tissue and 9058A>G at 0.2% 
allele frequency in P2 primary tumour tissue Supplementary Table 3). Heterogeneity was 
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Figure 1 Heteroplasmic mtDNA variants in tumour and normal tissue. 
Heteroplasmic mtDNA variants (vertical) detected by SMRT sequencing of tumour and normal tissue (horizontal) of 
eight cancer patients (P1 to P8). Ubiquitous, normal-only and tumour-only variants in respectively grey, blue and red, 
cfDNA variants of unknown tissue origin in green. Within the squares allele frequency (%) of the variant is indicated. 
The percentage of tumour cells in the analysed sections based on morphological estimations in HE-stained slides between 
brackets behind tissues.
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observed between the tumour and normal tissues: majority of the variants (80%) were 
present either only within the tumour tissue (n = 24) or only within the normal tissue 
(n = 27) (Figure 1). Generally, tumour-only variants had higher allele frequency than 
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normal-only variants (respectively median (interquartile range IQR) of 9.7% (23.7%) 
versus 1.9% (1.6%), Mann-Whitney U test P < 0.001).
Also, two of the ubiquitous variants (n = 13) showed heteroplasmic expansion between 
the normal and the tumour tissue (variants 6255G>A and 2305T>C in respectively P1 
and P6, Figure 1). Note that some of the ubiquitous variants at low heteroplasmy might 
not be present in the tumour cells but in normal cells residing the tumour tissue (i.e. 
variants 189A>G and 16390G>A in P2, 60T>C and 66G>T in P6, and 12302C>T in 
P8). A phylogenetic relationship based on the tumour-specific mtDNA variants was 
evident between the primary and the two metastatic tumour sites of P6 (Figure 2). 
Due to the long read-length of our sequencing approach – in the order of two 
thousand nucleotides – the detected variants could be grouped based on their presence 
on the same read or on separate reads and thus we could decipher if they originated from 
the same or another mtDNA molecule (phasing of variants). A total of 65 combinations 
of variants were close enough for phasing (Supplementary Table 4), of which 19 phased 
(partly) together and 46 were mutually exclusive. Interestingly, in tumour tissue the 
heteroplasmic variants 10657T>C and 11040T>C in P2 and variants 9398A>G and 
10407G>A in P3 phased together, but variants 1924T>C and 2305T>C in P6 were 
mutually exclusive.
Figure 2 Schematic of phylogenetic relationship between the sequenced colorectal cancer specimens of P6.
1924C
10914A
10160T
4048A
Primary   Metastasis 1   Metastasis 2
Heteroplasmic mtDNA variants within cfDNA
In the cfDNA samples, the number of heteroplasmic mtDNA variants (cf-mtDNA) ranged 
from 0 up to 9 per sample (Table 1), with detected allele frequencies between 0.04% 
and 99.4% (Figure 1) (Supplementary Table 3). Majority of the detected cf-mtDNA 
variants (59%) were not detected in the corresponding tissues we evaluated, and thus 
are of unknown tissue origin (n = 20). Some of the variants were detected within only 
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the normal tissue (n = 5) or both the tumour and normal tissue (n = 8), indicating that 
these are heteroplasmic patient-specific but not tumour-specific heteroplasmic mtDNA 
variants present as cf-mtDNA in the circulation. Of the twenty-four tumour-specific and 
two tumour-expanded heteroplasmic mtDNA variants present in the tumour specimens, 
only three were detected by sequencing the cfDNA (Figure 1): in P2 variant 9058A>G 
was present at 0.2% allele frequency in one of the two replicates of the primary tumour 
and 1.1% allele frequency in the cfDNA, in P7 variant 16278C>T was present at 64.7% 
allele frequency in the liver metastasis and 0.04% allele frequency in the cfDNA, and in 
P8 variant 16183A>C was present at 0.7% allele frequency in the liver metastasis and 
3.8% allele frequency in the cfDNA (Supplementary Table 3). Note that in P2 and P8 
the heteroplasmy level of the variant in the tumour tissue was very low. We confirmed 
by dPCR (orthogonal technique) the absence of one high-frequent tumour-specific or 
one high-frequent tumour-expanded variant in the sequenced cfDNA samples for both 
P1 and for P6 (Table 2). Note that the variant allele frequency of those variants in the 
tissue samples was comparable between SMRT sequencing and dPCR detection. For P1, 
we extended the number of cfDNA samples by three sera at different time-points. The 
cancer-antigen level in these three sera was extremely high (Figure 1, Table 3) indicative 
for a high tumour load at that point in time. In this patient, we detected by dPCR at 
low variant allele frequency the tumour-expanded cf-mtDNA variant prior to start of 
hormonal therapy (6255G>A 0.03% allele frequency) and both the tumour-expanded 
Table 2 Heteroplasmic mtDNA variants detected by dPCR in two patients.
Patient Tumour type Specimen
Variant 664G>A
(allele frequency)
Variant 6255G>A
(allele frequency)
P1 Breast Primary tumour-a
Primary tumour-b
Normal mammary-a
Normal mammary-b
Serum 1
Serum 2*
Serum 3*
Serum 4*
Serum 5
12.9%
5.4%
0.01%
0.05%
nd
nd
0.06%
nd
nd
46.2%
35.9%
0.9%
0.5%
nd
0.03%
0.3%
nd
nd
Patient Tumour type Specimen Variant 1924T>C
(allele frequency)
Variant 2305T>C
(allele frequency)
P6 Colon Primary tumour
Liver metastasis 1
Liver metastasis 2
Normal colon
Normal liver
Plasma
0.9%
36.2%
46.2%
0.3%
0.08%
nd
10.4%
40.1%
34.2%
1.1%
0.05%
nd
Asterisks indicate the samples that had not been analysed by SMRT sequencing. nd indicates not detected.
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and tumour-specific cf-mtDNA variants prior to start of chemotherapy (6255G>A 0.3%, 
664G>A 0.06% allele frequency) (Table 2, Figure 3).
Thus, out of the twelve cfDNA samples, a total of four contained cf-mtDNA variants 
that were also present in the tumour tissue evaluated, as detected by either sequencing or 
dPCR. To put these results into perspective, we evaluated the levels of other blood-based 
cancer biomarkers in these samples. Tumour-specific mutations in nuclear-encoded driver 
genes were detected in the cfDNA (cf-nDNA) of three sera and three plasma samples 
(Supplementary Table 5), mostly at much higher allele frequencies than the detected 
tumour-specific cf-mtDNA variants (Table 3, Supplementary Figures 2 and 3). Also, 
the level of cancer-antigen was increased in the blood of P1, P2, P3 and P5 (≥ 30 kU/L) 
(Table 3, Figure 3, Supplementary Figure 2) and circulating tumour cells were detected 
in the blood of P6 and P8 (Table 3, Supplementary Figure 3).
Discussion
In this work, we show that there is extensive heterogeneity in mtDNA variants between 
tumour and tumour-adjacent normal tissue, and that tumour-specific cf-mtDNA variants 
are hardly detectable in the circulation of cancer patients. 
To detect mtDNA variants, we used a SMRT sequencing approach to evaluate 
the whole mitochondrial genome [34] and included dPCR as an orthogonal method 
to evaluate a subset of the detected variants. The limit of detection for variants by our 
sequencing approach is mainly dependent on the sequencing depth at a position, with 
variants called based on at least five highly accurate single-molecule reads containing the 
variant at that position. We have recently shown that the SMRT sequencing approach 
is able to trace known low-frequent variants ≥ 0.1% allele frequency (sensitivity), and to 
reliably detect unknown variants ≥ 1.0% allele frequency (specificity) [34]. Therefore, 
we start with calling variants with at least 1.0% allele frequency in the evaluated samples 
(detection of unknown variants), and subsequently evaluate the presence of those called 
variants in the complete dataset (tracing of known variants). For some variants, we 
obtained a sequencing depth that allowed for tracing down to 0.04% allele frequency 
(Supplementary Table 3). Note that false positives due to random PCR errors are unlikely 
to be detected: we used minimally 100,000 input molecules (Supplementary Table 1) 
corresponding to a 0.001% allele frequency of random PCR errors (1 / 100,000), a high 
fidelity polymerase (error rate of ~10-7), and the number of PCR cycles was limited. To 
simultaneously evaluate the specificity of the method as well as the interference of nuclear 
insertions of mitochondrial origin (NUMTs), independent re-sequencing of four tissue 
specimens was performed after exonuclease-treatment of the DNA to specifically degrade 
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linear DNA and thus increase the circular mtDNA fraction. The latter is important since 
NUMTs can interfere with accurate variant detection due to their sequence similarity 
to mtDNA, and thus complicate investigation of mitochondrial heteroplasmy. Good 
concordance was observed: independent re-sequencing revealed that of the eighteen 
variants sixteen variants were confirmed. Two variants could not be confirmed: variant 
6255G>A in P1 was detected first at 0.8% allele frequency but was below the limit of 
detection (< 0.9% allele frequency) in the re-sequenced specimen, and variant 9058A>G 
in P2 was not detected at first (limit of detection < 0.2% allele frequency) but was detected 
at 0.2% allele frequency in the re-sequenced specimen. These variants were called because 
they were present ≥1.0% allele frequency in the cfDNA samples of the corresponding 
patients. Both variants are not at putative known NUMT positions as evaluated by 
nucleotide BLAST. From this we concluded that the limiting factor in tracing variants 
by our approach is the sequencing depth, which influences the limit of detection. 
The extensive heterogeneity we observe between tumour and tumour-adjacent normal 
tissue is in line with the observation by others that heteroplasmy patterns can differ in an 
allele-specific manner between tissues within an individual [3-6]. This is also evident from 
the high fraction of cf-mtDNA variants we detect that are of unknown tissue origin. Since 
the number of cell generations of epithelial tumour cells greatly exceeds that of non-tumour 
epithelial cells, it is likely that the intra-individual genetic drift observed between tissues 
within an individual likely also applies to tumour cells and their founder cells. Similarly, 
our observation that allele frequencies of tumour-specific variants are much higher than 
those observed in normal tissue, corresponds to the hypothesis that more cell generations 
equals more opportunity for either loss or expansion of a heteroplasmic mtDNA variant 
[35]. In line with this, only a low fraction of variants phase together in our work (19 of the 
65 variant combinations, 30%), indicative that extensive heterogeneity is present among 
heteroplasmic variants within an individual. Remarkably, P2 shows an exceptional high 
number of heteroplasmic variants detected in only the normal specimen (n = 11), and 
the tumour of this patient also contained the highest number of heteroplasmic variants (n 
=5). Note that the primary tumour specimens of P6 and P8 did not contain tumour cells 
on the morphological level as evaluated by HE-stained slides (Figure 1, Supplementary 
Table 1), but on the molecular level the primary tumour specimen of P6 did contain 
tumour cells as evaluated by the presence of KRAS mutated nDNA (Supplementary 
Table 5). Uncertainty in estimating tumour cell percentage in HE-slides have been pointed 
out in literature [36], and fresh-frozen tissue sections are of lower morphological quality 
compared to formalin-fixed paraffin-embedded tissue sections, hampering tumour cell 
percentage estimation. Notable, whereas in P6 also the normal colon and normal liver 
appeared non-tumorous by morphological evaluation, mutated KRAS was present at the 
molecular level (Supplementary Table 5), indicating tumour cells are present in these 
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specimens as well. Thus, some of the variants defined as ubiquitous might actually be 
tumour-specific in P6 – especially variant 2305T>C. Additionally, it is interesting to see 
in this case that even variants at high allele frequency can be present on different mtDNA 
molecules (1924T>C and 2305T>C in P6, Supplementary Table 4). 
With regard to the number of tumour-specific mtDNA variants per tumour, we 
observe a higher number compared to other studies. Specifically, other studies using large 
sample sizes showed that 75% of the breast cancer patients and 60% of the colon cancer 
patients harbour at least one mtDNA variant in their primary tumour based on massive 
parallel sequencing studies [7-9], whereas we observe in 100% (8/8) of the patients at 
least one tumour-specific mtDNA variant. Those studies applied a threshold on variant 
allele frequency between ≥ 3% and ≥ 15% allele frequency. We used an initial threshold at 
≥ 1.0% and no threshold on allele frequency when the variant was called within another 
sample of the same patient. Based on our previous work, it is unlikely that this is due to 
false positive calls, since those appeared ≤ 1.0% variant allele frequency [34]. The higher 
number may thus be due to the higher sensitivity of our SMRT sequencing approach, or 
statistical co-incidence due to the relatively small series we analysed. Noteworthy is that 
whereas other studies have reported on (near-)homoplasmic tumour-specific mtDNA 
variants [7-9], we only observed heteroplasmic tumour-specific mtDNA variants < 50% 
allele frequency. This is likely due to the non-tumour cells present in our specimens (i.e. 
infiltrating immune cells or tissue of origin): it would not be possible to reach 100% 
allele frequency for a tumour-specific mtDNA variant since non-tumour mtDNA will 
be present as well.
Importantly, despite the presence of tumour-specific mtDNA variants for each 
tumour tissue analysed, we were unable to detect the majority of these variants in blood-
circulating cfDNA (83% not detected). The few cf-mtDNA variants we detected were 
present at extremely low heteroplasmy levels (P1 and P7) or questionable in their true 
tumour-specific nature given the low heteroplasmy levels in the tumour tissue (P2 and P8). 
Specifically, in P2 variant 9058A>G was detected at 1.1% allele frequency in the cfDNA 
whereas it is present at 0.2% allele frequency in one of the two replicates of the primary 
tumour. In P2, the primary tumour also contained tumour-specific variants between 2% 
and 10% allele frequency (2724G>C, 10657T>C, 11040T>C and 16141A>G, Figure 
1) but those were not detected as cfDNA in the circulation (Figure 1) (Supplementary 
Table 3). This would mean that – since the primary tumour was not in situ when blood 
was drawn – the metastases in this patient originated from a clone that contained only 
9058A>G but not the other variants present in the primary tumour. Also, in P8 variant 
16183A>C present at 0.7% allele frequency in the liver metastasis was detected at 
3.8% allele frequency in the cfDNA. In this patient, the liver metastasis was still in situ 
when blood was drawn, but the tumour-specific variants present at 2% and 14% allele 
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frequency (8102G>A and 9196G>A, Figure 1) are not detected as cfDNA (Figure 1) 
(Supplementary Table 3). When comparing the detection of tumour-specific cf-mtDNA 
with other blood-based markers – including CTCs, cancer-antigens and mutations in 
cf-nDNA – the latter outperform cf-mtDNA since these could be detected in nearly all 
blood samples (Table 3). 
Our hypothesis was that mutated cf-mtDNA would be easily detectable in the 
circulation due to high stability (if circular) and high copy number per cell, and thus would 
require less sensitive methods to detect them. However, the fact that nuclear-encoded 
mutations are detected at much higher allele frequencies in the cfDNA could indicate 
that either more mtDNA from non-tumour cells is released in the circulation, or that the 
cf-mtDNA has a higher turnover than its nuclear counterpart rendering it undetectable 
by the techniques we applied. Because the mtDNA content is variable per cell, it could 
be that tissues (non-tumour) with higher mtDNA content than the tumour are shedding 
DNA into the circulatory system. This could in part be the tumour-adjacent normal tissue: 
three-quarter of the breast tumours harbour a reduction in tumour mtDNA content 
compared to adjacent normal mammary tissue [2, 37-42], whereas approximately half of 
the colorectal tumours have a reduction in tumour mtDNA content when compared to 
adjacent normal colon or rectum tissue [2, 43-47]. Another likely source of non-tumour 
cf-mtDNA in blood is thrombocytes, which do not contain a nucleus but do contain 
mitochondria. Before being frozen, our plasma samples were obtained via a centrifugation 
force that should be enough to remove 90% of the thrombocytes [48]. After thawing, 
an additional centrifugation step was applied to obtain thrombocyte-poor plasma, but it 
could be that part of the thrombocytes had been damaged by freezing-thawing and thus 
released their mtDNA already into the plasma. Especially when comparing the mtDNA 
content of serum and plasma (order of hundred versus order of thousands, Supplementary 
Table 1), it seems evident that the capture of thrombocytes in the fibrin clot of serum 
results in less release of their mtDNA in the blood-derivate. Another probability is that 
cf-mtDNA is so severely fragmented that it is not detectable by our applied methods, 
which require DNA of at least 108 base pairs in length for dPCR and of at least 1,700 
base pairs in length for SMRT sequencing (see amplicon sizes in Supplementary Table 
2). A study on the physical characteristics of plasma-derived cf-mtDNA indicates that 
the majority is associated with particles between 5 µm and 0.45 µm in size, since filtering 
the plasma reduces the amount of cf-mtDNA whereas cf-nDNA is retained (note that 
the diameter and length of mitochondria range from resp. 0.5 to 1 µm and 5 to 10 µm) 
[14]. Treatment of serum-derived cfDNA with an exonuclease that digests linear DNA 
but leaves circular DNA intact, resulted in undetectable levels of nDNA, whereas mtDNA 
concentrations reduced 5-10x (unpublished data), indicative that at least a fraction of the 
cf-mtDNA is in its circular form within serum. Other studies, based on whole genome 
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sequencing of plasma-derived cfDNA without prior fragmentation of the DNA (thus, 
only short fragments smaller than ~ 600 base pairs are efficiently sequenced), indicate 
that part of cf-mtDNA is severely fragmented [15-18]. In our own hands, such a whole 
genome sequencing approach applied to plasma-derived cfDNA of cancer patients resulted 
in median 0.85x coverage (range 0.35-1.73x) of the mitochondrial contig, whereas the 
nuclear DNA was covered by ~1x (unpublished data). Taking into account the mtDNA 
content of cells (in the order of thousands in our plasma samples, Supplementary Table 
2), this indicates that the largest proportion of cf-mtDNA is not sequenced by such a whole 
genome sequencing approach. This is in line with observations in hepatocellular cancer 
patients [16] and lung transplant recipients [17], where the fractional concentration of 
sequenced plasma cf-mtDNA was lower than expected. In the study on lung transplant 
recipients [17] and in another study on sepsis patients [18], the use of sequencing protocols 
that also include smaller DNA fragments (40 - 100 base pairs) increased the fraction of 
cf-mtDNA reads by 8- to 15-fold, but still cannot fully explain the low abundance of 
mtDNA in those experiments. Thus, it seems that a large proportion of the mtDNA is 
not sequenced in these studies, likely due to the fact that intact mtDNA is not efficiently 
sequenced during such approaches. It must be kept in mind that those results apply to 
plasma and not necessarily to serum. Another possibility why cf-mtDNA was rarely 
detectable might not be related to physical characteristics, but due to genetic drift: the 
tumour-specific variants present in the primary tumour are not present in the (micro-)
metastases anymore. Especially when the elapsed time is large (e.g. > 40 weeks in P2, > 
240 weeks P3 and > 400 weeks P5) it might be possible that the genetic make-up of the 
mtDNA in the tumours has changed, similar to the heterogeneity we observed between the 
tumour and tumour-adjacent normal tissue. Given the heterogeneity in mtDNA variants 
between tissues within an individual [3-6], it is not possible to evaluate all cf-mtDNA 
variants present in the circulation of a patient as tumour-specific ones, as illustrated by 
the number of cf-mtDNA variants from tumour-adjacent and of unknown origin in our 
study. Noteworthy, it could be that the total number of heteroplasmic cf-mtDNA variants 
present in the circulation is increased for (advanced) cancer patients, but this potentially 
is also the case for a patient affected with other morbidities (e.g. liver cirrhosis resulting in 
liver-specific cf-mtDNA variants, or colitis resulting in colon-specific cf-mtDNA variants). 
Our results demonstrate that extensive mtDNA heterogeneity is evident within an 
individual. We conclude that there is limited value in tracing tumour-specific cf-mtDNA 
variants as a blood-circulating biomarker with the current methods available.
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Materials and methods
Patient selection and sampling
We used material from our bio-bank at the department of Medical Oncology of the 
Erasmus MC Cancer Institute, Rotterdam, the Netherlands. Patient selection was based 
on availability of a frozen blood-derivate (plasma or serum) to obtain cfDNA and fresh 
frozen resection material of tumour tissue (primary or metastasis). For all except one 
case, fresh frozen material of normal tissue originating from the same resection material 
was available. Blood sampling was done in either serum separation tubes according to 
routine procedures in our hospital, or in EDTA tubes followed by cell separation within 
24 hours after blood draw (10 minutes at 800 x g). Obtained serum or plasma samples 
had been stored at -80°C until use. After thawing, plasma samples underwent additional 
sedimentation at 1020 x g for 10 minutes at 4°C, of which the supernatant was used. Use 
of the patient material was approved by the medical ethics committee of the Erasmus MC 
(MEC 02.953 and MEC 06.089) and conducted in accordance to the Code of Conduct 
of the Federation of Medical Scientific Societies in the Netherlands. 
DNA extraction
For fresh frozen tissue specimens, a DNA extraction method that enriches for mtDNA was 
performed as described before [34]. Briefly, 20 cryosections of 30 µm (average input of 30 
mg tissue, range of 16 - 59 mg) per specimen were lysed to solubilize cellular membrane 
and release all cellular compartments (10 minutes, 1 mL of 0.5x TBE containing 0.5% 
(v/v) Triton X-100). Cell nuclei were removed (10 minutes 1020 x g) and DNA was 
extracted from the remaining supernatant using the QIAamp Circulating Nucleic Acid Kit 
(Qiagen) according to the suppliers’ protocol. For four specimens, an additional sample 
was obtained by an independent DNA extraction (as described above) with subsequent 
enzymatic degradation for linear DNA as described before [34]. Briefly, those DNA 
extracts (max. 250 ng) were incubated with ATP-dependent exonuclease PlasmidSafe 
(Epicentre) (40 Units, 3 hours at 37°C), heat-inactivated (30 minutes 70°C) and purified 
(ethanol precipitation, 70% ethanol). For some frozen tissue specimens, DNA extracts 
were already available in our bio-bank, and had been obtained by either the PureLink 
Genomic DNA kit (Invitrogen) or the DNeasy Tissue Kit (Qiagen) as described by the 
supplier. For each tissue sample, 5 µm sections were obtained on microscopy slides and 
haematoxylin and eosin (HE)-stained to estimate the percentage of tumour cells within 
the sections used for DNA extraction. For the blood-derivates, after thawing at 4°C, DNA 
was extracted using the QIAamp Circulating Nucleic Acid Kit (Qiagen) according to the 
suppliers’ protocol. Serum input ranged from 450 to 500 µL and plasma supernatant input 
was 1000 µL. Specifications for each sample are provided in Supplementary Table 1.
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DNA quantification and mtDNA purity assessment 
All DNA extracts were quantified using the Qubit dsDNA HS assay kit (Life Technologies) 
according to the suppliers’ protocol. Purity of mtDNA was measured in duplicate runs 
of a multiplex qPCR assay targeting a nuclear and a mitochondrial encoded gene, to 
calculate the ratio of mtDNA molecules opposed to nDNA molecules by the relative 
quantitation method (2^ΔCq) as described before [49]. 
SMRT sequencing
SMRT sequencing was performed as described before [34]. Briefly, amplicons covering the 
complete mtDNA were generated by singleplex (tissue DNA) or multiplex (cfDNA) PCR 
reaction with initial denaturation for 3 minutes at 98°C, 15 or 18 cycles of a three-step 
PCR with 10 seconds denaturation (98°C), 30 seconds annealing (67°C) and 90 seconds 
extension (72°C), followed by a final extension (72°C) for 5 minutes. DNA input was set to 
contain at least 100,000 but maximally 50,000,000 copies mtDNA/reaction, based on the 
mtDNA content. Each 50 µL reaction contained DNA and 1 unit of Hot-Start Q5 High 
Fidelity DNA polymerase (NEB) in 1x Q5 reaction buffer, 200 µM dNTPs and 0.5 µM 
of 5’-M13 tailed forward and reverse primer (Supplementary Table 2). Specificity of the 
generated products was confirmed using microchip electrophoresis (DNA-12000 reagent 
kit, Shimadzu). Amplicons were equimolar pooled per sample and purified using AMPure 
PB paramagnetic beads (Pacific Biosciences) with a 0.6 beads:sample ratio according to the 
SMRTbell Template Prep Kit protocol and eluted in 10 mM Tris-HCl pH 8.5. The 5’-M13 
universal sequence tail of the primers allowed barcoding of each sample by performing 
5 amplification cycles of the three-step PCR as described above but with an annealing 
temperature of 58°C. Specificity of the generated products was confirmed using microchip 
electrophoresis (BioAnalyzer High Sensitivity DNA kit, Agilent). A final mix of barcoded 
fragments was obtained by pooling of multiple samples and subsequently purified using 
AMPure PB paramagnetic beads with a 0.6 beads:sample ratio. Concentration of the 
final mix was determined using the Qubit dsDNA HS assay kit, and SMRTbell library 
was generated according to the Amplicon Template Preparation and Sequencing guide 
(Pacific Biosciences). Sequencing was performed on Pacific Biosciences RSII with P6-C4 
sequencing chemistry and 360 minutes movie-time. For the tissue samples, a total of 
15 SMRT cells were used to reach a read depth estimated at 600x per sample, and for 
the cfDNA samples a total of 28 SMRT cells were used to reach a read depth estimated 
at 3000x per sample. Specifications for each sample are provided in Supplementary 
Table 1.
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Digital PCR
Digital PCR (dPCR) was performed on the Quantstudio 3D digital PCR system (Thermo 
Fisher) according to the supplier’s protocol. Detection of KRAS p.G12D, KRAS p.G12V, 
TP53 p.R248Q, TP53 p.R273H and PIK3CA p.H1047R was done by validated 
Taqman SNP genotyping assays (Thermo Fisher). Detection of mtDNA variants 664G>A, 
6255G>A, 1924T>C and 2305T>C was done by custom assays (Supplementary Table 
2) and carried out with an adaption to the DNA input due to high mtDNA copy number 
(set to contain at least 1E+3 but maximally 2E+4 copies mtDNA/reaction based on 
mtDNA content). Reactions contained DNA in 1x dPCR mastermix v2, 0.9 µM of each 
primer and 0.2 µM of each probe. After initial denaturation for 10 minutes at 96°C, 
the 40-cycle two-step PCR was performed at 30 seconds denaturation (98°C) and 120 
seconds annealing/extension (56°C), and followed by a final 2 minute extension (56°C). 
To calculate allele frequency of the alternative variant, the threshold for signal dots was 
set to at least two dots per dye. For samples where the variant was not detected, the limit 
of detection was calculated based on the total number of positive wildtype dots and two 
mutant signal dots (e.g. 5000 wildtype dots would correspond to a detection limit of 
2 / 5000 = 0.04%).
Bioinformatics
RS bax.h5 files were converted to Sequel BAM files, of which circular consensus reads 
(CCS) were generated using the CCS2 algorithm, and attributed to each sample using the 
sample-specific barcode [50]. Next, a minimum quality threshold of 99% and at least five 
passes of the SMRTbell were applied to select for highly accurate single-molecule reads. 
Selected CCS reads were trimmed (Cutadapt [51] for primers-tails) and subsequently 
aligned against a reference sequence (BWA-MEM parameters -k17 -W40 -r10 -A1 -B1 -O1 
-E1 -L0 [52]). As reference sequence, we used an extended version of rCRS to compensate 
for mapping bias due to circularity of the mitochondrial genome. Positions alternative to 
the reference sequence in pileup files (Bioconductor Rsamtools 1.26.2 pileup function 
with pileupParam min_base_quality=30, min_mapq=0, min_nucleotide_depth=5, 
min_minor_allele_depth=0, distinguish_strands=TRUE, distinguish_nucleotides=TRUE, 
ignore_query_Ns=TRUE, include_deletions=FALSE, include_insertions=FALSE) were 
converted back to rCRS positions and used for analyses. Allele frequency was calculated 
based on the alternative variant (alternative reads / total reads). First, all homoplasmic and 
high heteroplasmic alternative variants (> 50% allele frequency) were used for haplotyping 
(HaploGrep2 v2.1.0) to determine patient-specificity for each sample (Supplementary 
Figure 1). Then, initial variant selection was performed on the pileup files using a threshold 
of 1-99% alternative allele frequency. Those variants were manually inspected in Integrative 
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Genomics Viewer (IGV, Broad Institute) [53] to exclude mapping artefacts (as elaborated 
on in [34]). Of the remaining variants, their presence within the initial pileup file was 
determined in all examined samples of that patient to generate a final list of detected 
variants (Supplementary Table 3). Also, the detected heteroplasmic variants were used 
in a nucleotide BLAST against the human reference sequence (NCBI’s nucleotide web 
blast, https://blast.ncbi.nlm.nih.gov) with the surrounding reference sequence (30 bases 
5’ and 30 bases 3’) to uncover potential NUMT events, but none were recovered. For 
the samples in which variants were not called within the final list, limit of detection at 
that position was calculated based on the read depth at that position and an alternative 
variant read depth of 5 (e.g. a position with 5000x read depth would correspond to a 
detection limit of 5 / 5000 = 0.1%). 
Supplementary data
Supplementary data for this article are available online at Neoplasia 
(https://www.journals.elsevier.com/neoplasia/). 
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The past decades, somatic alterations have been characterized in the tumour’s DNA, 
increasing our knowledge of human cancer and paving the way toward new diagnostics and 
treatments. More recently, blood-circulating cell-free DNA (cfDNA) as cancer biomarker 
is extensively studied to uncover tumour-specific alterations in a minimal invasive 
manner, and might proof fruitful in early detection, providing prognostic or predictive 
information guiding therapy-decision making, or to monitor treatment response or the 
burden of residual disease. Nevertheless, almost oblivion in these endeavours is the human 
mitochondrial DNA (mtDNA), a gene-dense circular entity present as numerous copies 
within our cells. As described in Chapter 1, in this thesis we extended the exploration 
on the value of somatic mtDNA alterations, and cfDNA, as a cancer biomarker. 
In Chapter 2, we aimed to clarify the link between mtDNA content and a mesen-
chymal phenotype and its relation to prognosis of breast cancer patients. The number of 
mtDNA molecules per cell was quantified in 42 breast cancer cell lines and 207 primary 
breast tumour specimens. We did not find evidence between mtDNA content and the 
mesenchymal phenotype, but low mtDNA was associated with a poorer distant metastasis 
free survival. We concluded that mtDNA content might provide meaningful prognostic 
value for distant metastasis in breast cancer.
In Chapter 3, we aimed to explore whether low levels of mtDNA content in 
the primary tumour could predict better outcome for breast cancer patients receiving 
anthracycline-based therapies. The number of mtDNA molecules per cell was quantified 
in 295 primary breast tumour specimens. Low mtDNA was associated with better 
distant metastasis-free survival and progression-free survival when patients were treated 
with anthracyline-based chemotherapy, but not when treated with methotrexate-based 
chemotherapy. We concluded that mtDNA content in primary breast tumours may be 
exploited by guiding chemotherapeutic regimen decision-making.
In Chapter 4, we aimed to further understand the genomic changes and expression 
of the mtDNA within breast cancer. RNA sequencing data of 344 primary breast tumour 
specimens was analysed. The number of somatic variants within mtRNA was not associated 
with the mutational processes impacting the nuclear genome, but positively correlated 
with age at diagnosis. Also, mitochondrial expression was related to ER status or the 
primary tumour. We concluded that there is a large heterogeneity in somatic mutations of 
the mtDNA within primary breast tumours, and differences in mitochondrial expression 
among breast cancer subtypes.
In Chapter 5, we aimed to detect tumour-specific mutations in only minute amounts 
of serum-derived cfDNA by using a targeted next generation sequencing (NGS) approach. 
The nuclear DNA of primary tumour tissue (fresh frozen), tumour-adjacent normal tissue 
(formalin-fixed paraffin embedded), and three consecutive serum samples (frozen) from 
10 cancer patients was sequenced by a targeted-sequencing approach and a workflow 
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developed. We concluded that, our workflow was able to detect variants traceable as 
circulating tumour DNA (ctDNA) in minimal amounts of sera of cancer patients.
In Chapter 6, we aimed to develop a procedure to detect low-frequent single-
nucleotide mtDNA-specific variants. Four methods to extract mtDNA as pure as possible 
from frozen tumour tissue, and three methods for low-frequent variant detection were 
evaluated. We concluded that our sensitive procedure to detect low-frequent single-
nucleotide mtDNA variants from frozen tumour tissue is based on extraction of DNA 
from cytosol fractions followed by exonuclease treatment to obtain high mtDNA purity, 
and subsequent SMRT sequencing for (de novo) detection and allelic phasing of variants.
In Chapter 7, we aimed to explore the potential of tumour-specific cf-mtDNA 
variants as cancer marker in the blood of cancer patients. The entire mtDNA of primary 
tumour and/or metastatic sites, tumour-adjacent normal tissue, and cfDNA originating 
from 8 cancer patients was sequenced by the in Chapter 6 developed procedure. Extensive 
heterogeneity was observed among the heteroplasmic mtDNA variants present within 
each individual, and the few tumour-specific mtDNA variants detected in cfDNA were 
present at much lower allele frequencies as nuclear-encoded somatic mutations. We 
concluded that there is limited value in tracing tumour-specific mtDNA variants in 
blood-circulating cfDNA with the current methods available.
From this thesis, as described in Chapter 8, it can be concluded that the mtDNA 
content in the primary breast tumour is not associated with any of the traditional 
clinicopathological markers, mtDNA expression differs among breast cancer subtypes, 
and patients diagnosed at a higher age harbour more somatic mtDNA variants in their 
primary tumour. Also, there is large heterogeneity in somatic mtDNA variants within 
primary breast tumours. The absence of mutational hotspots in mtDNA, the extensive 
heterogeneity in heteroplasmic mtDNA variants within an individual, and the low 
occurrence of tumour-specific mtDNA variants in cfDNA, makes tracing tumour-specific 
cf-mtDNA variants as tumour biomarker in breast cancer a too-tailored approach. Also, 
a low level of mtDNA in the primary tumour indicates a more aggressive cancer, but at 
the same time also more susceptibility for anthracycline-based regimen. Hypothetically, 
this also applies other chemotherapeutic regimen known to induce high oxidative stress 
in the mitochondria. The susceptibility of non-tumour cells to treatments that induce 
(severe) oxidative stress and their contribution to cancer-related fatigue deserves to be 
studied. In the future, a complete picture on the role of mitochondrial variation in tumours 
should be obtained by studying primary tumour and metastatic sites for the interactions 
between the nuclear genome and the mitochondrial genome, taking into account both 
germline and somatic variation, but also tissue distribution and tissue dependence on 
oxidative phosphorylation.
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De afgelopen decennia is onze kennis van kanker bij de mens toegenomen, waarbij de 
meest voorkomende verkregen veranderingen in het DNA van tumoren in kaart zijn 
gebracht. Dit heeft deuren geopend voor nieuwe mogelijkheden binnen de diagnostiek 
en behandeling van kanker. Om deze tumor specifieke veranderingen op een minimaal 
invasieve manier te kunnen detecteren wordt op dit moment bloed-circulerend cel-vrij 
DNA (cfDNA) uitgebreid bestudeerd als bio-indicator. De verwachting is dat cfDNA 
waardevol kan zijn bij vroege detectie van kanker, het verschaffen van prognostische of 
voorspellende informatie voor therapiebeslissingen, het kunnen volgen van de effectiviteit 
van een antikankerbehandeling, en bij het bepalen of er nog resterende ziekte aanwezig 
is. In deze inspanningen wordt het mitochondriële DNA (mtDNA), een cirkelvormig 
DNA-molecuul aanwezig in talloze kopieën binnen onze cellen, vaak buiten beschouwing 
gelaten. Zoals beschreven in Hoofdstuk 1, hebben we in dit proefschrift getracht om 
de waarde van het mtDNA en cfDNA als een bio-indicator voor kanker uit te breiden.
In Hoofdstuk 2 hebben we het verband tussen de hoeveelheid mtDNA in tumor-
cellen en het mesenchymale fenotype, en de relatie tot de prognose van borstkanker-
patiënten onderzocht. Het aantal mtDNA-moleculen werd gekwantificeerd in 42 
borstkankercellijnen en 207 primaire-borsttumormonsters. We vonden geen aanwijzingen 
voor een relatie tussen de hoeveelheid mtDNA en het mesenchymale fenotype, maar een 
lage hoeveelheid mtDNA was geassocieerd met een slechtere metastase-vrije overleving. 
We concludeerden dat de hoeveelheid mtDNA in de primaire tumor van prognostische 
waarde zou kunnen zijn voor het voorspellen van uitzaaiingen op afstand bij borstkanker.
In Hoofdstuk 3 wilden we onderzoeken of een lage hoeveelheid mtDNA in 
de primaire tumor een betere uitkomst zou kunnen voorspellen voor borstkanker-
patiënten die behandeld worden met anthracycline-gebaseerde therapieën. Het aantal 
mtDNA-moleculen werd gekwantificeerd in 295 primaire-borsttumormonsters. Een 
lage hoeveelheid mtDNA werd geassocieerd met een betere metastasevrije overleving 
en progressievrije overleving wanneer patiënten werden behandeld met anthacylinege-
baseerde chemotherapie, maar dit was niet het geval wanneer ze werden behandeld met 
methotrexaatgebaseerde chemotherapie. We concludeerden dat de hoeveelheid mtDNA 
in primaire borsttumoren zou kunnen worden benut om de besluitvorming rond de 
chemotherapiekeuze te begeleiden.
In Hoofdstuk 4 wilden we veranderingen in en expressie van het mtDNA bij borst-
kanker verder uitdiepen. RNA-sequentiegegevens van 344 primaire-borsttumormonsters 
werden geanalyseerd. Het aantal verkregen varianten in het mtRNA was niet geassocieerd 
met de mutatieprocessen die invloed hadden op verkregen veranderingen in DNA uit de 
celkern, maar was wel positief gecorreleerd met de leeftijd waarop de kanker gediagnosti-
seerd werd. De mitochondriale expressie was gerelateerd aan de oestrogeenreceptorstatus 
van de primaire tumor. We concludeerden dat er een grote heterogeniteit bestaat in ver-
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kregen veranderingen in het mtDNA van primaire borsttumoren, en dat er verschillen 
zijn in mitochondriële expressie tussen subtypen van borstkanker.
In Hoofdstuk 5 hebben we ernaar gestreefd om tumorspecifieke veranderingen te 
detecteren in cfDNA uit slechts zeer kleine hoeveelheden bloedserum, door middel van 
een gerichte next generation sequencing-benadering (NGS). Het kern-DNA van primair-
tumorweefsel, tumor-aangrenzend normaal weefsel, en drie opeenvolgende bloedserum-
monsters van tien kankerpatiënten werden gericht gesequencet. We concludeerden dat 
onze werkwijze in staat was om tumorspecifieke veranderingen te traceren als bio-indicator 
in het cfDNA (verkregen uit minimale hoeveelheden bloedsera) van kankerpatiënten.
In Hoofdstuk 6 wilden we een procedure ontwikkelen om laagfrequente veran-
deringen in mtDNA te detecteren. Vier methoden om mtDNA zo zuiver mogelijk uit 
tumorweefsel te extraheren en drie methoden voor laagfrequente-variantdetectie werden 
geëvalueerd. We kwamen tot een werkwijze om laagfrequente veranderingen in mtDNA 
detecteren door de extractie van DNA uit cytosolfracties van tumorweefsel gevolgd door 
enzymatische exonucleasebehandeling om een hoge mtDNA-zuiverheid te verkrijgen, en 
daaropvolgend SMRT-sequensen voor detectie en allelfasering van mtDNA-varianten.
In Hoofdstuk 7 wilden we het potentieel van tumorspecifieke veranderingen in cf-
mtDNA als kanker bio-indicator in het bloed van patiënten onderzoeken. Het volledige 
mtDNA van weefsel van de primaire tumor en/of uitzaaiingen, tumor-aangrenzend 
normaal weefsel en cfDNA afkomstig van acht kankerpatiënten werd gesequencet volgens 
de werkwijze ontwikkeld in Hoofdstuk 6. Grote heterogeniteit werd waargenomen tussen 
de mtDNA-varianten die aanwezig waren in elk individu. De weinige tumorspecifieke 
veranderingen in mtDNA die werden gedetecteerd in cfDNA waren aanwezig met veel 
lagere allelfrequenties dan de gedetecteerde verkregen veranderingen in het kern-DNA. 
We concludeerden dat er met de huidige beschikbare methoden beperkte waarde is in 
het traceren van tumorspecifieke veranderingen in mtDNA als bloedcirculerend cfDNA.
Zoals beschreven in Hoofdstuk 8, kan uit dit proefschrift worden geconcludeerd 
dat de hoeveelheid mtDNA in de primaire borsttumor niet is geassocieerd met een van 
de traditionele klinisch-pathologische bio-indicatoren, dat mtDNA-expressie verschilt 
tussen subtypen van borstkanker, en dat er een hoger aantal verkregen mtDNA-varianten 
aanwezig zijn in de borsttumoren van patiënten die gediagnosticeerd zijn op een hogere 
leeftijd. Er is een grote heterogeniteit in de verkregen mtDNA-varianten binnen 
primaire borsttumoren. De afwezigheid van mutatie-hotspots in mtDNA, de uitgebreide 
heterogeniteit in mtDNA-varianten binnen een individu, en het zelden voorkomen van 
tumorspecifieke mtDNA-varianten in cfDNA maken het opsporen van tumorspecifieke 
cf-mtDNA-varianten als bio-indicator bij borstkanker een niet-generaliseerbare bena-
dering. Ook wijst een lage hoeveelheid mtDNA in de primaire borsttumor op een 
agressievere kanker, maar tegelijkertijd ook op meer gevoeligheid voor anthracycline-
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gebaseerde chemotherapie. Hypothetisch zou dit ook van toepassing kunnen zijn op 
andere chemotherapeutische behandelingen waarvan bekend is dat ze hoge oxidatieve 
stress in de mitochondriën veroorzaken. De gevoeligheid van niet-tumorcellen voor 
behandelingen die (ernstige) oxidatieve stress veroorzaken en de potentiele bijdrage hiervan 
aan kankergerelateerde vermoeidheid verdienen het om te worden onderzocht. In de 
toekomst zou een vollediger beeld van de rol van veranderingen in het mtDNA in kanker 
moeten worden verkregen, door de primaire tumor én uitzaaiingen te bestuderen voor de 
interacties tussen het nucleaire genoom en het mitochondriële genoom. Hier moeten zowel 
kiemlijn- als verkregen variatie, maar ook de weefselverdeling en weefselafhankelijkheid 
van oxidatieve fosforylering in acht moet worden genomen.
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